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ABSTRACT 
The relationship between the behavioural effects of cocaine and the increase in 
dopamine caused by its blockade of dopamine re-uptake has been a major focus of 
research interest. However, little is known regarding the involvement of recently-
cloned dopamine D2-like receptor subtypes (D2, D3 and D4) in different cocaine-
indu'ced behaviours. The purpose of the work described in this thesis was to use a 
series ~f beh~vioural tests to assess dopamine receptor subtype involvement in 
cocaine's effects. In the first series of experiments, we tested the effects of antagonists 
selective for receptors within the D2-like subfamily on the discriminative stimulus 
effects of cocaine (10 mg/kg), and compared them with the effects of a Dl-like 
receptor antagonist. A separate group of rats were trained to discriminate a low dose 
of cocaine (3 mg/kg). Neither U-99194A (a D3 antagonist) nor L-745,870 (a D4 
antagonist) substituted for cocaine, and neither drug shifted the dose-response 
function for cocaine at the higher training dose. On the other hand, pre-treatment with 
SCH 39166 (a selective Dl-like antagonist) produced significant dose-related 
rightward shifts in the cocaine generalisation curve, indicating effective antagonism. 
Three other centrally-acting D2-like antagonists (L-741,626; haloperidol and 
raclopride) produced rightward shifts in the dose-response function for cocaine at both 
training doses. The D2-like antagonists, however, produced dissimilar effects on 
cocaine-induced hypophagia and hyperactivity in the rat. The D3 and D4 antagonists 
(which produced minimal effects on feeding and motor behaviours on their own) 
failed to alter any of the behavioural effects induced by cocaine. The D21D3 
antagonist, raclopride, produced only a marginal attenuation of cocaine-induced 
hyperactivity and rearing, but a marked attenuation of cocaine-induced decreases in 
grooming. On the other-hand, a Dl-like antagonist potently reversed cocaine-induced 
hypophagia, hyperactivity and rearing, but failed to affect grooming behaviour. While 
drug discrimination studies suggests negligible i?volvement of D3 and D4 receptors 
in cocaine's effects, an import~t role for Dl-like and D2 receptors was observed. In 
contrast, it seems that the Dl-like subfamily may playa more prominent role than the 
D2-like subfamily in cocaine-induced hypophagia and motor hyperactivity, although 
cocaine-induced inhibition of grooming appears to be specifically a D2-mediated 
effect. 
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1.1 History of Cocaine Use 
According to archaeological evidence, the Inca people of what are now Peru and 
Boliv~a learned the practice of chewing the Coca leaf from the Aymara Indians of 
Bolivia, where records of cocaine use go back at least to 300 BC (Maisto, Galizio and 
Conpors; 1995). The Coca shrub (Erythroxylan Coca) in whose leaves cocaine (the 
alkaloid form) could be found, grew in the eastern highlands of the Andes mountains in 
Bolivia, Peru, Ecuador and Colombia. Coca chewers would take some lime or ash with 
the leaves to make the pH ofthe saliva more alkaline, thereby decreasing ionisation of the 
cocaine and promoting absorption across the mucous membranes of the oral cavity. 
Because the Inca people thought of Coca as a gift from the Sun God, use of the drug was 
initially restricted to ceremonial or religious occasions. However, Coca chewing later 
became widespread until the practice was banned by the Spanish Conquerors in the 
1500's. The Spaniards subsequently lifted the ban when they discovered that the Incan 
slaves worked harder and longer when allowed to chew Coca. 
1.1.2 Cocaine Use in the 19th Century 
Until the 1800's, use of the Coca plant was relatively unknown in Europe. 
Although Coca leaves were brought back to Europe from South America, Coca chewing 
never caught on in Europe, probably due to degradation of the active ingredient during 
the long sea voyage. The situation changed, however, when Niemann isolated and 
characterised the active alkaloid in 1859. Over the next 30 years, cocaine became 
tremendously popular as many notable scientists and physicians lauded its properties. A 
chemist named Mariani concocted an infamous mixture of cocaine and wine ('Vin 
Mariani '), while the Italian neurologist Mantegazza wrote, "I would rather have a life 
span of ten years with coca than one of a million centuries without coca" (Gold, 1990). 
With regard to cocaine specifically, perhaps the most famous user was Sigmund 
FreUd. Freud obtained a sample of cocaine in 1884 and, after taking it a few times, felt he 
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had come across a miracle drug that could cure many ailments. He advocated cocaine as a 
local anaesthetic and as a treatment for depression, indigestion, asthma and drug 
addiction (morphine). Only one of these therapeutic uses has turned out to be valid, 
namely the use of cocaine as a local anaesthetic. In 1884 Freud also performed the first 
recorded psychopharmacological experiments on cocaine and published the results in a 
paper (1885) entitled "A contribution to the knowledge of the effect of cocaine". The 
euphoria of the cocaine experience was described vividly: 
"The psychic effect of cocainum muriatiaum in doses of O. 05 - 0.10 g consists of 
exhileration and lasting euphoria, which does not differ in any way from the normal 
euphoria of a healthy person. The feeling of excitement which accompanies stimulus by 
alcohol is completely lacking; the characteristic urge for immediate activity which 
alcohol produces is also absent" (Freud, Cited In: Warburton, 1990). 
Freud was mistaken in many of his early claims about cocaine, and he helped 
launch a period of widespread cocaine abuse. One of the first documented cases of 
cocaine addiction concerned one of Freud's friends, Ernst Von-Fleisch!. Fleischl suffered 
from chronic pain and had become a morphine addict. Freud prescribed cocaine, and 
Fleischl began to consume larger and larger doses. Although doing quite well at 
abstaining from morphine, Fleischl was eventually consuming a gram of cocaine daily. 
Not only had Fleischl become one of the first European cocaine addicts, but he also began 
to show bizarre symptoms that we now recognise as characteristics of cocaine overdose. 
These symptoms included paranoid delusions, of the kind that are often seen in 
schizophrenia, and a feeling of itching called the 'formication syndrome', which is 
described as like having insects or snakes crawling on or under the skin. Surprised by the 
disastrous effects of cocaine on Fleischl, Freud in his later writings on cocaine was no 
longer enthusiastic, but the damage had already been done (Musto, 1992). 
The Parke-Davis Pharmaceutical Company declared that cocaine was potentially 
'the most important therapeutic discovery of the age' and began selling cocaine-
containing products such as coca cigarettes to treat throat infections. Cocaine' was 
promoted as a cure for practically everything, from seasickness to haemorrhoids. In 1886, 
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John Pemberton, a pharmacist from Atlanta, created a drink, 'Coca-Cola' made from a 
formula of Coca leaves, Kola nuts and a small amount of cocaine in a sugary, carbonated 
syrup. With such marketing and availability, it is not difficult to understand why cocaine 
became so popular, and with so many people using the drug, casualties soon began to 
emerge. With the increasing prevalence of cocaine-induced psychosis, deaths by 
overdose, and severe dependence on the drug, popular sentiment against cocaine began to 
rise. 
1.1.3 The Decline and Re-emergence of Cocaine Use 
Thus the enthusiasm that surrounded cocaine use in the 1880's soon dissipated as 
evidence mounted against the early claims of cocaine's safety. People realised that the 
SUbjective feelings of power and euphoria that initially accompany cocaine use 
deteriorated with repeated use into feelings of powerlessness and profound depression. In 
an attempt to curtail its abuse, the drug's availability was placed directly under a 
physician's control. However, even though cocaine could now be legally obtained only 
from a physician, a 'black market' for the sale of cocaine emerged. 
While cocaine use declined dramatically, users turned to amphetamines and other 
central nervous system stimulants that were first developed in the 1930's. Users reported 
that the effects of cocaine and amphetamines were virtually indistinguishable, with the 
possible exception that the 'high' from amphetamines lasts longer. From the 1920's to the 
1960's, cocaine use continued primarily among a relatively small group of 'avant garde' 
artists, musicians and other performers. It had become difficult and expensive to obtain, 
and being glamorised as the drug of 'movie stars' it thus acquired a reputation as the 
'champagne' of the stimulants. 
So why did cocaine re-emerge as a stimulant of choice? The ready commercial 
availability of cocaine was a key issue in its re-emergence from the 1970's onwards. A 
new method of cocaine administration called 'free-basing' allowed users to smoke the 
drug and absorb much higher doses than before. Freebase is smokable cocaine obtained 
by dissolving the white->rystalline powder, cocaine hydrochloride, in a strong base. 
Smoking 'crack' gives a quicker, more intense 'high' than inhaling cocaine powder 
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because the drug passes quickly and unhindered from the lungs to the bloodstream. Peak 
plasma levels after intranasal (crystalline) cocaine administration occur approximately 30 
minutes subsequent to inhalation, and cocaine has a half-life of about 40-60 minutes via 
this route (Johanson and Fischman, 1989). When cocaine is taken by the intranasal route, 
it limits its own absorption by causing constriction of the nasal mucous membranes 
(Johanson and Fischman, 1989). On the other hand, smoked cocaine has a 
pharmacokinetic profile and produces effects similar to those of intravenous 
administration. 
The arrival of the 'crack' form of cocaine in the mid-1980's signalled a major 
escalation in the problems associated with cocaine abuse. Freebase cocaine was mass-
produced, and the low cost of crack made it available to younger users. Within two 
decades, what was considered a typical 'dose' of cocaine changed significautly. Higher 
doses of the more potent forms of cocaine had transformed people's experiences of the 
drug and its impact on society. Concern with cocaine abuse was so great that an increased 
awareness developed of the need to understand the behavioural effects of cocaine and the 
determinants of those effects. 
1.2 Behavioural Effects of Cocaine 
1.2.1 Physiological and Psychological Effects In Humans, . 
Psycho stimulants such as cocaine are typically sympathomimetic drugs. That is, 
they act to stimulate or mimic activity in the sympathetic branch of the autonomic 
nervous system. Thus, many of their physiological effects are similar to those seen during 
emotional arousal: heart rate increases, blood pressure and respiratory rate both rise, 
sweating increases; blood flow to the viscera and extremities decreases, blood flow 
increases in the large muscle groups and the brain, body temperature is elevated and 
pupils are dilated (Kiritsy-Roy et aI., 1990; Tella et aI., 1992, 1993). 
Common SUbjective reports of cocaine's acute behavioural effects are present~d in 
Table 1.1. The table lists the most prominent effects of a low~to-average dose of cocaine, 
approximately 10-100 mg when inhaled. These effects occur from all methods of using 
cocaine, but may be more rapid and intense with smoking or intravenous use. Subjective 
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effects, such as measures of 'high', typically peak between 3 and 5 min after use and 
usually disappear within 30-40 min (Johanson and Fischman, 1989). 
1. Euphoria (seldom dysphoria) 
2. Increased sense of energy 
3. Feelings of enhanced mental acuity 
4. Increased sensory awareness (sexual, auditory, tactile, visual) 
5. Decreased appetite (anorexia) 
6. Increased anxiety and suspiciousness 
7. Decreased need for sleep 
8. Physical symptoms of a generalised sympathetic discharge 
Table 1.1. Acute effects of cocaine (From: Gold, 1993). 
The enjoyable psychological effects of low-to-average doses of cocaine begin as 
soon as cocaine reaches the brain; the precise nature of the effects varies depending on 
the dose, the level of drug tolerance and the route of administration. Typical features of 
the cocaine 'high' are feelings of exhilaration and euphoria, a sense of well-being, and 
greater self-confidence (Wallach and Gerson, 1971; Grinspoon and Bakalar, 1985; Spotts 
and Shontz, 1986). A moderate dose of cocaine markedly suppresses appetite, with 
consequent rebounds later (Jonas and Gold, 1986). Sleep is delayed and fatigue 
postponed (Gawin and Ellinwood, 1988; Shere et aI., 1988; Brady et aI., 1991); 
individuals show increased talkativeness and sociability (Spotts and Shontz, 1986). 
Clearly, one of the most important behavioural effects of cocaine is its mood-
altering property, particularly since it is generally believed that these effects are related to 
its abuse. The lack of studies on the SUbjective effects of cocaine within a treatment 
research context may be due, at least in part, to the risks of administering cocaine to 
patients seeking treatment. Measuring the SUbjective effects as indicators of dependence 
potential can only be possible in humans via their verbal abilities. Hence, subjective 
effects are assessed with questionnaires such as the Addiction Research Centre Inventory 
(ARCI; Haertzen, 1960) and the Profile of Mood States (POMS; McNair et aI., 1971), 
which measure the presellce and intensity of drug-induced perceptual changes (e.g. 
detachment, paranoia, cognition) and mood states (e.g. anger, vigour, fatigue, elation). 
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The ARCI is a 550-item true-false questionnaire grouped into scales labelled by drug . 
category, withdrawal state and personality assessment. Each of the scales purportedly 
measures mood effects characteristic of specific drugs or drug groups. The POMS is a list 
of adjectives describing different moods, and the participant indicates how he or she feels 
at a given moment in relation to a series of adjectives on a numerical scale from 'not at 
all' to 'extremely'. The adjectives have been grouped using factor analysis into separate 
scales that are constructed to measure unique mood' states, such as anxiety or elation. 
Many studies have shown that this instrument is a reliable and sensitive indicator of 
changes in mood after administration of drugs (Fischman et al., 1985). Fischman and 
colleagues demonstrated that cocaine produces typical psychomotor stimulant mood 
effects (Fischman and Scuster, 1982). For example, intravenous cocaine at doses ranging 
from 4-32 mg increases scores on the Benzedrine Group (BG) and Amphetamine scales 
of the ARCI in a dose-dependent manner. As the names of these scales imply, the 
changes produced by cocaine were similar to those produced by amphetamine. Cocaine 
and amphetamine also increased scores on the Morphine-Benzedrine Group scale, which 
is considered a measure of 'euphoria', and decreased scores on the Pentobarbitol-
Chlorpromazine-Alcohol Group scale (sedative-like effects); these changes were also 
dose-dependent (Fischman, 1984). 
1.2.2 Unconditioned Behavioural Effects In Animals 
In laboratory animals such as rodents, one of the defining behavioural 
characteristics of cocaine as a psychomotor stimulant is its ability to elicit increases in 
motor activity. Cocaine produces an alert response of increased exploration, locomotion, 
grooming and rearing (Scheel-Kruger et aI., 1977; Snoddy and Tessel, 1985). As the dose 
is increased, locomotor activity decreases and the behavioural patterns become 
stereotyped, i.e. there is a continuous repetition of one or a few items of behaviour 
(Scheel-Kruger, 1971; Scheel-Kruger et aI., 1977). In rats, the repetitive behaviour 
includes head bobbing, gnawing, sniffing and licking (Scheel-Kruger et aI., 1977). At'still 
higher doses, cocaine prodyces convulsions and death (Woolverton and Johnson, 1992). 
Cocaine is also an anorectic in animals and humans (Bedford et aI., 1980; Blavet and De 
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Feudis, 1982; Foltin et aI., 1983; Cooper and Van der Hoek, 1993); see section 1.6.1 for 
further discussion. 
1.3 Cocaine's Mechanisms of Action 
1.3.1 Neurochemical Effects 
Cocaine has long been known to be an inhibitor of the synaptosomal uptake of 
the monoamines such as dopamine (DA), noradrenaline (NE) and serotonin (5-
Hydroxytryptamine, 5-HT). It does so by interacting with the plasma membrane 
transporters for these neurotransmitters, thereby blocking cellular uptake of all three 
monoamines (Harris and Baldessarini, 1973; Taylor and Ho, 1978). These experiments 
demonstrated that cocaine binds to the three uptake sites with a similar, though not 
identical, potency. Cocaine-like analogues have been used to study structure-activity 
relationships for cocaine binding at the DA, NE and 5-HT transporter sites (Ritz et aI., 
1990). Measuring the transporter binding potencies of cocaine derivatives that involved 
N-substitution and/or C2 and C3 substituent modifications revealed differences in 
structure-activity relationships between the cocaine analogues. Removal of the N-methyl 
group produced little change in binding potency at the DA transporter but produced 
increases in binding potencies at the NE and 5-HT transporter sites. Modifications to the 
C2 and C3 substituents, especially substitution of a hydroxyl moiety, produced changes 
in affinity at NE and 5-HT transporters which were much greater than occurred at DA 
transporters (Ritz et aI., 1990). In general, the study indicated the unique structural 
requirements which exists for each transporter site, but it also showed that cocaine 
binding at DA and NE transporters can be described by more similar structure-activity 
relationships in comparison with binding at the 5-HT transporter. 
Consistently, microdialysis studies have demonstrated that acute cocame 
treatment causes increases in extracellular DA, NE and 5-HT levels (Reith et aI., 1986; 
Ritz et aI., 1987; Carboni et aI., 1989; Nomikos et aI., 1990) and that the time course of 
such increases is correlated with changes in extracellular cocaine concentration (Hurd, 
Kehr and Ungerstedt, 1988). Overall, these findings confirmed that the blockade of the 
monoamine transporters observed in vitro likewise occurs in vivo. 
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Although there are several binding sites for cocaine, the binding site that has been 
most clearly related to the drug's reinforcing properties is the DA transporter (Ritz et aI., 
1987; Bergman et aI., 1989). Thus, the DA transporter appears to be the critical site of 
action where events relevant to the reinforcing effects of cocaine are initiated. Indeed, 
many of cocaine's behavioural effects have been attributed to its ability to elevate DA 
levels specifically. For example, cocaine produces stereotyped behaviour and locomotor 
activity in rodents, behaviours that are associated with activation of the nigrostriatal and 
meso limbic DA systems, respectively (Scheel-Kruger et aI., 1977; Reith et aI., 1986). 
These motor effects are blocked by antagonists of post-synaptic DA receptors (Cabib et 
aI., 1991) and attenuated by other treatments that disrupt DA neurotransmission, such as 
lesions of DA fibers in the nucleus accumbens (Calcagnetti and Schuchter, 1992). In 
addition, structural analogs of cocaine produce behavioural effects similar to those of 
cocaine with potencies that correlate with their binding affinities at the DA transporter, 
both for locomotor activity (Cline et aI., 1992) and for the induction of stereotyped 
sniffing and biting (Reith et aI., 1986). Similar to its other behavioural effects, the only 
binding site that has been directly related to cocaine's reinforcing properties is the DA 
transporter (Ritz et aI., 1987; Bergman et aI., 1989). The DA hypothesis of the reinforcing 
properties of cocaine suggests that cocaine binds to the DA transporter of 
mesocorticolimbic neurons, which results in the inhibition of DA reuptake, the 
potentiation of dopaminergic transmission, and ultimately the behavioural phenomenon 
of reinforcement (Figure 1.1). In animal studies, electrical self-stimulation of these 
pathways produces reward-seeking behaviour that mirrors cocaine self-administration 
(Gawin, 1991). Both electrical self-stimulation of these pathways and administration of 
cocaine increase extracellular DA concentrations in brain nuclei that control reward 
behaviour; lesions of these pathways or treatment with DA receptor antagonists attenuate 
these effects of cocaine (e.g. Gawin, 1991). 
It should also be noted that at high concentrations, cocaine interacts with several 
membrane proteins in addition to the monoamine transporters. These proteins include (J 
(sigma) sites (Sharkey, Glen et aI., 1988); 5-HT3 receptors (Kilpatrick et aI., 1987); 
muscarinic cholinergic receptors (Sharkey et aI., 1988b) and most importantly, voltage-
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gated Na+ channels (Matthews and Collins, 1983). Because of its ability to block axonal 
Na+ channels, cocaine is a potent local anaesthetic. However, these additional properties 
of cocaine are generally not considered to be important to its reinforcing effects. 
Synaptic 
Gap 
Post .. 
synaptic 
Neuron 
Figure 1.1. The DA hypothesis of the reinforcing properties of cocaine. Cocaine 
binds to the DA transporter and blocks the reuptake of DA in neurons of the 
mesocorticolimbic pathway. This potentiates dopaminergic neurotransmission and 
initiates the sequence of events that ultimately cause the rewarding effects of the 
drug. (From Kuhar, 1992; In: Cocaine, Scientific and Social Dimensions, Wiley-
Interscience publication). 
1.3.2 Neural Systems Relevant to Reward 
Extensive behavioural and neuropharmacological evidence suggests that the 
_..-" 
mesolimbic (ML) DA neurons are critical for the development and regulation of goal-
directed behaviour established and maintained by various natural and drug reinforcers 
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(for reviews, see Kiyatkin, 1995; Robbins and Everitt, 1996). It has long been accepted 
that the psychomotor stimulants increase DA transmission and that such drug-induced 
changes in the activity of the ML DA system are of special importance in the initiation 
and maintenance of cocaine self-administration (Altman et aI., 1996). Generally, the 
effects of abused drugs are correlated with increased extracellular DA in the nucleus 
accumbens in the following rank order of effectiveness: stimulants (such as 
amphetamines and cocaine) > nicotine > opiates > ethanol > caffeine > 
benzodiazepineslbarbiturates (Wise, 1993; Di Chiara, 1995). 
There is also evidence for a more general link between reward and the ML DA 
system. For example, it has been shown that dopaminergic activity can be increased by 
presentation of a broad range of natural reinforcers: food (Phillips et aI., 1991; Damsma 
et aI., 1991) water (Phillips et aI., 1991) sex (Damsma et aI., 1992) and by electrical 
stimulation of the lateral hypothalamus (Hernandez and Hoebel, 1988b) associated with 
conditioned stimuli (Apicella et aI., 1991; Schultz et aI., 1992). Using in VIVO 
voitammetry, Phillips et ai. (1991) showed that DA levels increase in both the nucleus 
accumbens and neostriatum in response to a continuous stimulus for food. The elevation 
in DA levels persisted until and throughout the meal, finally decreasing to baseline 10-30 
min after the meal (Phillips et aI., 1991). 
The importance of ML DA function to reward has been supported by hundreds of 
studies, and is perhaps captured most vividly in Wise's famous "anhedonia hypothesis" 
(Wise, 1982). Wise elegantly mustered several lines of evidence to argue that moderate 
suppression of dopaminergic function reduces the hedonic value of various rewarding 
stimuli, such as provided by intracranial self-stimulation, drugs of abuse, and palatable 
foods. These effects are reportedly independent from any alterations of motor control or 
general arousal (Wise et aI., 1978). The anhedonia hypothesis implies a reduction in 
incentive motivation after suppression of dopamine function. In studies of the effects of 
DA antagonists on consumption of food or water, for example, the drugs appear. to 
specifically target appetitive rather than consummatory behaviour (see section 4.2). 
Prominent among these effucts is the ability of DA antagonists (including Dl-like and 
D2-like antagonists) to produce changes in intake patterns that mimic a natural dilution of 
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reward value. Such observations have typically been interpreted in terms of the anhedonia 
hypothesis and have provided support for the hypothesis that DA is an important 
mediator of food reward (Berridge, 1996). 
The ML DA neurons synthesise and release DA from their terminals and project 
to various limbic structures. The system originates in the Ventral Tegmental Area (VTA, 
also known as the AI0 region) and projects densely to the ventral striatum, which 
includes the nucleus accumbens, and to other limbic sites such as the amygdala and septal 
nuclei (Figure 1.2). A mesocortical DA system that also originates in the VTA and 
projects mainly to the prefrontal and cingulate cortices is sometimes viewed as a separate 
system, but is often grouped with the system innervating the ventral striatum and 
collectively is called the 'mesocorticolimbic DA system' (e.g. Feldman et aI., 1997). In 
the rat there are rich connections between 'limbic' forebrain structures and the ventral 
striatum. The basolateral amygdala, the hippocampal formation and specific regions of 
the medial pre-frontal cortex all project to the nucleus accumbens and ventromedial 
caudate-putamen, collectively known as the ventral striatum. The ventral striatum 
projects in large part to the ventral pallidum, which in turn projects via the medial dorsal 
nucleus of the thalamus to the prefrontal cortex, so providing the key element of re-
entrant cortico-striatal circuitry (Groenewegen at aI., 1990). 
By analogy, limbic input to the primate striatum is not restricted to the nucleus 
accumbens. In the monkey, the amygdala projects to ventral parts of the head of the 
caudate nucleus, ventromedial anterior putamen, and nucleus accumbens, and some fibers 
from this structure even reach the rostral dorsal putamen and ventral parts of the body and 
tail of caudate (Seleman and Goldman-Rakic, 1985). Orb ito frontal cortex and anterior 
cingulate cortex project to the very rostral parts of caudate, to ventral parts of anterior 
caudate and putamen, to ventral parts of the body and tail of the caudate (Seleman and 
Goldman-Rakic, 1985). Thus, the ventral striatum is strongly innervated by these cortical 
and subcortical limbic areas, although limbic inputs are to a lesser extent also directeq to 
more dorsal and posterior striatal territories. This makes the ventral striatum the 
~ 
predominant, albeit not exclusive, striatal territory with limbic input, thereby refuting a 
dichotomy of "associational" dorsal and "motivational" ventral striatum. 
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Figure 1.2. Neural circuits presumed to mediate the reinforcing effects of 
psychostimulant drugs. A critical part of this circuit involves DA pathways from the 
VTA to the nucleus accumbens, ventral caudate-putamen and frontal cortex. The 
accumbens is additionally regulated by limbic system afferents from the frontal 
cortex, amygdala, hippocampus and dorsomedial thalamus. The behavioural output 
of this circuit is thought to be mediated by efferent pathways from the accumbens to 
. the ventral pallidum and substantia nigra pars reticulata, which are components of 
the extrapyramidal motor system (From Feldman et aI., 1997). Complex processing 
at a cognitive level, such as memory processes, subjective attribution and craving 
are assumed to depend on neocortical mechanisms. The hippocampus and amygdala 
are responsive to conditioned aspects of the environment such as contextual or 
specific cues associated with drug taking. These limbic structures interface via their 
anatomical connections with DA-dependent processes of the ventral striatum 
(nucleus accumbens, core and shell compartments) to effect the control of 
instrumental actions and their outcomes. Descending pathways, including such 
regions as the central grey, may mediate the aversive aspects of drug dependence 
while outputs of the striatum via the globus pallidus to the brainstem are assumed 
to control drug-seeking behaviour. A further possible output from the nucleus 
accumbens includes the cholinergic neurons of the basal forebrain, which may play 
an important role in mediating cortical arousal and the subjective sequelae of drug 
reinforcement (Altman et aI., 1996). 
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In addition, the ventral pallidum projects directly to the brainstem motor areas, 
especially to the subthalamic nucleus, substantia nigra pars reticulata, as well as to 
midbrain DA neurons and the cholinergic neurons of the nucleus basalis magnocellularis, 
which project diffusely to the neocortex. Thus, the limbic cortex, via its projections 
through the ventral striatum, has access to motor output domains of the brainstem, as well 
as specific projections (via the thalamus) to the prefrontal cortex, and access to a major 
diffuse cholinergic cortical arousal system. 
It has been mentioned above that specific cortical areas and limbic structures send 
excitatory projections to selected portions of the striatum (comprising the caudate 
nucleus, putamen and ventral striatum), which is generally thought to represent the 
'input' stage of the basal ganglia. However, it is also important to note the striatal outputs 
of the above circuits. The basal ganglia output nuclei exert a tonic GAB A-mediated 
inhibitory effect on their target nuclei in the thalamus (Alexander and Crutcher, 1990). 
Within each circuit, this inhibitory outflow appears to be differentially modulated by two 
opposing but parallel pathways that pass from the striatum to the basal ganglia output 
nuclei. Each circuit includes a 'direct' pathway to the output nuclei, which arises from 
inhibitory striatal efferents (Albin et aI., 1989). Activation of this pathway tends to 
disinhibit the thalamic stage of the circuit. Each circuit also includes an 'indirect' 
pathway, which passes first to the external segment of the globus pallidus via striatal 
projection neurons, then from the globus pallidus to the subthalamic nucleus, and finally 
to the output nuclei via an excitatory projection from the subthalamic nucleus (Smith and 
Parent, 1988). The role of DA within the basal ganglia appears to be complex, and many 
issues remain unresolved. However, there is recent evidence that the nigrostriatal DA 
projections exert contrasting effects on the direct and indirect striatofugal pathways. 
Dopaminergic inputs appear to have, a net excitatory effect on striatal neurons that send 
GABAIsubstance P projections to the basal ganglia output nuclei (via the direct pathway), 
and a net inhibitory effect on those that send GABAIenkephalin projections to the glo~us 
pallidus (via the indirect pathway) (Bouras et aI., 1986). Thus, in effect, the overall 
influence of DA within the striatum may be to reinforce any cortically initiated activation 
of a particular basal ganglia-thalamocortical circuit by both facilitatory conduction 
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through that circuit's direct pathway (which has a net excitatory effect on the thalamus) 
and suppressing conduction through the indirect pathway (which has a net inhibitory 
effect on the thalamus) (Alexander and Crutcher, 1990). 
The nucleus accumbens has recently been described as comprising anatomically 
(and perhaps functionally) two distinct domains, the 'core' and 'shell' regions, further 
indicating its complexity (Heimer et aI., 1995). Each of these domains receives distinct 
patterns of cortical afferents and has distinct projections to medial and lateral pallidal 
sites. Mogenson et ai. (1980) first proposed that the nucleus accumbens serves as a 
critical interface between the limbic and motor systems, thus linking motivation with 
action. In this model, the VTA-accumbens dopaminergic pathway is seen as part of a 
gating mechanism that governs the translation of motive states into overt motor 
responses. For example, electrical stimulation of the amygdala or hippocampus elicits 
alterations in the firing of ventral striatal and ventral pallidal neurons that are subject to 
modulation by direct manipulations ofDA within the nucleus accumbens (Robbins et aI., 
1989; Mogenson and Yang, 1991). Therefore certain limbic structures, such as the 
amygdala and the hippocampus, and cortical structures such as the frontal cortex, may 
also be important to drug reward via modulation of nucleus accumbens activity. It is not 
clear why activation of this system is reinforcing; one hypothesis put forward is that the 
ML system has a critical role in the species-specific motor arousal associated with 
anticipation of reward (Robbins et aI., 1989; Koob, 1992; Dickinson and Balleine, 1994; 
Robbins and Everitt, 1996). 
An alternative interpretation was provided by Robinson and Berridge (1993) who 
proposed a theory of drug craving based on the concept of 'incentive-sensitisation'. This 
theory distinguishes between the motivational process of 'liking' (i.e. broadly 
synonymous with "pleasure") and the process of 'wanting' (which Robinson and 
Berridge formally refer to as the attribution of incentive salience to environmental 
stimuli). The latter process, which is not consciously experienced, causes the perception 
------or psychological representation of an object to become desirable and to be pursued. Most 
importantly, repeated exposure to an addictive drug in the presence of various drug-
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related stimuli IS hypothesised to produce conditioned sensitisation of the neural 
substrates (the ML DA system) that mediate attribution of incentive salience. 
Consequently, the user can experience an increasing desire for the drug, even though the 
person may actually 'like' the drug less and less. Therefore, the theory claims that ML 
DA subserves the 'wanting' aspect of drug abuse, but it fails to identify the brain 
mechanisms or receptors that mediate the SUbjective responses to such drugs. 
It is generally agreed that only a limited number of brain structures are likely to 
process the appetitive aspects of rewarding events. Neural activity related to reward 
occurs in several distinctive forms, many of which are not seen with DA neurons. It is no 
longer adequate to consider the ML DA system in isolation when exploring the neural 
bases underlying the effects of addictive drugs. There are clearly important afferent 
systems that regulate the firing frequency and pattern ofVTA DA neurons (Schultz et aI., 
1992). The anatomical substrate underlying these functions may comprise the conjunction 
of different afferents from limbic structures and ML DA neurons. Major limbic structures 
in primates, such as the anterior cingulate gyrus, orbitofrontal cortex and amygdala, 
project to the ventral striatum, including the nucleus accumbens, in a dense and 
interdigitating fashion, whereas their projections to the dorsal striatum are more sparse 
and scattered (Seleman and Goldman-Rakic, 1985). Interactions in the ventral striatum 
between afferents from the amygdala and from DA neurons appear to be necessary for 
mediating the effects of stimulus-reward associations on behaviour (Cador et aI., 1989). 
Investigations have also shown that the dorsal and ventral caudate neurons are activated 
when different kinds of food are shown to the animal (Nishino et aI., 1984) and that 
ventral striatal neurons respond to external stimuli associated with reward through prior 
conditioning (Cador et aI., 1989). The dorsal part of the striatum, or caudate putamen in 
the rat, is composed of at least two distinct compartments: the 'matrix' and the 
'striosomes' or patches (Gerfen, 1992). The matrix receives afferents from the superfic.ial 
layers of the medial prefrontal cortex and motor, somatosensory, and visual cortices 
.~ (Gerfen, 1992). In contrast, the striosome/patch compartment receives projections from 
the deep layers of the medial prefrontal and limbic cortices (Gerfen, 1992). Neurons in 
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both the ventral and dorsal parts of the striatum seem also to be involved during 
reinforcement (Apicella et aI., 1991). This notion has been supported by the recent 
finding that electrodes contacting the striosomes/patches of the rat caudoputamen sustain 
electrical self-stimulation more reliably than electrodes in the matrix that surrounds them 
(White and Hiroi, 1998). The idea that self-stimulation results from activation of cell 
bodies in the striosome/patch compartment suggests that strionigral neurons terminating 
in pars compacta may also be involved in the reinforcement process. Thus, the striatum 
may receive information about predictable environmental events from associative cortex, 
information about reward reception from subcortical limbic structures, and information 
about the presence of salient, incentive stimuli from DA neurons. Neurons on the dorsal 
striatum may have access to representations of several task events, such as instruction 
stimuli, hedonic responses and reward (Schultz et aI., 1992; White and Hiroi, 1998). 
It should be apparent from the above that it is now widely accepted that CNS DA 
. 
is an important mediator of reward-related behaviour, and plays a primary role in the 
behavioural effects of cocaine. Consequently, there has been substantial interest in 
determining the roles of the different types of DA receptor in cocaine's effects. In order 
to approach this issue, it is necessary to describe the molecular biology, distribution and 
pharmacology of the various DA receptor subtypes and to consider the behavioural 
effects of receptor-selective compounds. 
1.4 Dopamine Receptors: Molecular Biology and Behavioural Aspects 
Modem DA receptor research began in the early 1970's with the discovery ofDA-
stimulated adenylyl cyclase activity (Kebabian, Petzold and Greengard, 1972). 
Biochemical evidence for two distinct DA receptors was followed shortly by the 
designation of these sites as "D 1" and "D2" receptor subtypes (Kebabian and CaIne, 
1979). Dl receptors were shown to activate the enzyme adenylyl cyclase and to increase 
intracellular levels of cAMP, whereas D2 receptors exerted an inhibitory influence on this 
enzyme (Andersen, et aI., 1990). D2 receptors were also linked to additional second 
messenger systems, including activation of K+ channels and inhibition of Ca2+ channels 
and phospotidylinositol turnover (ValIer and Meldolesi, 1989). 
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Gradually, however, pharmacological and molecular biological evidence began 
accumulating to suggest that further receptor subtypes probably existed. A major 
breakthrough occurred with the cloning and characterisation of three novel DA receptor 
species; these are called D3 (Giros et aI., 1990; Sokoloff et aI., 1990), D4 (O'Malley et 
aI., 1992; Van Tol et aI., 1991) and D5 receptors (Grandy et aI., 1991; Sunahara et aI., 
1991; Weinshank et aI., 1991) (for review see, Jackson and Westlind-Danielsson, 1994). 
All of the known DA receptors belong to the G-protein-coupled receptor 
superfamily. The five subtypes have been well characterised, designated D1 through D5, 
and a sixth member of the family arises from the fact that the D2 receptor exists in two 
isoforms (termed D2S and D2L)' Many different names have been proposed for the different 
molecular forms of DA receptor. Sibley and Monsma Jr (1992) proposed a hierarchical 
nomenclature based on the pharmacology and molecular structure of the different 
receptors. This classification scheme recognises two families of DA receptors that 
correspond to the classically-recognised D1 and D2 receptors, now termed 'D1-like' and 
'D2-like' receptor subfamilies. There are important similarities between the D1 and D5 
subtypes and between the D2, D3 and D4 subtypes, hence their categorisation into D 1-
like and D2-like families, respectively (Table 1.2). The discussion below is organised on 
the basis of'D1-like' and 'D2-like' receptor subfamilies. 
1.4.1 The '01-Like' Receptor Subfamily 
A. 01 Receptors 
The D I receptor was first distinguished by virtue of its ability to stimulate 
adenylyl cyclase activity, and later by means of binding studies that differentiated it from 
the D2 SUbtype. The gene for the D 1 receptor was cloned by four different groups 
working independently (Dearry et aI., 1990; Monsma et aI., 1990; Sunahara et aI., 1990; 
Zhou et aI., 1990). As with other G-protein-coupled receptors, the structure of the D1 
receptor suggests the presence of seven membrane-spanning domains. 
A number of DA agonists have been developed that discriminate between D 1 
receptors and members of the D2-like subfamily. Among the most widely used D1-
selective agonists are members of a family of 1-phenyl-tetrahydrobenzazepines including 
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Alternative Nomenclature DIA DIB 
Amino Acids: 
Human 
Rat 
Introns in Gene 
Human Chromosome 
Effector Pathways 
\ 
mRNA Distribution 
Agonists 
Antagonists 
446 477 
446 475 
No No 
5 4 
tcAMP tcAMP 
caudate putamen hippocampus 
nucleus accumbens hypothalamus 
olfactory tubercle 
amygdala 
frontal cortex 
SKF 7560 SKF 77434 SKF 38393 
A-68930 Dihydrexidine 
SCH23390 
SK&F 83566 
SCH 23390 
SK&F 83566 
D2SID2L 
DZAS / DZAL 
414/443 
415/444 
Yes 
11 
-J, cAMP 
t K+ channels 
-J, Ca2+ channels 
caudate putamen 
nucleus accumbens 
olfactory tubercle 
limbic areas 
N-0437 
Bromocriptine 
Remoxipride 
Raclopride 
( -) Sulpiride 
L-741,626 
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D3 
D2B 
400 
446 
Yes 
3 
-J..cAMP? 
olfactory tubercles 
hypothalamus 
nucleus accumbens 
island of calleja 
Quinpirole 
7-0H-DPAT 
PD 128907 
(+)AJ76· 
(+) UH 232 
U-99194A 
GR 103691 
D4 
D2C 
387 
383 
Yes 
11 
-J, cAMP? 
frontal cortex 
medulla 
amygdala 
midbrain 
PD 168077 
Clozapine 
L-741,742 
L-745,870 
Table 1.2. DA receptor subtypes defined from physiological, pharmacological and biochemical studies. (Source from: Andersen et aI., 1990; Sibley et aI., 
1992; 1993; Strange, 1996). Drugs are listed as commonly used for the receptors given. 
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the prototypical compound SKF 38393 (l-phenyl-2,3,4,5-tetrahydro-7,8-dihydroxy-(IH)-
3-benzazepine) (Setler et aI., 1978; Stoof and Kebabian, 1984) along with a variety of 
congeners such as SKF 81297, SKF 82958 and SKF 82526 (fenoldopam) (Andersen and 
Jansen, 1990). Some of the benzazepine compounds, such as SKF 38393 and SKF 82526, 
are only partial D 1 agonists, as assessed by the stimulation of D I-sensitive adenylyl 
cyclase (Andersen and Jansen, 1990). Hence the maximal efficacy of these drugs is less 
than that ofDA itself. Dihydrexidine is an example of a non-benzazepine DA agonist that 
exhibits moderate selectivity between Dl-like and D2-1ike receptors and near-full 
efficacy (Brewster et aI., 1990). Recently, a potent and selective Dl-like receptor agonist 
has been the isochroman compound A-68930 (DeNinno et aI., 1990; Kebabian et aI., 
1990). A-68930 has a high affinity for the Dl-like receptor and stimulates carp retinal 
adenyl ate cyclase (DeNinno et aI., 1991); it also stimulates DA-sensitive adenyl ate 
cyclase in the rat caudate putamen, and acts as a full agonist in this assay (DeNinno et aI., 
1991). 
Several substituted benzazepines act as Dl-like receptor antagonists rather than 
agonists. The best known of these compounds are SCH 23390 (3-methyl-l-phenyl-
2,3,4,5-tetrahydro-7 -chloro-8-hydroxy-(IH)-3-benzazepine) and its brominated analog 
SKF 83566 (Hyttel, 1983). Other commonly used Dl-like antagonists include the 
benzonapthazepine, SCH 39166 (Chipkin et aI., 1988). 
The distribution of D 1 receptors in the rat brain has been mapped by means of in 
vitro autoradiography using several different agonists and antagonists. The highest 
receptor densities have been found in the terminal regions of the meso striatal system, 
namely the caudate-putamen, nucleus accumbens and olfactory tubercle, and in the 
substantia nigra (Monsma Jr et aI., 1990; Sunahara et aI., 1990; Zhou et aI., 1990; Table 
1.2). Intermediate levels of receptor binding occur in the ventral pallidum, 
entopeduncular nucleus, and in some of the nuclei of the amygdala. Low D 1 receptor 
levels have been found in the neocortex, thalamus, cerebellum, hippocampus, septum and 
most areas of the hypothalamus (Monsma Jr et aI., 1990; Sunahara et aI., 1990; Zhou et 
-------
aI., 1990). 
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In most instances, DA Dl receptor mRNA distribution, carried out using Northern 
blot analysis, agrees well with the distribution of the corresponding binding sites 
identified by autoradiography (Monsma et aI., 1990; Sunahara et aI., 1990; Zhou et aI., 
1990). An exception is the substantia nigra (SN), where considerable DA Dl receptor 
binding is evident, whereas DA Dl receptor mRNA expression is generally not 
detectable. This may imply that DA Dl receptors are not synthesised in the SN, but are 
transported to this site, presumably from the caudate putamen. 
B. 05 Receptors 
The only other known member of the Dl-like receptor subfamily is the D5 
receptor (Sunahara et aI., 1991; Weinshank et aI., 1991). Some investigators have used 
the terminology Dla and Dlb to refer to the Dl and D5 receptors, respectively (e.g. 
Jackson and Westlind-Danielsson, 1994). The two receptors have significant amino acid 
sequence homology, very similar pharmacological profiles, and both stimulate the 
formation of cAMP. It is interesting to note that in humans, but not in rats, the D5 
receptor exhibits a tenfold higher affinity for DA than the Dl receptor (Sunahara et aI., 
1991; Weinshank et aI., 1991). 
Because of the pharmacological similarity of the Dl and D5 receptors, the so-
called Dl-selective agonists and antagonists available at this time affect both Dl and D5 
receptors. However, D5 receptors appear to be expressed at very low levels in the brain, 
mainly in the hippocampus, the hypothalamus and the parafascicular nucleus of the 
thalamus (Meador-Woodruff et aI., 1992; Tiberi et aI., 1991). This might suggest that the 
behavioural effects caused by Dl-like agonists or antagonists may be better attributed to 
activation or blockade of the D 1 subtype rather than the D5 sUbtype. 
1.4.2. The '02-Like' Receptor Subfamily 
A. 02 Receptors 
D2-like receptors were first identified on the basis of their high affinity for 
antipsychotic (neuroleptic) drugs and by the fact that, unlike Dl-like receptors, they 
either inhibited adenylyl cyclase or had no effect on its activity (Kebabian and CaIne, 
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1979). The DA D2 receptor was first cloned in the rat by Bunzow et ai. (1988) followed 
by the human D2 receptor which was found to possess 96 % sequence homology with the 
rat receptor (Dal Toso et aI., 1989). Other studies demonstrated that two isoforms of the 
D2 receptor exist in both rats (Giros et aI., 1989) and humans (Dal Toso et aI., 1989). The 
DA D2 receptor isoform differs from the initially cloned DA D2 receptor by an additional 
29 amino acids. Hence, the longer and shorter forms are designated D2L and D2S 
respectively. 
Bromocriptine (which is an ergot derivative), LY-171555 (also called quinpirole) 
and apomorphine are some well-known D2-like receptor agonists with limited selectivity 
for D2 receptors within the D2-like subfamily. The classic antipsychotic drugs are DA 
receptor antagonists that possess varying degrees of selectivity for D2-like as compared 
with Dl-like receptors. Members of this group with D2-like selectivity include 
haloperidol, pimozide, raclopride and sulpiride (Meltzer et aI., 1989; Schwartz et aI., 
1993). Only recently have truly D2-selective drugs been developed; one such example is 
the compound L-741,626 (Kulagowski et aI., 1996; Bowery et aI., 1996). 
D2 receptors display a widespread but heterogeneous distribution in the brain. In 
rats, the highest levels ofD2 receptor binding have been detected in the caudate-putamen, 
nucleus accumbens, olfactory tubercle, substantia nigra pars compacta and the glomerular 
layer of the olfactory bulbs (Boyson et aI., 1986; Charuchinda et aI., 1987). Intermediate 
receptor levels have been found in the central nucleus of the amygdala, lateral septum, 
molecular layer of the hippocampus and the entorhinal cortex. It is interesting to note that 
in virtually all areas in which D 1 and D2 receptor densities were directly compared, 
levels ofDl receptors were distinctly greater (Boyson et aI., 1986). 
B. 03 Receptors 
The D3 receptor was first identified by Sokoloff et ai. (1990). Although D3 
receptor pharmacology is not unlike that of D2 receptors, some important distinctions 
should be noted. A few of the previously mentioned D2-like agonists, particularly 
quinpirole and pergolide, actually have a greater affinity for the D3 subtype. The 
~ 
compound 7-0H-DPAT (7-hydroxy-N-N-di-N-propyl-2-aminotetralin) is more D3-
selective in receptor binding studies (Levesque et aI., 1992) and this drug has been used 
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to investigate the possible behavioural and physiological effects ofD3 receptor activation 
(Levesque et aI., 1992). The novel naphthofurane compound, (+)-S-14297 «+)-[7-(N,N-
dipropylamino )-5,6,7 ,8-tetrahdronaphtho(2,2b )dihydro, 2,3-furane]) was the first reported 
selective D3 antagonist, with a 200-fold greater affinity for cloned human D3 than D2 
receptors (Millan et aI., 1994). Although ligands with high selectivity for the DA D3 
receptor are not available at present, data on compounds with some preferential affinity 
for D3 receptors, such as (+) AJ 76, (+) UH 232, and the phenylpiperidine, (-) DS121, 
suggest that these compounds do differ in their pharmacological profiles from 
"traditional" D2-like receptor agonists and antagonists (e.g. Svensson et aI., 1986; 
Sonesson et aI., 1993). More recently, the putative DA D3 receptor antagonist U-99194A 
has been shown to have a 20-30 fold preference for the D3 vs. D2 receptor subtype 
(Waters et aI., 1993). 
Highest densities of D3 receptor binding and mRNA are found in the islands of 
calleja, dense clusters of small granular neurons located mainly within the olfactory 
tubercle (Levesque et aI., 1992). Other areas of high D3 receptor concentration include 
the anterior nucleus accumbens, the olfactory tubercles, the bed nucleus of the stria 
terminalis, and the molecular layer of lobules 9 and 10 of the cerebellum (Giros et aI., 
1990; Sokoloffet aI., 1990; Bouthenet et aI., 1991). 
c. 04 Receptors 
Another D2-like receptor cloned from human and rat tissues is referred to as the 
D4 receptor (O'Malley et aI., 1992; Van Tol et aI., 1991). There appear to be multiple 
genetic variants of this receptor in the human popUlation, although the functional 
significance of such variation remains to be established (Van Tol et aI., 1992). In 
monkeys, rats and/or mice, D4 receptor mRNA has been identified in the frontal cortex, 
hypothalamus, thalamus, midbrain, medulla, amygdala, olfactory bulbs and the retina 
(Cohen et aI., 1992; Van Tol et aI., 1991). Only low levels have been found in the 
striatum. However, rat heart was shown to possess more D4 mRNA than the nervous 
system, suggesting that this receptor subtype may at least partially mediate the positive 
----inotropic effects of D2-like agonists on heart muscle (Zhao, Ferrell and Abel, 1990). As 
yet, the functional roles of the D4 receptor subtype still need to be determined. 
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The most conspicuous feature of the human DA D4 receptor is its high affinity for 
clozapine (Van Tol et aI., 1991). However, other groups (e.g. Malmberg et aI., 1993) have 
reported an affinity of clozapine for the DA D2 receptor subtype comparable to its 
originally-reported affinity for DA D4 receptors (Van Tol et aI., 1991). However, binding 
data from the rat receptor species has only demonstrated a KiD/ KiD4 quotient of 2-3 for 
clozapine (O'Malley et aI., 1992) which limits the usefulness of this compound for the 
study of DA D4 receptor function. Despite considerable interest in the physiological 
functions of the D4 receptor, pharmacological research has been hampered by the paucity 
of agonists and antagonists with selectivity for the receptor. Recently, the newly-
developed D4 receptor antagonists YM-5001 (Ki = 5.62nM; Hidaki et aI., 1996), U-
101307 (Ki = 10nM; Merchant et aI., 1996), and the most selective of them all, L-745,870 
(Ki = 0.42nM; Kulagowski et aI., 1996) enable one to characterise the functional role of 
this receptor subtype for the first time. 
1.5 Behavioural Effects of Selective Dopamine Receptor Subtype Agonists 
and Antagonists 
1.5.1 'D1-Like' Receptor Subfamily 
During the early 1980's, when the simple D11D2 classification still dominated DA 
receptor research, it is interesting to note that virtually all behavioural effects of DA were 
ascribed to its action at D2 receptors (Seeman, 1980). This was due primarily to the fact 
that the behavioural potencies of most DA agonists and antagonists then available 
correlated more strongly with their affinities for D2 than for D 1 receptors. 
DA has been implicated in many different behavioural processes, and various 
selective DA receptor subtype agonists and antagonists have been used to elucidate the 
receptors underlying these behavioural functions. For example, the most pronounced 
effect of D1-like agonists (e.g. SKF 38393) and D1-like antagonists at low doses (e.g. 
SCH 23390) in rats and mice is to stimulate grooming (Molloy and Waddington, 1984; 
Murray and Waddington, 1989; Starr and Starr, 1986a) an effect which D2-like agonists 
. ..---
or antagonists are unable to produce. SKF 38393-induced grooming in mice can be 
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inhibited by the i.c.v. injection of antisense oligonucleotides to D1 receptor mRNA 
(Zhang, Zhou and Weiss, 1994). 
With regard to the effects ofD1-like agonists on locomotor activity, the findings 
are ambivalent. For example, Molloy and Waddington (1984, 1985) first described a 
syndrome of diffuse behavioural activation, including mild locomotor stimulation, in rats 
treated with SKF 38393, but this profile was most robustly observed only after 
habituation for 2-5 hr to the test environment. This result has since been replicated 
(Molloy et aI., 1986; Molloy and Waddington, 1987) and has been observed with other 
D1-like agonists (e.g. Murray and Waddington, 1989). Others reporting significant 
locomotor stimulation by SKF 38393 in habituated rats include Mazurski et aI. (1991), 
Shannon et aI. (1991) and Zarrindast and Elliasi (1991). 
For non-habituated rats and mice, there have been few reports of locomotor 
hyperactivity following SKF 39393. However, Bruhwyler et al. (1991) demonstrated a 
significant increase in rat open-field activity after SKF 38393, and Tirelli and Terry 
(1993) showed a dose-related stimulation of activity in mice where the time-course effect 
was biphasic at high. doses (at doses of 100-300 mg/kg SC there was a dose-related 
locomotor depression followed by long-term hyperlocomotion). Direct infusion of D1-
like agonists into the striatum or nucleus accumbens elicits various patterns of locomotor 
hyperactivity and stereotyped behaviour (Bordi and Meller, 1989; Meyer et aI., 1993), 
convincingly demonstrating the functional relevance of central D1-like receptors in such 
behaviours. 
The typical effect of administering a DA receptor antagonist is a suppression of 
spontaneous exploratory and locomotor behaviour. D1-like antagonists, such as SCH 
23390, have been reported to inhibit motor activity in mice (Starr and Starr, 1986b) and 
to reduce horizontal activity (Gessa et aI., 1985, Hoffman and Beninger, 1985; Meyer et 
aI., 1993) and rearing in a dose-dependent manner in rats (Hoffman and Beninger, 1985; 
Meyer et aI., 1993). D1-like antagonists can also produce catalepsy in rats and mice, an 
effect which appears to be due to blockade of DA receptors in the striatum (Hoffman and 
~ 
Beninger, 1985; Chandler et aI., 1990). 
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1.5.2 'D2-Like' Receptor Subfamily 
D2-like receptor activation by D2-like agonists has been reported to produce 
hyperlocomotion and sniffing in rats (Molloy and Waddington, 1985). However, although 
D2-like receptor agonists are often assumed to stimulate activity especially in rats (Eilam 
et aI., 1991; 1992) they have been shown to produce hypo activity in mice over wide dose 
ranges (Jackson et aI., 1989a 1989b; Tirelli et aI., 1997), although a stimulant effect may 
emerge over long periods (Jackson et aI., 1990). Evidence from several sources suggests 
that the full expression of D2-like receptor-mediated effects requires concurrent 
occupancy of Dl receptors (DlID2 synergism, e.g. Waddington and Daley, 1993). For 
example, moderate to high doses of D2-like agonists such as quinpirole or RU 24213 
have been reported to produce increased locomotion, sniffing, repetitive scratching, 
gnawing and biting (Eilam et aI., 1992; Molloy et aI., 1986; Walters et aI., 1987) which 
can be blocked not only by administration of a D2-like antagonist, but also by a Dl-like 
antagonist or by depletion of endogenous DA (Waddington, 1986; Walters et aI., 1987). 
Moreover, combined administration of D I-like and D2-like agonists, either systemically 
or directly into the striatum, causes much more intense stereotyped behaviour than does 
either agonist alone (Bordi and Mellor, 1989; Walters et aI., 1987). Such results have 
given rise to the hypothesis of DIID2 synergism, which states that Dl-like receptor 
occupancy is necessary for the full expression of D2-like receptor-mediated effects 
(Waddington and Daly, 1993). 
As with Dl-like antagonists, D2-like receptor antagonists can also elicit catalepsy 
(Wanibuchi and Usuda, 1990). Moreover, receptors in the striatum appear to play an 
important role in both cases (Sanberg, 1980; Fletcher and Starr, 1988). These results are 
not inconsistent with the prevailing hypothesis ofDI1D2 receptor synergism and indicate 
that normal motor functioning requires continued activity at both subtypes in the striatum. 
The identification of the DA D3 receptor by Sokoloff et aI. (1990) enabled a 
number of selective DA D3 receptor agonists and antagonists to be developed, S0 
allowing investigation of the behavioural and physiological effects of D3 receptor 
-~-
activation or blockade. One such compound is the D3 agonist, 7-0H-DPAT (7-hydroxy-
N-N-di-n-propyl-2-aminotetralin) which has been shown to be among the most D3-
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selective in receptor binding studies (Levesque et ai., 1992). However, several reports 
suggest that this compound may be controversial as a selective D3-receptor ligand (e.g. 
Tirelli et ai., 1997). It has been shown that, given systemically, 7-0H-DPAT will produce 
biphasic effects on spontaneous sniffing and locomotor activity in rats: behaviours were 
inhibited at low doses but stimulated at higher doses (Daly and Waddington, 1993; 
McElroy et ai., 1993). These findings may suggest that D3 receptor-mediated effects are 
apparent at low doses, but that higher doses causes the additional stimulation of D2 
receptors, so changing the behavioural profile. 
A number of studies have looked at the effects of putative DA D3 receptor 
antagonists on locomotor activity (Svensson et ai., 1986). These compounds include (+) 
AJ 76 and (+) UH 232 (which display 3-5 times higher affinity for D3 than D2 receptors); 
it has also recently been suggested that these drugs may exert a preference for DA 
autoreceptors (Arethra et ai., 1995; 1996). It is possible that D3 receptor activation 
reduces locomotor activity due to an autoreceptor-mediated effect; however, various 
findings conflict with this hypothesis (e.g. Svensson et ai., 1994b). The lack of 
autoreceptor involvement is also supported by work using the antagonist U-99194A, a 
compound 3D-fold more selective for D3 than D2 receptors (Waters et ai., 1993, 1994). 
Waters et ai. (1993) demonstrated that U-99194A can increase locomotor activity without 
any concomitant effects on DA release. Kling-Petersen et ai. (1995) also showed that U-
99194A produced an increase in locomotor activity when injected into the nucleus 
accumbens at doses that did not affect DA release in the striatum or nucleus accumbens, 
areas which are established to be important to the behaviour. These results have led to the 
suggestion that the D3 receptor is functionally relevant primarily at the post-synaptic 
level, and that its blockade leads to stimulation of locomotor activity. Consistent with the 
effects ofD3 antagonism on locomotor activity, the D3-preferring antagonist nafadotride 
produces a biphasic effect on locomotor activity in rats, stimulating locomotor activity at 
lower doses and inhibiting it at higher doses (Sautel et ai., 1995). Doses of nafadotride 
which increased locomotor activity were shown to produce negligible occupancy of D2 
.. .--' 
receptors, while those which inhibited locomotor activity produced significant D2 
occupancy (Levant and Vansell, 1997). 
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Looking at other behaviours, Millan and co-workers (1995) recently reported that 
7-0H-DPAT induced hypothennia that could be completely blocked by the D3 antagonist 
S-14297. 7-0H-DPAT was recently found to decrease the rate of cocaine self-
administration (interpreted as an increase in reinforcing efficacy) and was also self-
administered when substituted for cocaine (Caine and Koob, 1995). D3 agonists also 
decrease alcohol consumption (Ahlenius and Larsson, 1995). Acri (1995) also reported 
that 7-0H-DPAT substituted for cocaine's discriminative stimulus effect in rats. 
Therefore recent evidence has indicated that postsynaptic D3 receptors may be involved 
in the regulation of locomotor behaviour, body temperature and reward. Based on the 
somewhat limited in vivo and in vitro pharmacological data currently available, it is 
possible that the D3 receptor may play a role in several other behavioural and 
physiological effects, such as yawning and hypothennia (Damsma et aI., 1993; Ahlenius 
and Salmi, 1994; Ferrari and Guiliani, 1995; Khroyan et aI., 1995), penile erection and 
ejaculatory behaviour (Ferrari and Guiliani, 1995), inhibition of climbing in mice (Sautel 
et aI., 1995), and emesis in the dog (Yoshida et aI., 1995). 
By contrast, the functional role of the D4 receptor subtype still needs to be 
detennined. The receptor has been little studied in the past, in part due to lack of 
availability of receptor-selective compounds. The recent emergence of a number of 
compounds acting specifically at the DA D4 receptor now make investigation possible. 
For example, the antagonists L-745,870 (Kulagowski et aI., 1996) and U-101387 
(Merchant et aI., 1996) have been shown to have negligible effects in behavioural tests of 
antipsychotic activity (Bristow et aI., 1996; Merchant et aI., 1996; Millan et aI., 1998) and 
anxiety tests in mice (Cao and Rodgers, 1997). As yet, there are no compounds available 
that act as agonists at the D4 receptor site, so impeding our understanding of this receptor. 
1.6 Methods to Study Dopamine Involvement in Cocaine's Behavioural 
Effects 
Animal models are recognised as indispensable tools for certain types of 
investigation, including mechanistic studies of brain substrates, the identification of sites 
of drug action, and the preclinical evaluation of novel agents. The usefulness of animal 
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models often depends on their validity as simulations of human behaviour. This can often 
be difficult to determine, in part because of the considerable differences in the 
methodologies used to study animal behaviour on one hand and human psychopathology 
on the other. However, in the case of animal models of addiction, these difficulties appear 
less acute. In the context of drug abuse research, the self-administration model is often 
used to analyse the neurochemical systems involved in drug reinforcement, and as a 
screening test for potential drugs of abuse. Similarly, the drug discrimination procedure is 
used both as a bioassay to examine drug actions on receptors and as a screening test for 
drugs with potential therapeutic applications. However, the drug discrimination procedure 
is sometimes used as an animal simulation of human 'subjective' responses to drugs. 
Such 'subjective' responses are often thought to be closely associated with abuse liability, 
and the drug discrimination procedure therefore represents a potential tool for studying 
this aspect of drug abuse. 
In order for a model to be accepted as a useful tool to investigate drug abuse, it 
ought to meet certain criteria. In this regard, three main criteria are often applied, 
although it is generally unrealistic for anyone model to meet all of these. These criteria 
have been outlined in reviews by Willner (1991; 1997). The model must have 
'predictive' validity, i.e. performance in the test must predict performance in the 
condition being modelled. 'Face' validity suggests that animal models of behavioural 
disorders should, ideally, resemble clinical syndromes in terms of aetiology, 
biochemistry, symptomatology and treatment. Finally, 'construct' validity presupposes 
that the model(s) used should have sound theoretical bases. 
1.6.1 Self-administration 
Many drugs of abuse are readily self-administered intravenously by animals, and 
In general, drugs that are self-administered have high abuse potential. Indeed, this 
relationship is so reliable that drug self-administration is widely considered to be an 
animal model that is predictive of abuse potential; hence it has been suggested that the 
procedure should be used for __ the preclinical assessment of the abuse liability of new 
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agents (Johanson, Balster and Bonese, 1976; Bozarth and Wise, 1985; Nader and 
Woolverton, 1992). 
Cocaine functions as a positive reinforcer to maintain self-administration in a 
variety of species, including humans, by several routes of administration (Johanson and 
Fischman, 1989). In most experiments, cocaine is delivered through a chronically 
indwelling intravenous catheter implanted during brief surgical anaesthesia. Rates and 
patterns of responding maintained by cocaine are determined for the schedule of 
reinforcement under which the drug is available (Woolverton and Johnson, 1992). 
Although cocaine is a highly efficacious positive reinforcer, environmental manipulations 
such as punishment, increasing the effort required to obtain the drug, or offering 
alternative reinforcers, are effective in decreasing cocaine self-administration (Johanson 
and Fischman, 1989; Carroll et aI., 1989; Nader and Woolverton, 1991). Pharmacological 
manipUlations can also increase the self-administration rate on a simple fixed ratio 
schedule resembling decreases in the unit dose, hence causing a shift to the right of the 
dose effect function and a decrease in the reinforcing potency of cocaine (Wilson and 
Schuster, 1972; Roberts and Vickers, 1984; Bergman et aI., 1990; Caine and Koob, 
1994). For example, low to moderate doses of DA receptor antagonists can increase 
cocaine self-administration maintained on such a schedule in a manner similar to 
decreasing the unit dose of cocaine (Wilson and Schuster, 1972; Roberts and Vickers, 
1984; Bergman et aI., 1990; Caine and Koob, 1994). This suggests that partial blockade 
ofDA receptors by competitive antagonists can reduce the reinforcing potency of cocaine 
(Koob, 1995). Conversely, DA agonists decrease cocaine self-administration in a manner 
similar to increasing the unit dose of cocaine (Yorkel and Wise, 1978; Woolverton et aI., 
1981; Self and Stein, 1992; Weed et aI., 1993), suggesting that the effects of 
administering DA agonists together with cocaine can be additive, perhaps due to their 
mutual activation of the same neural substrates. 
The use of different schedules of reinforcement in drug self-administration can 
provide important controls for non-specific motor and motivational factors. For example, 
.-/ 
fixed-interval schedules of self-administration can be designed to measure response rate 
independently of frequency of reinforcement (Altman et aI., 1996). Progressive ratio 
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schedules have been used to evaluate the reinforcing efficacy of cocaine by increasing the 
response requirements for successive reinforcements and determining the breaking point, 
i.e. the point at which the animal will no longer respond. A variety of evidence supports 
the hypothesis that this schedule is effective in determining the rank order of reinforcing 
efficacy for different reinforcers, including cocaine (Griffiths et aI., 1978; Roberts et aI., 
1989). 
Intravenous drug self-administration in animals is reliable and has predictive 
validity. The dependent variable is reliable as a measure of the motivation to obtain drugs 
(the amount of work an animal will perform to obtain the drug). It also has predictive 
validity because doses of drugs that are highly reinforcing in animals are reported to have 
reinforcing effects in humans, as measured by both operant tests and subjective reports. 
Construct validity refers to the extent to which the model has a sound theoretical 
rationale; its evaluation requires a good theoretical understanding of both the model and 
the condition modelled. Unfortunately, both sides of this equation are rarely met; in the 
present case, drug intake by animals is now well understood (at least under steady-state 
conditions), but a coherent theoretical understanding of substance abuse by people 
remains elusive. It is difficult to assess the construct validity of the self-administration 
model because of the tenuous nature of the constructs of abuse and dependence. 
However, some of the findings from self-administration studies potentially have profound 
implications for the construct of dependence (e.g. with reference to the importance of 
withdrawal in dependence). 
1.6.2 Conditioned Place Preference 
The reinforcing effects of cocaine have also been investigated usmg place-
conditioning procedures (e.g. Spyraki et aI., 1982; Schenk et aI., 1986; Morency and 
Benninger, 1986). In such studies, a distinctive environment is paired repeatedly with 
administration of drug, and a different environment is associated with the undrugged 
state. Typically, the environments differ with respect to visual cues (e.g. brightness), 
tactile cues (e.g. textured floors}andlor odour. Reinforcement is measured as an increase 
in the time spent in the compartment previously paired with drug. It is assumed that the 
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environmental cues take on secondary (conditioned) reinforcing effects due to their 
previous temporal association with the effects of the drug itself, and that the animals are 
displaying approach behaviour directed towards these conditioned reinforcers (Stolerman, 
1992). Evidence that this effect is related to classical conditioning was provided by Bardo 
et al. (1986) since partial reinforcement (i.e. sometimes exposing the animal to the 
chamber, or CS, in the absence of drug) attenuated the place preference. The advantages 
of place conditioning as a model for evaluating cocaine's effects are similar to those of 
drug self-administration, but also include (a) a high sensitivity to low doses of cocaine; 
(b) potential utility in studying both sides of hedonic valence (e.g. both positive and 
negative reinforcement); (c) testing for drug reinforcement is under drug-free conditions 
and (d) it allows for precise control over the interaction of environmental cues with drug 
administration (Carr et aI., 1989). The major disadvantages of place conditioning are the 
enormous cost, effort and time required to generate meaningful results. 
To what extent does the conditioned place preference procedure meet the various 
criteria by which an animal model of drug dependence should be assessed? The model 
has a reasonable degree of predictive validity. The procedure has as not yet been used to 
compare drugs in terms of their relative abuse potential: it therefore is less useful in this 
respect than the self-administration model. Indeed, it is often difficult to generate graded 
dose effect curves with anyone drug (Carr et aI., 1989) so it is difficult even to compare 
the relative efficacies of different doses of the same drug. As far as face validity is 
concerned, the procedure makes no attempt to model the symptomatology of drug abuse, 
although people may well seek out drug-associated stimuli and environments for their 
conditioned incentive effects. Thus the model may possess face validity to an extent that 
remains to be seen. The conditioned place preference procedure gains most of its 
validation from the fact that it is a measure of drug-induced reward. As this concept is 
central to most conceptualisations of drug abuse, the model clearly has some degree of 
construct validity. However, conditioned place preference models are not 'pure' measures· 
of reward, but they do provide a useful alternative to the self-administration procedure. 
-~ 
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1.6.3 Drug Discrimination 
Individual's feelings are said to be private events that can only be revealed by 
verbal, written, or other modes of communication unique to humans. Because of this, the 
development of animal models of subjective drug effects poses a substantial challenge. A 
methodology holding considerable promise in this regard is drug discrimination 
(Holtzman, 1990). In a typical drug discrimination experiment, animals are injected with 
drug or placebo on separate test sessions. Depending upon which solution is 
administered, responding on one of two levers results in the delivery of a reinforcer 
(usually as food) according to a particular schedule of reinforcement. Stimuli that are 
uniquely associated with the availability of a reinforcer are called 'discriminative stimuli' 
when they acquire control over the frequency of a response that is reinforced in their 
presence. The accuracy of the discrimination can be tested by administering the training 
drug or placebo during test sessions. Sensitivity and specificity of the discrimination are 
evaluated by administering different doses of the training drug and other test drugs. Test 
drugs may include those that are likely to be discriminated as the training drug (usually 
drugs from the same pharmacological class) or positive controls (usually compounds 
from different pharmacological classes). 
Animals readily learn to discriminate cocaine from vehicle injections. 
Discriminative control by cocaine in rats was first shown by Colpaert, Niemegeers and 
Janssen (1976), and has been demonstrated subsequently in other species, such as 
pigeons, rhesus monkeys and squirrel monkeys (de la Garza and Johanson, 1983; 1985; 
Woolverton and Trost, 1978). Discrimination of cocaine from saline can be achieved 
under a variety of schedule conditions and different routes of administration. Wood et ai. 
(1987) demonstrated that the DS properties of cocaine were mediated centrally by 
showing that intracerebroventricular (i.c.v.) injections resulted in cocaine-appropriate 
responding in rats trained to discriminate intraperitoneal (i.p.) cocaine from saline. 
Evaluation of the DS effects of cocaine has shown the drug to be similar to other· 
psychomotor stimulants. For instance, in studies with animals trained with either cocaine 
------or amphetamine, generalisation tests have shown that the DS effects of these drugs fully 
cross-generalise (Emmett-Oglesby et aI., 1983). A number of good reviews can be found 
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on drug discrimination methodology (e.g. Jarbe, 1989; Holtzman, 1990; Goudie, 1991; 
Goudie and Leathley, 1993), of which a summary is given below. 
1.6.4 Methods of Training and Testing For Drug Discrimination Procedures 
A. Species 
Drug discrimination studies have been conducted usmg a variety of animal 
species, including rats, mice, gerbils, pigeons, rhesus and squirrel monkeys. However, 
there have been no indications of species differences between these studies. Therefore, 
the choice of species can be based upon cost factors, research facilities available and 
personal experience and preference. 
B. Paradigm 
Virtually all drug discrimination studies today are carried out usmg operant 
behavioural procedures. Most commonly, differential responding for drug and vehicle is 
maintained by food reinforcement. For example, a rat is placed in a standard operant 
chamber with two levers as the response manipulanda (Figure 1.3). The rat is trained to 
press one lever during sessions that follow injection of the training drug, and to press the 
other lever during sessions that follow injection of drug vehicle. The rat receives a food 
pellet for emitting a particular number of responses (e.g. FRIO or FR20, fixed ratio of 10 
or 20 responses, respectively) on the injection-appropriate lever. Various schedules of 
reinforcement are commonly used. For example, in fixed interval schedules (FI), 
responding is reinforced for the first response x seconds after the last reinforcement, and 
in fixed ratio schedules (FRn) , responding is reinforced on the last response of a fixed 
number (n) of responses. Responding may also be maintained by variable interval (VI) or 
variable ratio (VR) schedules where the response requirements are expressed as an 
average for a range of possible values. 
When animals are responding reliably (both levers) on the appropriate schedule, 
discrimination training begins with the drug arid its vehicle being administered in a· 
pseudorandom sequence prior to testing. Drug and vehicle sessions are held on different 
-~ 
days according to a single alternation schedule (e.g. Drug, Vehicle, Drug, Vehicle, Drug, 
Vehicle, etc.), or by double alteration schedules (e.g. drug, drug, vehicle, vehicle, etc.), or 
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Figure 1.3. A rat in one of the operant chambers. The rat is trained to press the levers (response) to activate a food 
delivery mechanism (reinforcement). 
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some other balanced schedule of treatment. Numerous variations of this sort of sequence 
can be devised, but the alternation scheduies have numerous advantages, such as (Goudie 
and Leathley, 1993): 
1. To avoid lever bias, there are equal numbers of drug and vehicle sessions. 
2. To facilitate learning there are not more than about two to three consecutive sessions 
of administration of either drug or vehicle. 
Operant sessions usually run for 15-30 min, and the animals are typically maintained at 
approximately 80% of their ad-lib body weights. To avoid any effects of inherent lever 
bias, for half of the group of animals the drug-appropriate lever should be different from 
that of the other half. Even though studies often differ in methodology, these 
methodological differences do not seem to make much difference to the results. 
C. Assessment of Discriminative Responding 
During training, the development of discriminative control over lever selection 
can be measured by recording the total number of responses accumulated by each 
individual animal on both levers prior to presentation of the first reinforcer or over a 
series of reinforcers. Results are usually derived in one of two ways. With the 
'quantitative' method, the amount of responding on the lever appropriate to the training 
drug is expressed as a percentage of the total number of responses emitted during a test 
epoch (i.e. drug-appropriate plus vehicle-appropriate responses). The 'quantal' method 
derives from the view that discrimination of drug-induced stimuli is an all-or-none event 
rather than occurring along a stepwise continuum of intensity. The subject either does or 
does not discriminate the test drug as being similar to the training drug. With the quantal 
method, the percentage of animals receiving the first reinforcement of the session on the 
drug-appropriate lever is the principal dependent measure (rather than percentage of drug-
appropriate responses). Quantal assays are necessarily only used with large groups 
(typically, N>8) since each subject on test will only generate one data point (that is, the 
subject will make only one of the two possible response options). In contrast, with 
quantitative assays, it is possible to obtain from a single subject a dose-response curve 
~ 
since, in repeated tests with different doses, the subject will emit quantitatively different 
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degrees of responding. Thus, if one is working with a restricted number of animals, it is 
more appropriate to use a quantitative assay (Goudie and Leathley, 1993). 
D. Training Dose 
The rate at which a discrimination is learned is a key factor in choosing a training 
dose. Therefore, the optimal procedure is to use a large dose so that the discrimination 
can be learned relatively rapidly. In studies requiring low training doses, it is possible to 
train animals initially to discriminate a higher dose and then to 'fade' the dose down to a 
level that animals would not have been able to discriminate if they had been trained on it 
initially. However, such 'fading' techniques take a considerable amount of time and 
therefore have practical limitations (Holtzman, 1990). Most studies assessing cocaine's 
DS effects in rats have used a training dose of 10 mg/kg (e.g. Barrett and Appel, 1989; 
Broadbent et aI., 1989; Callahan et aI., 1991; Callahan and Cunningham, 1991; Baker et 
aI., 1993). However, lower training doses of cocaine (e.g. 3 mg/kg) have also been used, 
and such studies have sometimes demonstrated qualitative as well as quantitative 
differences in the drug substitution profiles of compounds (e.g. Terry et aI., 1994). 
Recently, a novel discrimination procedure has been devised, whereby rats are trained to 
discriminate between two doses of cocaine (2.5 vs. 10 mg/kg; Kleven and Koek, 1998). 
The authors claimed an advantages of the dose versus dose discrimination procedure for 
interaction studies, since sensitivity to pre-treatments may be enhanced as a consequence 
of the steeper dose-response function in dose-dose trained animals. Compounds that 
partially substitute in drug versus saline trained animals are therefore expected to 
engender primarily low-dose lever selection, so minimising the influence of baseline, 
high-dose-Iever selection following pre-treatments that may have partial cocaine-like 
effects when given alone. 
E. Pharmacological Characteristics of Discriminative Stimulus Control 
An important attraction of the drug discrimination methodology is that for many 
classes of drugs the discriminative stimulus effects satisfy the criteria for receptor-
mediated events. For example: _____ 
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1. Drugs that interact with the same defined population of receptors on other assay 
systems have qualitatively similar discriminative stimulus properties, as reflected by 
their ability to generalise with one another. 
2. Drugs do so with an order of potency that parallels their potencies in those other assay 
systems. 
3. Antagonists that bind reversibly to the receptor block the discriminative effects of 
drugs of the same class in a competitive (i.e. surmountable) manner (Holtzman, 
1990). 
These features enable the investigator to determine dose-response curves; slopes can then 
be compared and differences in the potencies of drugs can be established. Hence, the 
drug discrimination procedure provides a discrete and objectively quantifiable 
behavioural endpoint that reflects the actions of a drug at the cellular level (Slangen, 
1991). In summary, the drug discrimination procedure has relatively low predictive 
validity as a model of abuse potential, since many drugs (some of which are not abused 
by humans) act as discriminative stimuli. The model does have some predictive value in 
that it has a high degree of pharmacological specificity, and allows researchers to 
compare novel drugs with known drugs of abuse, and to determine whether they have 
similar mechanisms of action. However, the model does not attempt to reflect aspects of 
the symptomatology of drug abuse (face validity). But the model implies that human 
'subjective' responses to drugs of abuse, which are important determinants of abuse 
potential, can be measured in animals (Goudie, 1991). 
1.6.5 Reasons for Using The Drug Discrimination Model 
The advantages of intravenous self-administration and drug discrimination as 
preclinical models for studying the psychological effects of drugs are several. Drug self-
administration has potential utility in studying both the positive and negative reinforcing 
effects of drugs. Both procedures have predictive validity and are reliable. They also lend 
themselves to within-subjects designs, limiting the number of subjects required. Indeed, 
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once an animal is trained, full dose-effect functions can be generated for different drugs, 
and the animal can be tested for weeks or months. 
The disadvantages of intravenous self-administration are largely technical. Special 
skills and procedures are required to implement and maintain a chronic catheter 
preparation, and success in maintaining viable catheter preparations in rodent studies can 
be difficult to achieve. Disadvantages of drug discrimination studies are that subjects 
receive numerous doses of the training drug and any neuropharmacological changes 
caused by such phenomena as sensitisation or tolerance cannot be measured easily. 
However, tolerance and sensitisation to cocaine's effects do not usually seem to occur as 
indicated by test-retest similarities of dose-response curves (Emmett-Oglesby et aI., 
1983). The major disadvantage of place conditioning is the enormous cost, effort, and 
time required to generate results. Each drug dose requires testing 8-12 animals in an 
independent (between subjects) design, and although each animal is tested numerous 
times it yields only one independent data point. Also, there is some concern, as 
mentioned previously, as to what precisely is being measured in the model. 
The importance of animal models used to measure the psychological effects of 
cocaine lies in the assumption that the findings obtained in the animal models will have 
relevance to the problems of drug abuse and addiction in man. Certainly, some animal 
models can predict abuse potential, but the value of these animal models goes far beyond 
just the capacity to predict abuse potential. Animal models can provide a means of 
studying both the behavioural and biological bases of drug addiction. The drug-
discrimination method will therefore be used as a model to examine DA receptor subtype 
involvement in cocaine's effects. 
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CHAPTER 2: 
DOPAMINE RECEPTOR SUBTYPE INVOLVEMENT IN THE 
DISCRIMINATIVE STIMULUS EFFECTS OF COCAINE 
2.1 Introduction 
Drug discrimination procedures have been particularly useful in characterising 
the neuronal mechanism(s) underlying the in vivo effects of cocaine. Cocaine has 
been known for a long time to serve as a discriminative stimulus and has been 
extensively studied in this regard. For example, in 1976 Colpaert and colleagues were 
first to demonstrate that 10 mg/kg of cocaine could function as a DS in rats (Colpaert 
et aI., 1976). Many subsequent studies have shown that cocaine is capable of 
controlling differential responding in a variety of other species including pigeons (e.g. 
de la Garza and Johanson, 1985; Jarbe, 1981, 1984) squirrel monkeys (e.g. 
Woolverton and Trost, 1978) and rhesus monkeys (e.g. de la Garza and Johanson, 
1983). Furthermore, the cocaine/saline discrimination can be trained under a variety 
of schedule conditions and using different routes of administration. The purpose of the 
present chapter is to provide a brief review of the scientific evidence that supports 
dopaminergic involvement in the DS effects of cocaine and to identify research 
questions that need to be answered in order to further elucidate these neurochemical 
processes. 
2.2 Effects of Monoamine Re-uptake Inhibitors: 
DA appears to play a prominent role in the DS effects of cocaine. DA re-
uptake inhibitors such as GBR 12909, mazindol, nomifensine and bupropion readily 
substitute for cocaine in rats (Broadbent et aI., 1991; Cunningham and Callahan, 
1991; Witkin et aI., 1991; Baker et aI., 1993), monkeys (Kleven et aI., 1990; 
Spealman, 1995), pigeons (Johanson and Barrett, 1993), and mice (Middaugh et aI., 
1998) trained to discriminate cocaine from saline (Table 2.1). These findings 
consistently indicate that the DS properties of cocaine are reproduced by compounds 
------that block DA re-uptake. In contrast, selective noradrenergic (NE) and serotonergic 
(5-HT) uptake inhibitors do not produce responding on the cocaine-appropriate lever. 
However, there have been reports that NE may playa more important role when low 
training doses of cocaine are used (Terry et aI., 1994), or in species 
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TABLE 2.1 
Summary of substitution tests with monoamine re-uptake inhibitors assessed in species trained to discriminate cocaine from saline. 
Study 
Kleven et al. (1990) 
Broadbent et al. (1991) 
Cunningham and Callahan 
(1991) 
Witkin et al. (1991) 
Baker et al. (1993) 
\ 
Species Dose (mg/kg) 
Rhesus Monkeys 0.2 - 0.4 
Rat 10.0 
Rat 10.0 
Rat 10.0 
Rat 10.0 
40 
Drug Used 
GBR 12909 (DA) 
Mazindol 
Nomifensine 
Bupropion 
Tomoxetine (NE) 
Nisoxetine 
Fluoxetine (S-HT) 
Nomifensine (DA) 
GBR 12909 
Bupropion 
Nisoxetine (NE) 
Desipramine 
Imipramine 
GBR 12909 (DA) 
Desipramine (NE) & 
Fluoxetine (S-HT) 
GBR 12909 (DA) 
WIN3S,428 
Mazindol 
Mazindol (DA) 
Nomifensine 
GBR 12909 
Bupropion 
Desipramine (NE) 
Citalopram 
Fluoxetine (S-HT) 
Comment 
Generalisation to cocaine 
No effect 
No effect 
Complete substitution. Order of potency : 
Nomifensine > GBR 12909> Bupropion 
Partial effect 
Complete substitution 
No effect by itself - coadministration with low 
doses of cocaine enhanced discriminative 
stimulus effects of cocaine 
Full substitution 
Complete substitution. Order of potency: 
Mazindol > Nomifensine > GBR 12909 > 
Bupropion 
Partial effect 
No effect 
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Johanson and Barrett Pigeons 1.0 - 1.7 L-deprenyl(DA) Substitution 
(1993) Imipramine (NE) 
Tomoxetine 
Bupropion 
Fluoxetine (5-HT) Partial substitution 
GBR 12909 (DA) 
Terry et al. (1994) Rat 3.0 WIN 35,428 (DA) Fully substituted for cocaine 
GBR 12909 
Tomoxetine (NE) Fully substituted for cocaine 
Nisoxetine (NE) 
Fluoxetine (5-HT) No effect 
\ 
Squirrel Monkeys GBR 12909 (DA) Substituted for all conditions Spealman (1 995a) 0.18-1.0 
Talsupram (NE) Substituted for cocaine for low dose training 
Tomoxetine conditions 
Nisoxetine 
Desipramine 
Schama et al. (1997) Squirrel Monkeys 0.3 - 1.0 Fluoxetine (5-HT) No effect on its own - In combination with cocaine 
enhanced discriminative stimulus effects of 
cocaine 
Middaugh et al. (1998) Mice 10.0 Mazindol (DA) Substituted completely for cocaine 
Nomifensine 
Nisoxetine (NE) No effect 
Fluoxetine (5-HT) No effect 
Kleven and Koek (1998) Rat 2.5 vs. 10.0 Paroxetine Citalopram (5-HT) Dose-related increases in high dose lever selection 
Fluoxetine Alaproclate when injected with combination oflow training 
dose of cocaine 
Desipramine Talsupram (NE) Same as above 
Nortriptyline 
Nisoxetine (NE) Intermediate levels of responding 
Key: (DA) - Dopaminergic, (NE) - Noradrenergic, (5-HT) - Serotonergic mediated events. 
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other than rodents, since Johanson and Barrett (1993) and Spealman (1995) showed 
that NE re-uptake inhibitors substitute for cocaine in pigeons and squirrel monkeys, 
respectively. Nevertheless, drug discrimination studies suggests that DA plays a more 
important role in the behavioural effects of cocaine than NE: compounds that act 
primarily through noradrenergic (NE) mechanisms (e.g. desipramine, imipramine, 
nisoxetine) substitute fully for cocaine in squirrel monkeys (Spealman, 1995a) at best 
only partially in rats (Broadbent et aI., 1991; Baker et aI., 1993) or not at all in mice 
(Middaugh et aI., 1998). By contrast, the highly selective DA re-uptake inhibitor, 
GBR 12909, substitutes completely for cocaine in both monkeys (Kleven et aI., 1990; 
Spealman, 1995a) and rats (Broadbent et aI., 1991; Cunningham and Callahan, 1991; 
Witkin et aI., 1991; Baker et aI., 1993) regardless of training dose. It could be that 
species andlor training conditions are important determinants of the extent to which 
NE is involved in the DS effects of cocaine. Even so, taken together with findings that 
selective NE inhibitors enhance the DS effects of cocaine in rats and non-human 
primates (Kleven et aI., 1990), it is conceivable that NE may exert a modulatory 
function in both species .. 
Likewise, the involvement of 5-HT in the DS effects of cocaine should not be 
discounted. 5-HT re-uptake blockade reliably enhances the DS effects of cocaine 
when combined with cocaine (Cunningham and Callahan, 1991; Schama et aI., 1997; 
Kleven and Koek, 1998), but has negligible effects when tested alone for substitution 
in a variety of species (Kleven et aI., 1990; Baker et aI., 1993; Terry et aI., 1994, 
Middaugh et aI., 1998). Also, Schama et aI. (1997) showed that fluoxetine, a 5-HT re-
uptake inhibitor, did not substitute for cocaine in squirrel monkeys trained to 
discriminate a range of cocaine doses (0.3 - 10 mg/kg), but in combination with a low 
dose of cocaine it enhanced the DS effects of cocaine. In a different discrimination 
procedure, where rats were trained to discriminate between two doses of cocaine (2.5 
vs. 10 mg/kg; Kleven and Koek, 1998) it was shown that paroxetine, citalopram, 
fluoxetine, and alaproclate (all 5-HT re-uptake inhibitors), as well as desipramine, 
~. 
talsupram and nortriptyline (all NE re-uptake inhibitors) caused dose-related increases 
in high-dose lever selection when injected in combination with the low training dose 
of cocaine. It has been suggested that, like NE re-uptake inhibition, 5-HT re-uptake 
blockade may playa modulatory function in the DS effects of cocaine (see Walsh and 
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Cunningham, 1997, for review). In conclusion, the evidence so far points to DA as 
being paramount to the DS effects of cocaine. If this is the case, then it is important to 
evaluate the effects ofDA receptor-selective compounds in rats trained to discriminate 
cocaine from saline in order to determine whether specific DA receptors are critical to 
cocaine's DS effects. 
2.3 Effects of D1-like and D2-like Agonists: 
Over recent years, extensive work has been carried out to identify the relative 
contriljutions of different DA receptor subtypes to the DS effects of cocaine. Several 
studies have addressed this question by examining the effects of selective DA receptor 
agonists in subjects trained to discriminate cocaine from saline injections. For 
example, Barrett and Appel (1989) found that the D2-like agonist, quinpirole, fully 
substituted for cocaine in rats trained to discriminate 10 mg/kg cocaine from saline. In 
contrast, the D1-like agonist, SKF 38393, produced a maximum of only 40 % drug-
appropriate responding in· the same subjects. Other studies with rats have found 
qualitatively similar effects, although the maximal effects of the agonists have varied. 
For example, quinpirole has been reported to produce approximately 85 % (Callahan, 
Appel and Cunningham, 1991; Callahan et al., 1991; Callahan and Cunningham, 
1993) or 40 % (Witkin et al., 1991; Callahan, Appel and Cunningham, 1991) cocaine-
appropriate responding; SKF 38393 has been reported to produce approximately 75 % 
(Callahan et al., 1991) or 60 % (Witkin et al., 1991) cocaine-appropriate responding 
(Table 2.2). However, it is clear that both quinpirole and SKF 38393 substitute to 
some extent for cocaine. These findings have led to the conclusion that effects 
mediated by both D1-like and D2-like receptors contribute to the effects of cocaine, 
but that stimulation of either receptor subtype alone is generally not sufficient to fully 
reproduce the DS effects of cocaine (Witkin et al., 1991). 
In contrast to the data from rats, neither SKF 38393 nor quinpirole produced 
any cocaine-like responding in rhesus monkeys trained to discriminate cocaine from 
saline (Kleven et al., 1990), al!!J.Ough both D1-like and D2-like agonists have been 
shown to substitute near-fully in squirrel monkeys (Spealman et al., 1991). Katz and 
Witkin (1992) showed that when SKF 38393 and quinpirole were combined in 
. squirrel monkeys trained to discriminate cocaine from saline, the combinations was no 
more effective than quinpirole alone. In pigeons, these two drugs only produce partial 
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TABLE 2.2 
Summary of substitution tests with DA receptor agonists assessed in species trained to discriminate cocaine from saline. 
Study Species Dose (mg/kg) Drug Used Comment 
Barrett and Appel (1989) Rat 10.0 SKF 38393 (Dl) No effect 
Quinpirole (D2) Complete generalisation 
Kleven et al. (1990) \ Rhesus Monkeys 0.2 - 0.4 SKF 38393 (Dl) No effect Quinpirole (D2) 
Spealman et al. (1991) Squirrel Monkeys 0.3 SKF 82958 (Dl) Substitution on average of only 54 - 77% 
SKF 82917 responding 
[(+) - PHNO] (02) 
Quinpirole 
Quinelorane 
CY 208-248 
(-) - apomorphine (DIID2) 
Callahan and Cunningham Rat 10.0 SKF 38393 (01) Partial substitution 
(1991) Quinpirole (D2) Full substitution 
Callahan, Appel and Rat 10.0 SKF 38393 (01) Partial substitution 
Cunningham (1991) Quinpirole (D2) Full substitution 
Witkin et al. (1991) Rat 10.0 (-) - apomorphine (DI/D2) Full substitution 
SKF 38393 SKF 75670 (DI) Partial substitution (40-80%) 
CY 208-243 Pergolide (D2) 
(-) - NPA RU 24213 
N-0434 N-0437 
Katz and Witkin (1992) Squirrel Monkeys 0.3 SKF 38393 (01) No effect 
Quinpirole (D2) Partial generalisation 
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Johanson and Barrett (1993) 
Callahan and Cunningham 
(1993) 
Terry et aJ. (1994) 
Spealman (1 995b) 
Vanover and Woolverton 
(1994) 
Acri et a!. (1995) 
Lamas et aJ. (1996) 
Spealroan (I 996) 
\ 
Pigeons 1.0 - 1. 7 
Rat 10.0 
Rat 3.0 
Squirrel Monkeys 0.3 
Rhesus Monkeys 0.2 - 0.4 
Rat 10.0 
Rhesus Monkeys 0.4 
Squirrel Monkeys 0.3 
Key: (DA) - Dopaminergic, (D1) - DA D1 receptor, (D2) - DA D2 receptor mediated events. 
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(SKF 38393 and Quinpirole combined) 
SKF 75670 (Dl) 
Quinpirole (D2) 
Bromocriptine Quinpirole 
(Full D2 agonists) 
Not effective when compared to quinpirole alone 
Partial substitution 
Complete substitution 
Preclamol Terguride Less than 50% responding 
(partial D2 agonists) 
SKF 38393 SKF 77434 (01) Fully substituted for cocaine 
SKF 75670 
Quinpirole (D3/D2) Fully substituted for cocaine . 
N-0434 (-) - NPA (D2) < 32% responding 
SDZ208-912 
Terguride SDZ 208-911 No effect 
SDZ208-912 
(partial D2 agonists) 
PD 128483 
(High affinity partial D2 
agonist - DA autoreceptors) 
(+) - PD 128907 (D3/D2) 
(±) - 7 -OH-DPA T 
Quinpirole (03/D2) 
(±) -7-0H-DPAT 
PD 128907 (03/D2) 
(±) -7-0H-DPAT 
Quinpirole 
Substituted for cocaine - did not work as an 
antagonist 
Substituted for cocaine 
Completely generalised to cocaine 
Complete generalisation in 2/4 monkeys 
PartiaJly reproduce the discriminative stimulus 
effects of cocaine. Additive when combined with 
cocaine 
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substitution (Johanson and Barrett, 1993). 
Together, these results suggest that species difference may be important in 
evaluating the DS effects of cocaine, especially with regard to D 1 receptor 
involvement. For example, recent findings have shown that the efficacies of the D1-
like agonists SKF 38393, SKF 81297 and R(+)-6-Br-APB in stimulating adenylate 
cyclase activity in caudate membranes of squirrel monkeys is limited compared to rats 
(lzenwasser and Katz, 1993). This implies that the behavioural effects ofDA D1-like 
agonists in monkeys will not always correspond to their effects on the activity of 
adenylate cyclase in rats. In addition, the apparently different interoceptive effects of 
SKF 38393, on the one hand, and SKF 81297 / SKF 82958 on the other, may reflect 
differences in the intrinsic activity of these drugs at DA D1-like receptors. Whereas 
SKF 38393 is less effective than DA in stimulating adenylate cyclase in vitro, SKF 
81297 and SKF 82958 have efficacies approaching or exceeding that of DA itself 
(Andersen and Jansen, 1990). 
Studies of DA receptor involvement in the DS effects of psychostimulants 
other than cocaine, such as amphetamine, and other indirect agents such as GBR 
12909 and bupropion, have yielded both similar and dissimilar results. For example, 
neither the full DA D1-like agonist SKF 81297 nor the partial DA D1-like agonist 
SKF 38393 generalise to amphetamine (Amt, 1988; Nielsen et aI., 1989; Callahan et 
aI., 1991; Vangroll and Appel, 1992) suggesting that DA D1-like receptors are not 
critically involved in mediating the amphetamine cue. However, agonists of the DA 
D2-like receptor family, such as quinpirole, pergolide and piribedil, do generalise to 
amphetamine in various species (Amt, 1988; Nielsen et aI., 1989; Sasaki et aI., 1995), 
although negative results have been reported by Vangroll and Appel (1992) using 
quinpirole. A similar lack of substitution by SKF 38393 has also been observed in 
monkeys trained to discriminate GBR 12909 from saline (Kamien and Woolverton, 
1989; Melia and Spealman, 1991). Partial substitution was also only found for D1-like 
and D2-like drugs in rats trained to discriminate bupropion from saline (Terry and 
-------Katz, 1997). In conclusion, these studies involving DA receptor subtypeagonists 
suggest that amphetamine and GBR 12909 produces DS effects which are different 
from those of cocaine. However, more work still needs to be carried out with GBR 
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12909. The results for bupropion, on the other hand, indicate that it may well share 
similar actions to cocaine. 
Although differences in training parameters or species may explain the partial 
substitution of Dl-like and D2-like agonists for cocaine (Kamien and Woolverton, 
1989; Kleven et aI., 1990; Witkin et aI., 1991; Spealman et aI., 1991) it might also be. 
explained by the choice of dose and/or pre-treatment intervals at which these agonists 
preferentially stimulate post synaptic receptors (Callahan and Cunningham, 1993). 
For example, by extending the pre-treatment time for bromocriptine and quinpirole 
(D2-like agonists), Callahan and Cunningham (1993) obtained full substitution of 
these drugs for cocaine, whereas they obtained only partial substitution at shorter pre-
treatment times. 
Partial D2-like receptor agonists, such as preclamol and terguride, have been 
shown to antagonise the cocaine DS (Callahan and Cunningham, 1993). The authors' 
explanation of this effect was that partial D2-like agonists may act as 'buffers' to 
reduce excessive dopaminergic activity, while their weak agonist activity maintains 
sufficient postsynaptic dopaminergic tone. Thus, the pharmacological profile of a 
compound with low intrinsic activity would shift from that of an agonist to an 
antagonist in the presence of an endogenous ligand competing for the same receptor. 
However, in another study the putative partial DA D2-like agonists SDZ 208-911 and 
SDZ 208-912 had no such effects in squirrel monkeys (Spealman, 1995). 
Most studies therefore have not indicated a preferential involvement of one 
class of receptor over the other; however, DA Dl-like receptors may be more 
important at low training doses of cocaine in rats (Terry et aI., 1994; Kantak et aI., 
1995). Training rats to discriminate a low dose of cocaine from saline can alter the 
profile ofDA receptor subtype agonist substitution, with Dl-like agonists substituting 
fully and D2-like agonists showing either full (quinpirole) or minimal substitution 
((-)-NPA, N-0434, SDZ 208-912). Given that quinpirole has a higher affinity for the 
D3 than the D2 receptor (Sokoloff et aI., 1990), differential selectivities at subtypes of 
D2-like receptors may exprain some of the different outcomes described above. 
However, in no previous experiments using a training dose of 10 mg/kg cocaine have 
Dl-like agonists fully substituted or substituted for cocaine more completely than D2-
like agonists (Barrett and Appel, 1989; Witkin et aI., 1991; Callahan et aI., 1991). The 
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findings therefore suggest a preferential effect of relatively high doses of cocaine (10 
mg/kg) at the D2-like receptor subtype, with increasing Dl-like receptor involvement 
at lower training doses. 
Little is known concerning the effects of agonists at specific DA receptor 
subtypes within each of the two receptor sub-families (i.e. the DA Dl, D5, and D2, 
D3, D4 receptors). Acri et ai. (1995) demonstrated full substitution of a relatively 
selective DA D3 receptor agonist (PD 128907) for the DS effects of cocaine, albeit at 
doses where response rates were very low. This has been supported in other species 
using the D3/D2 agonists quinpirole and (±) 7-0H-DPAT (Lamas et aI., 1996). 
Spealman (1996) showed that these same compounds, together with PD 128907, only 
partially reproduced the DS effects of cocaine in squirrel monkeys, but there was an 
additive effect in combination with a low dose of cocaine. Since these compounds are 
not completely selective for the DA D3 receptor subtype or may be functionally more 
active at D2 sites, the possibility that substitution for cocaine occurs via the DA D2-
receptor subtype cannot be ruled out. In conclusion, it can be said that Dl-like and 
D2-like agonists substitute at least partially for cocaine, with D2-like agonists being 
more efficacious at high training doses. 
2.4 Effects of 01-like and 02-like Antagonists: 
Antagonist experiments further support a role for DA receptors in the DS 
effects of cocaine. The non-selective DA antagonist cis-flupenthixol produces 
rightward shifts in the cocaine-dose response function in squirrel monkeys (Spealman 
et aI., 1991). Studies in rats, monkeys and pigeons have shown that responding on the 
cocaine-trained lever is reduced by treatment with either aDA Dl-like or a D2-like 
receptor antagonist (Kleven et aI., 1988; Barrett and Appel, 1989; Kleven et aI., 1990; 
Witkin et aI., 1991; Spealman et aI., 1991; Callahan et aI., 1991; Baker et aI., 1993 
and Johanson and Barrett, 1993) (Table 2.3). However, studies in rodents have not 
always demonstrated antagonis7the DS effects of cocaine by DA D2-like receptor. 
antagonists (e.g. Barrett and Appel, 1989; Witkin et aI., 1991). Antagonism, especially 
--" 
by the D2-like antagonist haloperidol, has often been less pronounced in rats than in 
primates (Kleven et aI., 1990; Spealman et aI., 1991) even when comparable doses, 
routes of injection and pre-treatment times have been used across species. In an effort 
to resolve these inconsistencies for haloperidol, Callahan and Cunningham (1993) 
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TABLE 2.3 
Summary of antagonism tests with DA receptor antagonists assessed in species trained to discriminate cocaine from saline; plus 
miscellaneous substitution/antagonist tests. 
Study Species Dose (mg/kg) Drug Used Comment 
Kleven et al. (1988) Rhesus Monkeys 0.2 SCH 23390 (01) Blockade of cue 
Barrett and Appel (1989) \ Rat 10.0 SCH 23390 (01) Blockade of cue 
Spiperone (02) Partial blockade of cue 
Haloperidol (02) No effect 
Kleven et al. (1990) Rhesus Monkeys 0.2 - 0.4 SCH 23390 (01) Blockade of cue 
Haloperidol (02) Blockade of cue 
Spealman et al. (1991) Squirrel monkeys 0.3 SCH 39166 (01) Blockade of cue - rightward shifts indicative of 
YM 09151-2 (02) surmountable antagonism 
Cis-flupenthixol (01/02) 
Witkin et al. (1991) Rat 10.0 Haloperidol (02) No effect 
SCH 23390 (01) 50% blockade of cue 
Callahan et al. (1991) Rat 10.0 SCH 23390 (01) Complete attenuation of cue 
Haloperidol (02) 
Baker et al. (1993) Rat 10.0 SCH 23390 (01) Cis-flupenthixol and SCH 23390 showed greater 
Cis-flupenthixol (01102) attenuation than Haloperidol or (±) Sulpiride 
(±) Sulpiride (02) 
Johanson and Barrett (1993) Pigeons 1.0 - 1.7 SCH 23390 (01) Blockade of cue 
Raclopride (02) Blockade of cue 
Callahan and Cunningham Rat 10.0 Bromuride (02) Blockade of cue 
(1993) Haloperidol (02) Blockade of cue 
Callahan et al. (1994) Rat 10.0 Microinjection of Cocaine Into the nucleus accumbens engendered 
full substitution 
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Callahan et al. (1995) Rat 10.0 
Clark et al. (1995) Rat 5.0 
\ 
Geter-Douglass and Riley Rat 7.5 - 13.0 
(1996) 
Meert et al. (1996) Rat 10.0 
Baker et al. (1997) Rat 10.0 
MISCELLANEOUS COMPOUNDS: 
Johanson and Barrett (1993) Pigeons 1.0 - 1.7 
Spealman (1995a) Squirrel Monkeys 0.18 - 1.0 
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Microinjection of SCH 23390 (Dl) 
Systemic administration of cocaine 
Bilateral injections of cocaine into 
central amygdala 
Bilateral injection ofSCH 23390 (Dl) 
into central amygdala 
(-)-DS 121 
(autoreceptor antagonist) 
SCH 23390 (Dl) and 
Haloperidol (D2) combination 
SCH 23390 (Dl) and 
Haloperidol (D2) combination 
PNU-99194A (03) 
8-0H-DPAT (5-HT t. agonist) 
NAN-190 (5-HTta antagonist) 
Prazosin (at antagonist) 
ST 587 & SDZ NYI 085 (at agonist) 
Clonidine & UK 14,304 (a2 agonist) 
Clenbuterol (I3t/2 agonist) 
Completely antagonised when 
administered into nucleus accumbens, a 
dose of cocaine that produced> 90% 
responding 
Produced dose-related increase in 
cocaine-lever responding 
Partial substitution « 60% drug-lever 
responding) 
Blockade of systemic dose of cocaine 
Partially substituted - but not dose-
dependent. Small reduction in 
responding when combined with 
cocaine 
Complete blockade of cue 
Complete antagonism of cueing 
properties of cocaine 
Did not substitute for cocaine nor block 
the cocaine cue, or potentiated a low 
dose of cocaine 
Blockade of cue 
No Effect 
Schama et al. (1997) Squirrel Monkeys 0.3 - 1.0 
Kleven and Koek (1997) Rat 2.5 vs. 10.0 
\ 
Kleven and Koek (1998) Rat 2.5 vs. 10.0 
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prazosin (u) antagonist) 
Efaroxon (U2 antagonist) 
Phentolamine (non-selective u blocker) 
Propranolol (~ blocker) 
Quipazine (non-selective 5-HT agonist) 
Ketanserin & Ri tanserin 
(5-HT2 antagonists) 
(-) - Propranolol (~ blocker) 
Tertatolol (~112 blocker) 
rer 118,551 (~2 blocker) 
Blockade of cocaine cue for both 
training conditions 
No effect 
Generalised to cocaine - additive when 
combined with cocaine 
Attenuation of discriminative stimulus 
effects of cocaine 
Discriminative stimulus effects of 
low dose of cocaine were enhanced by 
pre-treatment with centrally acting 
~ - adrenergic antagonists 
Nadolol (peripheral ~ antagonist) No effect, therefore, ~2 effect 
Betaxolol (centrally active ~) antagonist) 
Prazosin (u) antagonist) Did not decrease cocaine-enhancing 
effects of Desipramine - suggesting 
negligible NE activity. However it did 
reverse enhancing effects of 
(-) - Propranolol suggesting that NE 
mechanisms may mediate the DS effects 
of cocaine 
Key: (DA) - Dopaminergic, (DI) - DA DI receptor, (D2) - DA D2 receptor, (5-HT) - Serotenergic, (u and ~) - Noradrenergic mediated events 
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demonstrated that by increasing the time interval from 30 min to 120 min between 
injection of haloperidol (0.5 mg/kg) and testing for recognition of the cocaine cue in 
rats the percentage of cocaine antagonism increased from 20% to 85%. Thus, 
antagonism of the DS effects of cocaine in rats by haloperidol appears to require 
optimal DA D2-like receptor occupancy~ 
The finding that the selective Dl-like antagonist SCH 23390 blocks the 
cocaine cue more effectively than haloperidol is consistent across species (e.g. in rats: 
Barrett and Appel, 1989; Callahan et aI., 1991; Witkin et aI., 1991; Baker et aI., 1993; 
in monkeys: Kleven et aI., 1990), and supports the view that Dl-like receptors playa 
particularly important role in cocaine's DS effect. However, the significance of 
cocaine's indirect effects at D2-like receptors should not be downplayed since in 
addition to reports of antagonism by haloperidol, both sulpiride and YM-0915-2 (D2-
like antagonists) reliably suppress cocaine-lever responding (Baker et aI., 1993; 
Spealman et aI., 1991). In addition to the influence of pre-treatment time, the 
occasional inconsistencies with D2-like receptor antagonists may be related to factors 
such as the age of the animals, their previous drug history, animal species (monkeys 
versus rats), doses and routes of cocaine administration (0.3 - 0.5 mg/kg i.v. in 
monkeys versus 10 mg/kg i.p. in rats) or the method of testing. For example, many 
studies in rats have used independent groups, and animals have usually been tested 
with antagonists only against the training dose of cocaine (Barrett and Appel, 1989; 
Witkin et aI., 1991; Callahan et aI., 1991; Baker et aI., 1993; Callahan and 
Cmmingham, 1993). On the other hand, studies using monkeys have tested 
antagonists against the full cocaine dose-response curve (Kleven et aI., 1988, 1990; 
Spealman et aI., 1991), an approach that as yet, has not been carried out in rats. This 
method has the advantage of allowing tests for changes in efficacy, potency and 
parallelism (non-parallelism indicating different mechanisms of action). 
Pharmacological antagonism can therefore be shown when the antagonist shifts the 
dose-response curve of the training drug to the right and the observed antagonism is 
surmountable by increasing the dose of the training drug. Despite these findings from 
antagonist experiments, little is known concerning the extent to which the D3 and D4 
receptors (within the D2-like subfamily) contribute to the DS effects of cocaine, and 
this issue therefore warrants further investigation. 
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CHAPTER 3: 
PHARMACOLOGICAL CHARACTERISATION OF THE STIMULUS 
EFFECTS OF COCAINE: ASSESSMENT BY THE USE OF DOPAMINE 'D2-
LIKE' AND 'Dt-LIKE' ANTAGONISTS 
3.1 Aims Of The Drug Discrimination Experiments: 
The results to date suggest that indirect stimulation of either DA D1-like or 
D2-like receptors by cocaine is necessary but not always sufficient for the full 
expression of the DS effects of cocaine. However, it remains unclear which of the 
recently-cloned DA receptors (D2, D3 and D4 receptors; Sibley and Monsma, 1992) 
within the D2-like receptor subfamily may be involved in cocaine's effects. The 
further examination of specific DA receptor subtype involvement in the DS effects of 
cocaine has been hampered by the limited availability of selective drugs. However, 
two compounds currently available are the selective DA D3 and D4 receptor subtype 
antagonists, U-99194A (Waters et aI., 1993) and L-745,870 (Kulagowski et aI., 1996) 
respectively. U-99194A [5,6-di-methoxy-2-( dipropylamino )indan-hydrochloride] is 
reported to have 25-40 fold preference for the DA D3 receptor over the DA D2 
receptor subtype. It is also reported to increase locomotor activity in rats at doses (I-
10 mg/kg) that do not significantly increase DA release in the striatum or nucleus 
accumbens (Waters et aI., 1993), suggesting that U-99194A might be producing its 
behavioural effects via post synaptic D3 receptors. In contrast, L-745,870 [(3-([4-(4-
chlororphenyl) piperazin-1-yl] methyl)-lH-pyrrolo [2,3-b] pyridine)] has been shown 
to have >2000- and >5000-fold binding selectivity for the D4 receptor relative to D2 
and D3 receptors respectively, and > 20 OOO-foid selectivity over DA D1-like 
receptors (Kulagowski et aI., 1996; Patel et aI., 1996). L-745,870 does not have any 
agonist activity at doses of 0.1 - 10 mglkg p.o. but inhibits in vivo binding of [3H] 
SKF 10,047 in mouse brain - a model for in vivo sigma binding used to determine 
brain penetration and to estimate occupancy of central D4 receptors (Patel et aI., 
1996b). At doses up to 1 mg/kg p.o. in rats, any effects observed with this compound 
are likely to be mediated via D4 receptor antagonism, since at this dose L-745,870 
will occupy > 90% of D4 receptors in the eNS but not other receptors. At higher 
doses, L-745,870 begins to occupy other receptors; for example, at 3 mg/kg L-
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745,870 occupIes 50 % of CNS sigma binding sites, and at > 10 mg/kg any 
antagonism may be attributed to blockade of D2 receptors (Patel, personal 
communication). At this higher dose of 10 mg/kg the drug does not effect DA 
metabolism in mouse striatum or nucleus accumbens, indicating that the drug acts on 
postsynaptic sites up to relatively high doses (Patel et aI., 1996b). 
The purpose ofthe present experiments was to: 
(1) Investigate for the first time the roles of D3 and D4 receptor subtypes in the DS 
effect of cocaine. Many of the inconsistent results reported to date with antagonists 
may be due to methodological differences, such as repeated measures vs. independent 
groups of animals, or the testing of rats with antagonists only against the training dose 
of cocaine vs. use of full dose-response curves in monkeys. The present study 
therefore adapted a within-subject design testing against the full cocaine dose 
response curve; no studies to date have used this approach in rats. For comparison, the 
effects of a DA Dl-like receptor antagonist, SCH 39166 ((-)-trans-6,7,7a,8,9, 13b-
hexahydro-3-chloro-N-methyl-5H-benzop[ d]napthop[2, I-b ]azepine; Chipkin et aI., 
1988) were also tested. 
(2) Terry et ai. (1994) showed that training dose may also be an important determinant 
of the extent to which DA receptor subtypes are involved in the DS effects of cocaine. 
Therefore in another series of experiments, rats were trained to discriminate cocaine 
from saline using two different training doses. One group of rats was trained to 
discriminate a low dose of cocaine, 3 mg/kg i.p., and a second group was trained at 
the conventional dose, 10 mglkg i.p. Since the study by Terry et ai. (1994) used 
agonist compounds that were non-selective for D2-like receptors within the subfamily 
we followed up the earlier study by testing three compounds that display different 
receptor affinities within the D2-like receptor subtype family. The three centrally 
acting D2-like receptor antagonists were haloperidol, raclopride and L-741,626; the 
effects of these were then compared with those of SCH 39166, a selective Dl-like 
receptor antagonist. 
~ 
Haloperidol has been used as the prototypical antagonist for DA D2 receptors 
(Table 2.3, Section 2.4). However, it binds to all receptors within the D2-like receptor 
subfamily: it is roughly equipotent across all three receptor subtypes: Ki = 2.6 nM for 
D2 versus 1.5 nM for D3 and 5.0 nM for D4 human DA receptor subtypes (Freedman 
54 
Chapter 3: Pharmacological characterisation of the stimulus effects of cocaine: ... 
et aI., 1994; Van Tol et aI., 1991). It is also a non-selective antagonist for NMDA and 
sigma sites (Lynch and Gallagher, 1996). Raclopride, on the other hand, has been 
shown to have equal affinity for rat DA D3 and D2 receptors, but much lower affinity 
for DA D4 receptors: Ki = 1.8 nM and 3.5 nM for D2 and D3 receptors, compared to 
237 nM for D4 receptors (Van Tol, 1991). In contrast, L-741,626 \ (3-{[4-(4-
chlorophenyl)-4-hydroxy]piperidin-1-yl}methyl-1H-indole HCI) is 40-fold selective 
for the human D2 receptor over the D3 receptor, although its selectivity is reduced to 
10-fold in the rat: Ki = 12 nM versus 120 nM for rat D2 and D3 receptors, 
respectively (Bowery et aI., 1996; Bristow et aI., 1998). L-741,626 penetrates the 
brain well and is functionally active in vivo at a dose range of 1-5 mg/kg (Bristow, 
personal communication); it is one of the most selective DA D2 receptor antagonists 
identified to date. 
A number of positive control drugs were also tested including for the first time 
the selective NE/5-HT re-uptake inhibitor venlafaxine (Holliday and Benfield, 1995), 
a drug with no affinity for the DA transporter. 
3.2 Materials and methods 
3.2.1 Subjects: 
Male Sprague-Dawley rats (Charles River, Margate, Kent) weighing 320-400 g, were 
housed with free access to water under a 12 h light/dark cycle (lights on 07:00). All 
testing was between 09:00 and 11 :00. Rats were fed 15 g standard diet daily, 30 min 
after testing. Two groups of eight were trained at the 'high' dose of cocaine, 10mg/kg, 
and another two groups of eight were trained at the low 'dose' of cocaine, 3mg/kg. 
These groups were not tested at the same time but over a 2 year period. 
3.2.2 Apparatus: 
Two-lever operant chambers (Coulbourn and Med-Associates, all controlled by Med-
PC software), housed within fan-ventilated, light- and sound-attenuating shells. 
Ambient illumination was by ~Jamp set centrally above the two levers (10 cm above 
the cage floor). The levers, were set 17 cm apart and 7 cm from the cage floor and 
required a force of OAN through 1mm to register a lever press. Reinforced presses 
activated an audible click, and dispensed one 45 mg pellet (Noyes Precision) into a 
centrally located food tray. 
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3.2.3 Procedure: 
Rats were trained initially to press both levers separately under a fixed-ratio 1 (FRl) 
schedule of food reinforcement. They were then trained after FRIO to discriminate i.p. 
injections of cocaine (10 mg/kg) from i.p. injections of saline. After cocaine, 
responses on only one lever were reinforced; after saline, responses on the other lever 
were reinforced. The assignment of cocaine and saline-appropriate levers was 
counterbalanced across rats. Rats were placed in the chambers directly after injection, 
and a 5-min time-out period was initiated, during which lamps were off and 
responding was not reinforced. Lamps were then illuminated, and responses on the 
appropriate lever were reinforced; each reinforcement was followed by a 20 s time-
out. The FR value was increased to FR20 over several sessions, and responses on the 
inappropriate lever reset the FR requirement on the appropriate lever. Sessions ended 
after 20 food presentations or 20 min, whichever occurred first. As the FR value 
reached 20, training sessions with cocaine and saline were scheduled in a double-
alternating sequence. The criteria for successful completion of a session were: at least 
85% injection-appropriate responding overall, and during the first FR of the session. 
In the second two subsets of eight rats, a fading procedure was used to 
establish discriminative control by a low dose of cocaine. Initially, the rats were 
trained to discriminate 10 mg/kg of cocaine from saline (at FRIO), as described. As 
the discrimination was acquired, the training dose was first reduced to 5.6 mg/kg at 
FR15 and then finally to 3 mg/kg at FR20. 
Substitution tests began after 6 consecutive successful training sessions at 
FR20: tests were identical to training sessions, except that 20 consecutive responses 
on either lever were reinforced. Thereafter, tests were conducted when a given rat met 
criterion on both preceding saline and cocaine training sessions. Cocaine was injected 
immediately before chamber entry; injections of the antagonists (random order within 
drug) were 30 min beforehand. 
3.2.4 Data Analysis: 
Data from any rat that pressed fewer than 20 times were not included in the 
calculation of mean cocaine-appropriate responding on that test, and if fewer than 
three rats met the requirement, no mean value was derived on that test. Mean response 
rates were calculated for all rats on each test. Standard analysis of variance (ANOV A) 
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and regression were used for difference testing and to calculate EDso values, their 95% 
confidence limits (CL), and relative potency estimates (the dose of standard drug 
(mg/kg) equal to 1 mg/kg of comparison drug; a significant difference was assumed if 
the 95% CL did not include 1.0). pA2 values were calculated by 'Schild' analysis 
using a specially-written programme. 
3.2.5 Drugs: 
(-)-Cocaine HCI, Chlordiazepoxide HCI, d-amphetamine sulphate (Sigma Chemicals, 
Poole, UK); Pentobarbitone sodium (Segatal) (RMB Animal Health Ltd, Dagenhanl, 
UK); S(-)-Raclopride L-tartrate (RBI, St. Albans, Herts, UK); Venlafaxine HCI 
(Wyeth-Ayerst Research, Princeton NJ, USA) and SCH 39166 HCI (Schering 
Corporation, Bloomfield NJ, USA) were dissolved in 0.9% saline; L-745,870 HCI 
(Tocris Cookson, Bristol, UK) was dissolved in distilled water. L-741,626 (Tocris 
Cookson, Bristol, UK) was dissolved in distilled water and suspended in solution with 
Tween 80; while Haloperidol (Tocris Cookson, Bristol, UK) was dissolved in distilled 
water with a few drops of acetic acid and neutralised to a pH of 7.0 with 1M NaOH 
solution. All drugs were injected i.p. at 1 mllkg. 
3.3 Results 
All eight rats in each subset learned to discriminate 10 mg/kg cocaine from 
drug vehicle (0.9 % saline) requiring 50.25 ± 5.29 and 68.63 ± 2.66 (mean ± S.E.M.) 
training sessions. The 10 mg/kg training dose of cocaine reliably maintained cocaine-
appropriate responding (> 95%) throughout the period during which substitution tests 
were conducted. There was no apparent difference between the two subsets of rats 
trained at 10 mg/kg of cocaine in terms of the potency of cocaine's DS effects; EDso 
values for the two subsets were 2.37 mg/kg (95% CL: 1.55-3.61 mg/kg) and 2.49 
mg/kg (95% CL: 1.86-3.29 mg/kg) (Table 3.1). 
For the 3 mg/kg training dose of cocaine, two groups of eight rats were 
initially trained. However, only a total of eight rats (6 from one group and 2 from the 
other) reliably learned to discriminate this dose, requiring 76.13 ± 2.30 training 
sessions. The EDso value for the 3 mg/kg cocaine training dose was 1.00 mg/kg (95% 
CL: 0.71-1.40 mg/kg). This corresponds to a significant difference in potency when 
compared with the 10 mg/kg training dose of cocaine (estimated relative potency: 
2.70; 95% CL: ... 1.83-3.90) showing that the two training conditions are not 
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overlapping and that the DS effects are quantitatively different from each other. 
Response rates did not differ significantly between cocaine and vehicle training 
sessions in either of the two training dose conditions. 
EDso values for cocaine from two separate determinations on all three groups, 
spanning more than a year for each, are presented in Table 3.1. All test-retest values 
are similar: there were no significant differences in the potency of the drug between 
these replications. 
Figure 3.1 shows the dose-response curve for the DS effects of cocaine in rats 
trained to discriminate 10 mg/kg cocaine from vehicle. Cocaine produced a dose-
dependent increase in cocaine lever responses. Response rates did not differ 
significantly between cocaine and vehicle test sessions across the doses (Figure 3.1, 
lower panel). A series of compounds were tested to establish the pharmacological 
specificity of the discrimination. First, the effects of d-amphetamine in substitution 
tests are shown. D-amphetamine (1-3 mg/kg) substituted fully for cocaine ( > 80 % 
drug lever responses) with an EDso value of 0.36 mg/kg (95% CL: 0.13-1.02 mg/kg), 
being approximately 6 times more potent than cocaine (Table 3.1). Response rates 
were reduced to < 30 % vehicle rates at the highest dose of d-amphetamine. However, 
neither the benzodiazepine, chlordiazepoxide (CDP), nor the barbiturate, 
pentobarbitone, elicited reliable cocaine-appropriate responding (Figure 3.2 and 3.3, 
respectively), with only partial substitution (35 % drug lever responses) at the highest 
dose of CDP (10 mg/kg), and negligible substitution with pentobarbitone. Each of 
these drugs was tested across a range of doses, from those that had no effect on 
response rates to those that decreased response rates to less than 20 % of control rates. 
This was also the case when pentobarbitone was tested in the low training dose group: 
pentobarbitone failed to produce cocaine-appropriate responding (Figure 3.4 and 
Table 3.1). 
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DRUGS 
TRAINING DOSE (10 mg/kg) 
COCAINE (1 ST GROUP) 
1 ST DETERMINATION 
2ND DETERMINATION 
COCAINE (2ND GROUP) 
1 ST DETERMINATION 
2ND DETERMINATION 
TRAINING DOSE (3 mg/kg) 
1ST DETERMINATION 
2ND DETERMINATION 
TABLE 3.1 
EDso (95 % CL) 
2.37 (1.55 - 3.61) 
1.74 (1.39 - 2.17) 
2.49 (1.86 - 3.29) 
2.77 (2.07 - 3.71) 
1.00 (0.71 - 1.40) 
1.08 (0.84 - 1.39) 
RELATIVE POTENCY 
(I" DETERMINATION RELATIVE TO 
2'~ DETERMINATION) 
1.36 (0.83 - 2.29) 
0.89 (0.62 - 1.29) 
0.94 (0.61 - 1.43) 
............. --- .......................................................................................... -- .. - ............................ .. 
(POTENCY RELATIVE TO COCAINE) 
TRAINING DOSE (10 mg/kg) 
COCAINE (1 ST GROUP) 2.37 (1.55 - 3.61) 1.00 
AMPHETAMINE 0.36 (0.13 - 1.02) 5.80 (2.78 - 14.89) 
COCAINE (2ND GROUP) 2.49 (1.86 - 3.29) 1.00 
CDP a 
PENTOBARBITONE a 
TRAINING DOSE (3 mg/kg) 
COCAINE 1.00 (0.71 - 1.40) 1.00 
PENTOBARBITONE a 
a = No value could be calculated due to lack of substitution 
ED so values (mg/kg) and relative potencies for compounds tested for substitution for 
discriminative stimulus effects-or 10 mg/kg and 3 mg/kg cocaine. N=8 for each group. 
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Figure 3.1 Upper panel: Effects of cocaine and d-amphetamine on the percentages of 
responding on the cocaine-correlated lever for rats trained at 10 mg/kg. Lower panel: 
Rates of responding expressed with respect to vehicle response rates. Each point 
represents mean performance of at least three out of eight rats tested at each dose 
. (upper panel) 
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Figure 3.2 Upper panel: Effects of cocaine and chlordiazepoxide (administered 30 
min pre-test) on the percentages of responding on the cocaine-correlated lever for rats 
trained at 10 mg/kg. Lower panel: Rates of responding expressed with respect to 
vehicle response rates. Each point represents mean performance of at least three out of 
eight rats tested at each dose (upper panel) 
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Figure 3.3 Upper panel: Effects of cocaine and pentobarbitone (administered 30 min 
pre-test) on the· percentages of responding on the cocaine-correlated lever for rats 
trained at 10 mg/kg. Lower panel: Rates of responding expressed with respect to 
vehicle response rates. Each point represents mean performance of at least three out of 
eight rats tested at each dose (upper panel) 
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Figure 3.4 Upper panel: Effects of cocaine and pentobarbitone (administered 30 min 
pre-test) on the percentages of responding on the cocaine-correlated lever for rats 
trained at 3 mg/kg. Lower panel: Rates of responding expressed with respect to 
. vehicle response rates. Each point represents mean performance of at least three out of 
eight rats tested at each dose (upper panel) 
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3.3.1 The effects of OA 03 and 04 receptor subtype antagonists, and a 
01-Like antagonist, on the OS effects of 10 mg/kg cocaine. 
Neither of two doses of the DA D3 receptor antagonist U-99194A (3 and 10 mg/kg) 
substituted for cocaine, and neither dose shifted cocaine's dose-effect function (Table 
3.2 and Figure 3.5). However, at the highest dose of U-99194A, there was some 
indication that the effects of the lowest dose of cocaine might be potentiated (Figure 
3.5), but this effect was not significant [F(2,12) = 3.61, P = 0.059]. The DA D3 
receptor antagonist produced no significant effect on response rates [F(1,6) = 3.0, 
NS], and no interaction with cocaine [F(3,18) = 0.85, NS] (Figure 3.5, lower panel), 
although at 10 mg/kg alone it reduced responding to approximately 50 % of control 
levels. Figure 3.5 clearly shows no evidence that U-99194A attenuated cocaine's DS 
effects. 
At 1, 3 and 10 mg/kg, the DA D4 receptor antagonist L-745,870 produced no 
reliable cocaine-appropriate responding in the absence of cocaine, and was without 
effect when administered as a pre-treatment to a series of cocaine doses (Figure 3.6, 
upper panel). The EDso values for the DS effects of cocaine were similar whether 
preceded by 0, 1 or 3 mg/kg ofL-745,870 (Table 3.2). Although EDso values could not 
be calculated for the combination with 10 mg/kg of L-745,870, the graph shows no 
indication of blockade at either 1, 3 or 10 mg/kg cocaine. Despite the lack of effect in 
terms of lever-choice behaviour, the antagonist produced a significant dose-related 
decrease in response rates [F(3,12) = 18.60, P<O.OOl] but no interaction with cocaine 
dose [F(9,36) = 0.57, NS] (Figure 3.6, lower panel). 
In clear contrast, pre-treatment with the DA D1-like receptor antagonist SCH 
39166 (0.03 and 0.3 mg/kg) produced a significant rightward shift in the dose-
response function for cocaine's effects, indicating antagonism (Figure 3.7). There was 
a significant reduction in relative potency for the DS effects of cocaine when preceded 
by injection with 0.03 and 0.3 mg/kg SCH 39166 (Table 3.2). The DA D1-like 
receptor antagonist also produced a dose-related decrease in response rates [F(2,12) = 
26.10, P<O.OOl] but no interaction with cocaine dose [F(6,36) = 1.66, NS] (Figure 3.7, 
lower panel). 
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TABLE 3.2 
DRUGS EDso (95 % CL) 
TRAINING DOSE (10 mg/kg) 1ST GROUP 
DOPAMINE D3 RECEPTOR ANTAGONIST 
COCAINE ALONE (N=7) 
+ 3 mglkg U-99194A 
+ 10 mg/kg U-99194A 
1.74 (1.39 - 2.17) 
1.10 (0.68 - 1.79) 
a 
DOPAMINE D4 RECEPTOR ANTAGONIST 
COCAINE ALONE (N=5) 
+ 1 mglkg L-745,870 
+ 3 mg/kg L-745,870 
+ 10 mglkg L-745,870 
1.89 (1.52 - 2.35) 
1.67 (1.20 - 2.32) 
2.29 (1.63 - 3.23) 
a 
DOPAMINE Dl-LIKE RECEPTOR ANTAGONIST 
COCAINE ALONE (N=7) 
+ 0.03 mglkg SCH 39166 
+ 0.3 mglkg SCH 39166 
1.31 (0.51 - 3.39) 
5.01 (2.99 - 8.39) 
8.47 (3.71 - 19.33) 
a = insufficient data to calculate EDso values 
POTENCY RELATIVE TO 
COCAINE 
1.00 
1.28 (0.93 - 1.80) 
1.00 
1.07 (0.79 - 1.46) 
0.84 (0.59 - 1.19) 
a 
1.00 
0.46 (0.16 - 0.97) 
0.29 (0.10 - 0.58) 
. EDso values (mg/kg) and relative potencies for the DS effects of cocaine in combination 
with aDA D3 (U-99194A), D4 (L-74S,S70) and Dl-like (Sell 39166) receptor 
antagonist. 
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Figure 3.5 Upper panel: Effects of the DA D3 receptor antagonist U-99194A alone 
and in combination with 1, 3 and 10 mg/kg of cocaine in rats trained at 10 mg/kg. The 
antagonist was administered 30 min before cocaine ( or vehicle). Lower panel: Rates 
of responding expressed with respect to saline response rates. Each point represents 
the mean of at least three out of seven rats tested at each dose (upper panel) 
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Figure 3.6 Upper panel: Effects of the DA D4 receptor antagonist L-745,870 alone 
and in combination with 1, 3 and 10 mg/kg of cocaine in rats trained at 10 mg/kg. The 
antagonist was administered 30 min before cocaine (or vehicle). Lower panel: Rates 
. of responding expressed with respect to saline response rates. Each point represents 
the mean of at least three out of five rats tested at each dose (upper panel) 
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Figure 3.7 Upper panel: Effects of the DA D1-like receptor antagonist SCH 39166 
alone and in combination with 1, 3 and 10 mg/kg of cocaine in rats trained at 10 
mg/kg. The antagonist was administered 30 min before cocaine ( or vehicle). Lower 
panel: Rates of responding expressed with respect to saline response rates. Each point 
represents the mean of at least three out of seven rats tested at each dose (upper panel) 
. . 
68 
Chapter 3: Pharmacological characterisation of the stimulus effects of cocaine: •.. 
3.3.2 The effects of D2-Like (L-741,626, haloperidol, raclopride) and 01-
Like (SCH 39166) receptor antagonists on the discriminative stimulus 
effects of cocaine in rats trained at 10 mg/kg or 3 mg/kg. 
(i) Rats Trained At The Higher Dose (10 mg/kg): 
When given 30 min before administration of 10 mg/kg cocaine, all three centrally 
acting D2-like antagonists, L-7 41,626 (3, 6 mg/kg) haloperidol (0.3 mg/kg) and 
raclopride (0.3 mg/kg) produced rightward shifts in the dose-response function for 
cocaine's DS effects (Figures 3.8-3.10, upper panels). All dose-response functions 
were parallel to the cocaine curve (Table 3.3). By comparing the minimum dose of 
each antagonist to produce a similar change in potency, the rank order of potencies 
was shown to be haloperidol> = raclopride > L-741,626. When these D2-like 
antagonists were administered alone, they all produced DS effects that were not 
significantly different from saline (Figures 3.8-3.10, upper panels), but they all 
produced significant decreases in response rates when compared with saline (Figures 
3.8-3.10, lower panels). Dose-effect curves for response rates also revealed a dose-
related decrease in response rates for all of the D2-like receptor antagonists tested in 
the presence of cocaine [L-741,626: F(2,14) = 10.44, P<0.01; haloperidol: F(1,7) = 
53.28, P<0.01; and raclopride: F(1,7) = 42.07, P<0.01]. Only haloperidol produced an 
interaction with cocaine dose [F(3,21) = 3.52, P<0.05] (Figures 3.8-3.10, lower 
panels). This interaction between haloperidol and cocaine for response rates suggests 
that haloperidol is attenuating the rate-suppressant effects of cocaine. Although this 
interaction was not statistically supported for L-7 41,626 and raclopride, Figures 3.8 
and 3.10 clearly show a similar trend. 
(ii) Rats Trained At The Lower Dose (3 mg/kg): 
At 1 mg/kg, the D2 receptor antagonist L-741,626, had no effect when 
administered as a pre-treatment to cocaine in rats trained at the low dose (3 mg/kg) 
(Figure 3.11, upper panel). However, there was evidence of antagonism when it was 
administered in combination with 1 mg/kg of cocaine. An increase in EDso value 
occurred, together with a decrease in cocaine's potency; however, this was 
accompanied by a significant deviation from linearity which prevented a reliable 
relative potency estimate (Table 3.3). On the other hand, the higher dose of 5 mg/kg 
L-741,626 decreased cocaine-appropriate responding to 58 % at the training dose, an 
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effect that was accompanied by a significant decrease in response rates [F(2,14) = 
32.58, P<0.01] (Figure 3.11, lower panel). An EDso value could not be calculated due 
to insufficient data, but a relative potency value could still be calculated; the higher 
dose ofL-741,626 reduced cocaine's potency approximately three-fold (Table 3.3). 
As at the high training dose, the D2-like receptor antagonists haloperidol and 
raclopride produced rightward shifts of the dose-response curves for rats trained at the 
low dose (Figure 3.12 and 3.13, upper panel). The EDso value for cocaine in 
combination with the highest dose of each D2-like antagonist was significantly 
different from that of cocaine alone (3.91 mg/kg for haloperidol and 2.54 mg/kg for 
raclopride). The order of potencies for these drugs paralleled that in the high dose-
training conditions, with raclopride marginally more potent than haloperidol, and both 
more potent than L-741,626 (Table 3.3). Again, as for the high dose trained rats, when 
the D2-like antagonists were administered alone they all produced DS effects that 
were not significantly different from saline (Figures 3.11-3.13, upper panels). 
Response rates also decreased when the D2-like antagonists were combined with 
cocaine: [haloperidol: F(2,14) = 10.24, P<0.05; raclopride: F(1,7) = 22.20, P<0.05] 
but there was no interaction with cocaine dose [F(6,42) = 0.65, NS; F(3,18) = 0.60, 
NS; respectively) (Figures 3.12 and 3.13, lower panels). 
Pre-treatment with the DA D1-like receptor antagonist SCH 39166 (0.1 
mg/kg) also produced significant rightward shift in the percentage of drug lever 
responding observed after cocaine (Figure 3.14, upper panel). The EDso value of 
cocaine with SCH 39166 increased significantly, its potency reduced approximately 
three times (Table 3.3). The DA D1-like receptor antagonist also produced a decrease 
in response rates [F(1,6) = 15.87, P<O.Ol] but there was no interaction with cocaine 
(Figure 3.14, lower panel). 
pA2 values calculated by 'Schild analysis' characterising the receptor subtypes 
at which these antagonists are acting for the two different training doses of cocaine are 
given in Table 3.4. These represent the -log values of the concentration of the 
antagonist that necessitates an X::fold increase in agonist concentration (i.e. cocaine) 
applied in order to obtain a standard response. This is based on selective antagonism 
and is quantitated by determining a derivative of Kd for antagonist binding, since pA2 
- pKB == -Log Kd. This information tells us, by comparing the pA2 values obtained 
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for each compound, whether they are acting at the same receptor sUbtype. From, table 
3.4, it is difficult to conclude that the DA receptor antagonists employed in the present 
study are acting across different receptors, although the values for L-7 41,626 seem to 
distinguish it from the other compounds. 
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Figure 3.8 Upper panel: Effects of the DA D2 receptor antagonist L-741,626 alone 
and in combination with 1,3, 10 and 17 mg/kg of cocaine in rats trained at 10 mglkg. 
The antagonist was administered 30 min before cocaine ( or vehicle). Lower panel: 
Rates of responding expressed with respect to vehicle response rates. Each point 
represents the mean of at least three out of six rats tested at each dose (upper panel) 
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alone and in combination with 3, 10 and 17 mglkg of cocaine in rats trained at 10 
mg/kg. The antagonist was administered 30 min before cocaine (or vehicle). Lower 
panel: Rates of responding expressed with respect to vehicle response rates. Each 
point represents the mean of at least three out of eight rats tested at each dose (upper 
panel) 
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Figure 3.10 Upper panel: Effects of the DA D2-like receptor antagonist raclopride 
alone and in combination with 3, 10 and 17 mglkg of cocaine in rats trained at 10 
mglkg. The antagonist was administered 30 min before cocaine ( or vehicle). Lower 
panel: Rates of responding expressed with respect to vehicle response rates. Each 
point represents the mean of at least three out of eight rats tested at each dose (upper 
panel) 
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Figure 3.11 Upper panel:-Effects of the DA D2-like receptor antagonist L-741,626 
alone and in combination with 1, 3 and 10 mg/kg of cocaine in rats trained at 3 mg/kg. 
The antagonist was administered 30 min before cocaine (or vehicle). Lower panel: 
Rates of responding expressed with respect to vehicle response rates. Each point 
represents the mean of at least three out of six rats tested at each dose (upper panel) 
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Figure 3.12 Upper panel: Effects of the DA D2-like receptor antagonist haloperidol 
----alone and in combination with 0.3, 1, 3 and 10 mg/kg of cocaine in rats trained at 3 
mg/kg. The antagonist was administered 30 min before cocaine ( or vehicle). Lower 
panel: Rates of responding expressed with respect to vehicle response rates. Each 
point represents the mean of at least three out of eight rats tested at each dose (upper 
panel) 
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Figure 3.13 Upper panel: Effects of the DA D2-like receptor antagonist raclopride 
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The antagonist was administered 30 min before cocaine (or vehicle). Lower panel: 
Rates of responding expressed with respect to vehicle response rates. Each point 
represents the mean of at least three out of seven rats tested at each dose (upper panel) 
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Figure 3.14 Upper panel: Effects of the DA D1-like receptor antagonist SCH 39166 
alone and in combination with 1, 3 and 10 mg/kg of cocaine in rats trained at 3 mg/kg. 
The antagonist was administered 30 min before cocaine (or vehicle). Lower panel: 
Rates of responding expressed with respect to vehicle response rates. Each point 
represents the mean of at least three out of seven rats tested at each dose (upper panel) 
78 
Chapter 3: Pharmacological characterisation of the stimulus effects of cocaine: ... 
TABLE 3.3 
DRUGS EDso (95 % CL) 
TRAINING DOSE (10 mg/kg) 2ND GROUP 
DOPAMINE D2-LIKE RECEPTOR ANTAGONISTS 
COCAINE ALONE (N=6) 2.75 (1.95 - 3.89) 
+ 3 mg/kg L-741,626 4.49 (3.66 - 5.49) 
+ 6 mg/kg L-741,626 8.55 (5.05 - 14.40) 
COCAINE ALONE (N=8) 2.49 (1.86 - 3.29) 
+ 0.3 mg/kg haloperidol 8.27 (6.43 - 10.64) 
COCAINE ALONE (N=8) 2.49 (1.86 - 3.29) 
+ 0.3 mg/kg rac10pride 5.17 (3.18 - 8.38) 
TRAINING DOSE (3 mg/kg) 
DOPAMINE D2-LIKE RECEPTOR ANTAGONISTS 
COCAINE ALONE (N=6) 0.95 (0.66 - 1.38) 
+ 1 mg/kg L-741,626 2.08 (1.97-2.18)" 
+ 5 mg/kg L-741,626 b 
COCAINE ALONE (N=8) 1.00 (0.71 - 1.40) 
+ 0.1 mg/kg haloperidol 1.64 (0.84 - 3.19) 
+ 0.3 mg/kg haloperidol 3.91 (2.40 - 6.37) 
COCAINE ALONE (N=7) 1.02 (0.68 - 1.52) 
+ 0.1 mg/kg rac10pride 2.54 (1.83 - 3.54) 
DOPAMINE Dl-LIKE RECEPTOR ANTAGONIST 
COCAINE ALONE (N=7) 
+ 0.1 mg/kg SCH 39166 
a = Significant deviation from linearity 
b = insufficient data to calculate EDso value 
/ 
1.02 (0.68 - 1.52) 
3.22 (2.25 - 4.62) 
POTENCY RELATIVE TO 
COCAINE 
1.00 
0.62 (0.42 - 0.88) 
0.32 (0.17 - 0.58) 
1.00 
0.30 (0.20 - 0.46) 
1.00 
0.46 (0.29 - 0.72) 
1.00 
0.47 (0.34-0.65)' 
0.34 (0.20 - 0.68) 
1.00 
0.69 (0.34 - 1.26) 
0.29 (0.16 - 0.50) 
1.00 
0.40 (0.24 - 0.68) 
1.00 
0.32 (0.18 - 0.54) 
EDso values (mg/kg) and relative potencies for the DS effects of 10 mg/kg and 3 mg/kg cocaine in 
combination with DA D2-like (L-741,626, haloperidol and raclopride) and DA Dl-like 
(SCH 39166) receptor antagonists. 
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Dl-like antagonists 
L-741,626 
Haloperidol 
Rac10pride 
D I-like antagonist 
SCH 39166 
TABLE 3.4 
3.0 
5.61 
6.51 
6.87 
6.88 
Training Dose (mg/kg) 
10.0 
4.97 
6.50 
6.25 
7.16 
Schild analysis results: mean pA2 values for the effects of the D2-like antagonists 
and the Dl-like antagonist on the DS effects of two different training doses of 
cocaine. 
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3.3.3 Substitution tests with a selective NE/S-HT re-uptake inhibitor, 
venlafaxine, on high (10 mg/kg) and low (3 mg/kg) cocaine trained rats. 
The selective NE/5-HT re-uptake inhibitor, venlafaxine, produced partial substitution 
for cocaine's DS effects in both training conditions, with ED50 values of 37.24 and 
8.11 mg/kg for the high and low dose groups, respectively (Figures 3.15-3.16). 
However, the slopes of the dose-effect curves for the two training doses deviated 
significantly from linearity, and the lack of parallelism between the cocaine curve 
suggests that venlafaxine maybe producing its DS effects through mechanisms 
different from those of cocaine. When tested in the high training dose condition, 
venlafaxine produced a maximum of 55 % substitution, whereas in the low training 
dose it produced a maximum of 68 % cocaine-appropriate responding. Venlafaxine 
was tested across a range of doses, from those that were inactive to those that 
decreased response rates to less than 40 and 30 % of control rates for the high and low 
training dose conditions, respectively. 
The slope of the dose-effect curve also deviated significantly from parallelism 
with the cocaine dose-effect curve in both training conditions, preventing a reliable 
estimate of relative potency. Comparing the two curves for each training condition, it 
is evident from the ED50 values obtained that there is an apparent potency shift with 
training dose. The potency to substitute for cocaine increases as the training dose 
decreases, approximately 4-fold. 
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Figure 3.15 Upper panel: Effects of cocaine and venlafaxine (administered 30 min 
pre-test) on the percentages of responding on the cocaine-correlated lever for rats 
trained at 10 mg/kg. Lower panel: Rates of responding expressed with respect to 
vehicle response rates. Each point represents mean performance of at least three out of 
eight rats tested at each dose (upper panel) 
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Figure 3.16 Upper panel: Effects of cocaine and venlafaxine (administered 30 min 
pre-test) on the percentages of responding on the cocaine-correlated lever for rats 
trained at 3 mg/kg. Lower panel: Rates of responding expressed with respect to 
vehicle response rates. Each point represents mean performance of at least three out of 
seven rats tested at each dose (upper panel) 
83 
Chapter 3: Pharmacological characterisation of the stimulus effects of cocaine: ..• 
3.4 Discussion 
Reliable discriminative control of perfonnance by cocaine was maintained at a 
high level throughout the study at two different training doses. D-amphetamine, 
another psychomotor stimulant, substituted fully for cocaine in rats trained at the high 
dose. However, neither a benzodiazepine, CDP, nor a barbiturate, pentobarbitone, 
elicited full cocaine-appropriate responding, although partial substitution was 
obtained at the highest dose of CDP tested. Each of these drugs was tested across a 
range of doses, from those that had no effect on response rates to those that decreased 
response rates to less than 20 % of control. 
D-amphetamine is a prototypic stimulant that has a well-established potential 
for abuse. It produces a range of neurochemical effects including the release of DA 
and NE from pre-synaptic tenninals and blockade of transmitter re-uptake from the 
synapse (Harris and Baldessarini, 1973; Azzaro et aI., 1974; Taylor and Ho, 1978). It 
is well known that cocaine and phenylethylamines such as d-amphetamine and 
methamphetamine can produce similar behavioural effects (e.g. hyperiocomotion, 
stereotyped behaviours and reinforcing effects). Cocaine and amphetamine or 
methamphetamine have been shown to cross-generalize or exhibit cross-tolerance in 
drug discrimination procedures (Colpaert et aI., 1978; Wood and Emmett-Oglesby, 
1986; Woolverton and Cervo, 1986; Suzuki et aI., 1996). The present results are 
consistent with others showing that the DS effects of d-amphetamine are similar to 
those of cocaine. 
Pentobarbitone is a sedative from the barbiturate class and has no common 
mechanism of action with cocaine: pentobarbitone did not substitute for cocaine, 
supporting the pharmacological specificity of the cocaine discrimination. The failure 
of pentobarbitone to substitute for cocaine is in accordance with results indicating that 
GABAergic mechanisms are minimally involved in the DS effects of cocaine (Kleven 
et aI., 1990; Cunningham and Callahan, 1991, Baker et aI., 1991; Terry et aI., 1994). It 
was therefore surprising to obtain partial substitution (albeit weak: 35 % maximum 
substitution) of CDP for cocaine in the present study, since both pentobarbitone and 
-~ 
CDP share some similarities in tenns of mechanisms of action. CDP is a 
benzodiazepine, widely used as a sedative or anxiolytiC. Benzodiazepines are believed 
to exert their actions (anxiolytic, sedative, anticonvulsant, muscle relaxant) by 
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enhancing the inhibitory activity of gamma aminobutyric acid (GABA) at GABAa 
inhibitory synapses (Choi et aI., 1977; MacDonald and Barker, 1978). One possible 
explanation for its variety of effects is that there are at least three different 
benzodiazepine binding sites: BZ1, BZ2 and BZ3 (occasionally known as 0)1, 0)2, 
0)3). The attachment of a benzodiazepine to its binding site causes an allosteric 
change in the GABAa receptor such that GABA binding is enhanced (Choi et aI., 
1977; MacDonald and Barker, 1978). However, studies are emerging to suggest a 
modulatory role for GABA on meso limbic dopaminergic pathways (Kita and Kitai, 
1988; Bernath and Zigmund, 1989; Pirot et aI., 1992; Seutin et aI., 1994). GABA 
neurons in both the nucleus accumbens (NAC) and ventral pallidum project to the 
A10 region of the ventral tegmental area (VTA) , providing an inhibitory feedback 
loop (Henry et aI., 1989). 
No other studies so far have examined the role ofbenzodiazepine binding sites 
in the DS effects of cocaine. However, in the only study to-date looking at the effects 
of CDP on the reinforcing effects of cocaine, Goeders et ai. (1989) showed that it 
could modify cocaine self-administration in rodents. The results suggested that CDP 
decreased the reinforcing efficacy of cocaine through indirect GABAergic 
mechanisms by binding to benzodiazepine sites located near to the GABA site which 
enhanced its overall effect. This work has been supported by recent findings that 
bac10fen (a GABAb agonist) could selectively attenuate the reinforcing effects of 
cocaine in rats (Roberts et aI., 1996; Shoaib et aI., 1998). Therefore, the partial 
substitution for the DS effects of cocaine reported within may be produced by indirect 
GABA activation and release of DA from the mesolimbic dopaminergic pathways. 
Self-administration data strongly suggest that GABAb agonists should be considered 
as candidate pharmacotherapeutic agents for cocaine addiction. Guderman et al. 
(1996) have investigated the effects of b ac10 fen (20-60 mg/day) in an open trial. Very 
preliminary data suggest that bac10fen may suppress cocaine craving during the early 
phase of cocaine withdrawal. There is, therefore, a need for more experiments with 
direct GABAalb agonists on the DS effects of cocaine in order to understand better the 
possible involvement of GABA. The finding that pentobarbitone (which also 
modulates GABA transmission) does not substitute for the DS effects of cocaine, 
suggests that the barbiturate receptor site is not critical for GABA-DA modulation. 
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The present study examined the role of novel DA D2-like receptor subtype 
antagonists (with some specificities for the D3 and D4 receptor subtypes) on the DS 
effects of cocaine. The results of these experiments indicate that U-99194A does not 
produce stimulus effects similar to those of cocaine. The present findings also indicate 
that U-99194A (up to 10 mg/kg) does not block cocaine's DS effects. These results 
support those of Baker et al. (1997), who showed that U-99194A did not significantly 
block cocaine's DS effects in rats trained at 10 mg/kg, nor did they see any 
potentiation of cocaine's DS effects by the D3 antagonist. The doses of the antagonist 
in Baker's study corresponded with those in the present one (1-10 mg/kg). Support 
that behaviourally-active doses were used is provided by the drug's effect on response 
rate, i.e. U-99194A at the highest dose reduced response rates to < 60% control. 
Support also comes from other behavioural experiments, in which it has been shown 
that doses ofU-99194A needed to affect locomotor activity (Smith et aI., 1999a) and 
progressive ratio responding (Smith et aI., 1999b) are in the range of2-10 mg/kg. Two 
other D3-preferring antagonists, (+)-UH 232 and (+)-AJ76, also fail to produce DS 
effects like those of cocaine, nor do they reduce cocaine discrimination to the extent 
that has been observed with DA D1-like or other D2-like DA antagonists (Clark et aI., 
1995; also see Table 2.3, section 2.4). 
In contrast, the DA D3-preferring agonists, 7-0H-DPAT and (+)-PD 128907, 
were recently shown to produce stimulus generalisation in rats trained to discriminate 
cocaine from saline, although at doses that markedly decreased response rate (Acri et 
aI., 1995). However, the extent to which the DS effects of these agents were produced 
by D3 receptor-mediated actions was examined in two separate studies by testing 
these putative D3 agonists in combination with the more selective DA D3 antagonist 
U-99194A. Depoortere et al. (1998) recently showed that U-99194A failed to 
antagonise the DS effects of the DA D31D2 receptor agonist 7-0H-DPAT. It was 
found instead to markedly shift the 7-0H-DPAT generalisation curve to the left, 
suggesting that it potentiated the DS effects of 7-0H-DPAT. Baker (1998) showed 
only partial stimulus generalisation by 7-0H-DPAT in rats trained to discriminate 5 
mg/kg cocaine from saline, but complete stimulus generalisation in rats trained to 
discriminate d-amphetamine from saline. U-99194A, on the other hand, produced 
partial substitution for both training drugs but failed to block the stimulus 
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generalisation produced by 7-0H-DPAT in rats trained to discriminate d-
amphetamine. These results suggest that the DS effects of psycho stimulants and their 
similarities to 7-0H-DPAT are not critically dependent on D3 receptor activation. 
This is supported by Boulay et ai. (1998) who showed that the in vivo effects of 7-
OH-DPAT, cocaine and U-99194A were still present in DA D3 knock-out mice 
suggesting that these compounds (7-0H-DPAT and U-99194A) can produce 
behavioural effects which are not mediated by activity at DA D3 receptors. 
The DA D4 receptor antagonist, L-745,870, failed to alter the DS effects of 
cocaine. Confirmation that the dose-range of the antagonist extended to 
behaviourally-active doses was provided by the drug's dose-dependent effect on 
response rate. The lack of any interaction with cocaine dose on response rates also 
suggests independence of mechanism in the regulation of this aspect of behaviour. 
The effect on response rate is one of few behavioural effects identified for drugs that 
selectively block DA D4 receptors. In terms of cocaine's DS effects, Spealman (1996) 
found no relationship between the substitution potencies of various DA receptor 
agonists and their intrinsic efficacies or binding affinities at DA D4 receptors: instead, 
drug action at DA D3 receptors seemed most clearly relevant. In that study, it was 
shown that the cocaine-like DS effects of the most selective of the D3-agonists, 
PD128907 were attenuated by D2-like receptor antagonists with an order of potency: 
nemonapride > eticlopride > YM 436611 which corresponded more closely to their 
reported order of affinity at cloned human D3 than either D2 or D4 receptors. 
Although such findings point to a role for D3 receptors in the DS effects of cocaine, 
the evidence is so far inferential since, as mentioned, the present study and Baker et 
ai. (1997) have shown that the DS effects of cocaine cannot be blocked by a selective 
D3 receptor antagonist, and other results suggest that substitution for cocaine by 
putative D3 agonists may not be mediated by the D3 receptor. 
The study is the first to investigate DA D4 receptor involvement in the DS 
effects of cocaine. No evidence for involvement was found. DA D4 receptor 
distribution among brain regions still requires clarification: there is agreement that 
such receptors are expressed in midbrain nuclei, amygdala and frontal cortex (e.g. Van 
Tol et aI., 1991), but there are conflicting reports as to whether they are expressed in 
nucleus accumbens and basal ganglia (e.g. Defagot and Antonelli, 1997). The brain 
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substrates of cocaine's DS effects have not been widely studied, but intra-accumbens 
infusions of cocaine and DA receptor antagonists support a critical role for this region 
(Callahan et aI., 1997). Limited expression of DA D4 receptors in nucleus accumbens 
(if confirmed) might therefore explain the ineffectiveness of L-745,870 here. 
However, recent studies have shown that the DS effects of cocaine are also dependent 
upon at least two brain regions that have consistently shown DA D4 receptor 
expression: the amygdala and frontal cortex (Callahan et aI., 1995; 1997). DA Dl-like 
receptor antagonists injected into these regions block cocaine's DS effects. The 
present findings therefore suggest that DA D4 receptors in the amygdala and frontal 
cortex are probably not important to cocaine's DS effects. So far, no other compounds 
specific to this receptor subtype have been tested on the DS effects of cocaine. 
Experiments using other selective DA D4 receptor antagonists and agonists (when 
available) should be conducted to confirm this outcome. However, L-745,870 has 
been used as a tool to elucidate the DS properties of the atypical neuroleptic 
clozapine, a drug with some affinity for the DA D4 receptor (Goudie et aI., 1998). In 
rats trained to discriminate clozapine (5 mglkg i.p.) from saline, L-745,870 only 
produced 14 % generalisation, suggesting that DA D4 receptors are not involved in 
clozapine's DS effects. Hence clozapine should not be used as a putative D4 
antagonist. 
Using the selective DA Dl-like receptor antagonist SCH 39166 for 
comparison with the D2-like compounds confirmed previous studies, demonstrating 
the importance ofDA Dl-like receptors to the DS effects of cocaine (e.g. Callahan et 
aI., 1997). Previous studies with rats have only tested antagonists against the training 
dose of cocaine (e.g. Barrett and Appel, 1989; Spealman et aI., 1991; Witkin et aI., 
1991; Callahan et aI., 1991; Baker et aI., 1993; Callahan et aI., 1997). Our results, 
testing the full cocaine dose-response curve, suggests that DA Dl-like antagonists are 
sufficient to produce surmountable antagonism of cocaine's DS effects: tests using 
monkeys have yielded similar results (e.g. Kleven et aI., 1990; Spealman et aI., 1991). 
DA D2-like antagonists that are less selective than U-99194A and L-745,870 
have been shown to attenuate the DS effects of indirect DA agonists in both rats 
(Arnt, 1988; Callahan et aI., 1991) and monkeys (Kleven et aI., 1990; Melia and 
Spealman, 1991; Spealman et aI., 1991). However, as stated earlier (section 2.4), 
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several studies have reported that DA D2-like antagonists do not consistently block 
the DS properties of cocaine or amphetamine (e.g. Barrett and Appel, 1989; Kamien 
and Woolverton, 1989; Witkin et aI., 1991). Terry et al. (1994) also showed that 
training dose may be an important determinant of the extent to which DA D2-like 
receptors are involved in the DS effects of cocaine. 
In the present study, haloperidol, raclopride and L-741,626 (three centrally 
acting D2-like receptor antagonists) attenuated the DS effects of cocaine in high dose 
training conditions with an order of potency: haloperidol> = raclopride> L-741,626. 
As stated (section 2.4), several studies have reported that haloperidol does not 
consistently block the DS properties of cocaine (Barrett and Appel, 1989; Kamien and 
Woolverton, 1989; Witkin et aI., 1991) even at doses much higher than used in the 
present study (0.3-1.6 mg/kg). As remarked earlier (section 2.4), in some cases, 
pharmacodynamic and/or pharmacokinetic variables may account for incomplete 
blockade of the stimulus effects of cocaine by haloperidol. For example, Callahan and 
Cunningham (1993) showed that by increasing the interval from 30 min to 120 min 
between injection of haloperidol (0.5 mg/kg) and testing for recognition of the cocaine 
cue, cocaine antagonism increased from 20 to 85 %. This result contrasts with the 
present one, as not only did we see a clear attenuation with haloperidol at 0.3 mg/kg, 
but we also used a pre-treatment time of 30 min. In contrast, the only study using 
raclopride in drug discrimination was by Johanson and Barrett (1993), where it was 
shown that raclopride (1-1.7 mg/kg) attenuated the DS effects of cocaine in pigeons. 
The result is similar to the present study, albeit with different doses and species. The 
most obvious difference between studies using haloperidol that failed to produce any 
antagonism and the present study is the procedure for testing antagonism. Unlike 
previous studies, which tested antagonists only against the training dose of cocaine, 
the present study tested the antagonists against the full cocaine dose-response curve, 
which offers the advantage of minimal disruption of response rates when tested 
against cocaine (also see section 1.6.3). 
Looking at the effects of the D2-like antagonists in the low dose training 
group, the profiles observed were very similar, in that haloperidol and rac10pride were 
more potent in attenuating cocaine's DS effects than L-741 ,626. The present study is 
the first to investigate DA antagonist compounds at the 3 mg/kg training dose of 
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cocaine. Unlike Terry et al. (1994), who used D1-like and D2-like agonists, a different 
picture is observed using antagonist compounds in terms of attributing receptor 
subtype involvement in cocaine's DS effects. Not only does the present study support 
D1-like receptor subtype involvement in low dose training conditions (as shown by 
the selective blockade by the Dl-like antagonist SCH 39166), but it also supports D2-
like receptor subtype involvement in the low dose DS effects. 
In characterising further the receptor subtypes at which these antagonists are 
acting to block the DS properties of cocaine, 'Schild analysis' was employed to 
calculate pA2 values for the individual DA antagonist compounds. This information 
tells us, by comparing the pA2 values obtained for each compound, whether they are 
acting on the same receptor SUbtypes. The results in table 3.4 make it difficult to 
conclude that the DA receptor antagonists employed in the present study are acting at 
different receptors. However, it is interesting to note that although L-7 41,626, 
haloperidol and raclopride are each effective in attenuating cocaine's DS effects in 
high dose training conditions, the actions of L-7 41,626 may be mediated via different 
receptor subtypes (i.e. pA2 values obtained are 4.97,6.50 and 6.87, respectively). This 
result fits with the drug's binding affinities, since haloperidol and raclopride not only 
display affinity for different receptors within the D2-like receptor subfamily, but they 
also bind to other receptors (as mentioned previously), unlike L-741,626 which is 
reported to act exclusively at the DA D2 receptor SUbtype. 
Since our antagonist studies argue against a role for DA D4 receptors, and 
whilst clarification using more selective D2 and D3 receptor antagonists is still 
needed, these data suggest that the DA D2 receptor is the critical subtype within the 
D2-like subfamily that is involved in the DS effects of cocaine. Also, the similar 
effectiveness of haloperidol (i.e. D2=D3=D4) and raclopride (i.e. D2=D3»D4) at 
blocking the cocaine cue also supports the absence of a role for DA D4 receptors in 
cocaine's DS effects. Once again, pA2 values obtained in the low dose training. 
conditions paralleled those of the high dose training group, suggesting that similar 
mechanisms of action were engaged in the two training groups. 
Finally, in an additional experiment, the selective NE/5-HT re-uptake inhibitor 
venlafaxine partially substituted for the DS effects of cocaine, suggesting that 
neurotransmitters other than DA may be involved in cocaine's DS effects. Although 
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significant deviations from parallelism were observed in both training conditions 
(suggesting that venlafaxine may be producing its effects via a different mechanism of 
action compared to cocaine), more cocaine-appropriate responding was found in the 
low dose training condition. Venlafaxine is a potent inhibitor of 5-HT and NE re-
uptake, but it may also inhibit the re-uptake of DA in vitro at concentrations only 10-
fold higher (Holliday and Benfield, 1995). However, as doses were used in a range 
where the dopaminergic effects of venlafaxine are not apparent (~ 30 mg/kg; Reneric 
and Lucki, 1998) one can probably rule out any dopaminergic involvement in the 
present results. This is supported by other behavioural assays where venlafaxine has 
been used as a selective NE/5-HT inhibitor at doses of 10 and 30 mg/kg p.o. (Jackson 
et aI., 1997). It would be interesting to see whether a sub-maximal dose ofvenlafaxine 
can potentiate the DS effects of cocaine. If so, venlafaxine may be worth investigating 
further as a therapeutic agent for cocaine abuse. 
Because cocaine can be considered a strong inhibitor of 5-HT re-uptake, it is 
conceivable that this monoamine could be involved in its DS effects and may 
contribute to the substitution of venlafaxine for cocaine. However, 5-HT receptor 
antagonists do not block the DS effects of cocaine (Meert and Janssen, 1992; Peltier et 
aI., 1994), and moreover the selective 5-HT re-uptake inhibitors have been shown not 
to substitute for cocaine. For example, citalopram (Baker et aI., 1993) and fluoxetine 
(Kleven et aI., 1990; Cunningham and Callahan, 1991; Baker et aI., 1993) do not 
mimic the stimulus effects of cocaine. However, pre-treatment with either fluoxetine 
or sertraline can shift the dose-effect curve for cocaine to the left; for example, both 
1.25 and 4 mg/kg fluoxetine enhances the stimulus properties of cocaine in rats 
(Cunningham and Callahan, 1991; Kleven and Koek, 1998) and in squirrel monkeys 
(Schama et aI., 1997). In this context, the in vivo 5-HT re-uptake blocking properties 
of cocaine contribute little to its DS effects. Even so, it is clear that combined 
administration of cocaine and 5-HT re-uptake blockers influences its behavioural. 
effects (Walsh and Cunningham, 1997) which suggests that 5-HT could playa 
modulatory role. _____ 
Several recent pharmacological characterisations of the DS effects of low 
doses of cocaine indicate that NE involvement may be more important than 
previously believed. That is, NE re-uptake blockers (e.g. desipramine, nisoxetine or 
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talsupram) engender more complete substitution for the DS effects of a low training 
dose in either rats (Terry et aI., 1994) or monkeys (Spealman, 1995), in contrast to 
findings obtained in animals trained with higher doses (Broadbent et aI., 1991; Baker 
et aI., 1993; Spealman, 1995). It could be that species and/or training conditions are 
important determinants of the extent that NE is involved in the DS effects of cocaine. 
Taken together, the study with venlafaxine suggests that although it may not produce 
full substitution for cocaine in the high dose training group, there seems to be a 
potency shift as the training dose is decreased. The apparent blockade ofNE and 5-HT 
re-uptake by venlafaxine does not seem to produce a greater effect compared to when 
these selective NE and 5-HT re-uptake inhibitors are used alone. The possibility that 
venlafaxine may potentiate the DS effects of low doses of cocaine still needs to be 
determined in order to characterise fully the involvement of NE/5-HT in the DS 
effects of cocaine. 
In summary, it can be stated conclusively that the DA D3 and D4 receptor 
subtypes do not contribute to the DS effects of cocaine. Instead, the present study 
using selective antagonists within the Dl-like and D2-like receptor subtype families 
has suggested a role for the Dl-like and the D2 receptor subtype specifically. In 
addition, it also suggests that Dl-like and D2 receptor subtype antagonists are not 
differentially effective between the two training doses. Thus for DA D2-like receptor 
antagonists with different affinities for receptors within the D2-like subfamily, 
blockade of cocaine's DS effects cannot be attributed to the D3 or D4 receptor 
SUbtypes: the D2 receptor is likely to be critical. 
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CHAPTER 4: 
THE ROLE OF DOPAMINE ON FEEDING AND LOCOMOTOR 
ACTIVITY IN THE RAT 
4.1 Introduction 
In the previous chapter, it was concluded that DA D3 and D4 receptors playa 
negligible role in the DS effects of cocaine. It would now be useful to assess the 
generality of these results by examining other behavioural effects of cocaine. For 
example, cocaine has been shown to suppress appetite (Bedford et aI., 1980; Blavet 
and De Feudis, 1982; Foltin et aI., 1983) and to increase activity (e.g. Reith and 
Fischette, 1991). At still higher doses, repetitive motor activity (stereotyped 
behaviour) often occurs (e.g. Ujike et aI., 1990). Any or all of these behaviours could 
be used to investigate DA receptor subtype involvement in cocaine's effects (e.g. 
Scheel-Kruger et aI., 1977; Costall and Naylor, 1979; Beninger, 1983; Rapoza and 
Woolverton, 1991). Although DA clearly plays a major role in several of the 
behavioural effects of cocaine, the involvement of the recently cloned D3 and D4 
receptors in such effects of cocaine has not been extensively examined. At the same 
time, the in vivo effects of DA D3 and D4 receptor antagonists themselves have not 
yet been determined. Since DA has been implicated in many different processes, such 
as ingestive and motor behaviours (section 1.5), the need to investigate the effects of 
these antagonists alone is an essential prelude to combination studies with cocaine. In 
section 1.5, the effects of selective DA receptor agonists and antagonists on locomotor 
activity were described; these are also summarised in Table 4.1. The following section 
will now briefly describe the effects that agonists and antagonists of these receptor 
subfamilies have on ingestive behaviour. 
4.2 Dopamine and Food Reward 
There is considerable evidence for an association between feeding behaviours 
and the release of DA in the nucleus accumbens (Hernandez and Hoebel, 1988a; 
McCullough and Salamone,t992; Yoshida et aI., 1992). The nucleus accumbens is 
located within the ventromedial striatum and is a critical neural substrate for 
reinforcement processes and appetitive behaviour. The anatomical organisation of the 
nucleus accumbens is well-suited for this role. Information in the form of affective 
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and motivational states from the limbic structures such as the amygdala, 
hippocampus, prefrontal cortex and brainstem autonomic centres (Kelley et aI., 1982) 
converges on the nucleus accumbens. From here, it has extensive connections to 
motor output systems (Groenewegen et aI., 1980). Hence the nucleus accumbens has 
been viewed as an interface between the corticolimbic and motor systems where 
processing of affective information is translated into motor actions (Mogenson et aI., 
1980). The nucleus accumbens is no longer considered to be a homologous structure 
but to comprise of three major sub-territories, termed the core, shell and rostral pole. 
The core subregion connects extensively to classic basal ganglia output structures 
such as the ventral pallidum, subthalamic nucleus and substantia nigra. The shell 
subregion, in contrast, projects most heavily to subcortical limbic regions such as the 
lateral hypothalamus and ventral tegmental area (Deutch and Cameron, 1992). A 
functional link may therefore exist between these brain regions, whereby the shell 
subregion may exert an important modulating influence on the lateral hypothalamic 
neurones which regulates food intake. It may also be that cocaine has a direct effect 
on food intake per se by signalling satiety signals within the hypothalamus. A recent 
study by Kristensen et ai. (1998) has shown that a brain-located peptide named CART 
(cocaine and amphetamine regulated transcript) is a satiety factor closely associated 
with the actions of two important regulators of food intake, leptin and neuropeptide Y. 
When injected intracerebroventricularly into rats, recombinant CART peptide inhibits 
both normal and starvation-induced feeding, and completely blocks the feeding 
response caused by neuropeptide Y. 
As stated earlier, there are also a number of studies suggesting a specific linle 
between reward and the mesolimbic dopamine system. For example, accumbens DA 
release has been shown to be potentiated by many non alimentary rewarding stimuli 
such as psychostimulant drug administration (Kiyotkin, 1993), sexual behaviour 
(Dam sma et ai., 1992), and electrical stimulation of the lateral hypothalamus 
(Hernandez and Hoebel, 1988b). Compounds that facilitate DA neurotransmission, 
such as cocaine, cause an overall increase in DA levels in the nucleus accumbens and 
have been shown to reduce food ingestion. Compounds which lower DA tone within 
the system such as DA receptor antagonists (Hodge et ai., 1994; Hsiao and Smith, 
1995) also reduce ingestion of palatable foods. Hence, there is a relationship between 
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meso limbic DA system activity and reward, including food reward (Martel and 
Fantino, 1996); basal DA tone within the system appears to contribute to the 
regulation of food intake. 
4.3 Role of Dopamine Receptor Subtypes in Ingestive Behaviour 
4.3.1 'D1-Like' and 'D2-Like' Agonists 
To date, studies of the effects of dopaminergic drugs on ingestive behaviour 
have utilised compounds that are selective for either the DA D1-like or D2-like 
receptor sub-families (cf. Terry, 1996). While both D1-like and D2-like receptor 
agonists reduce the size of meals, it is quite clear that they achieve this effect by 
different means. Gilbert and Cooper (1985) first reported that a selective D1-like 
receptor agonist, the benzazepine SK&F 38393, produced a dose-dependent 
suppression of palatable food consumption in non-deprived rats. A microstructural 
analysis of the anorectic effect of SK&F 38393 revealed that it reduced the duration 
and rate of eating (Cooper et a1., 1990). However, as the selective D1-like receptor 
antagonist SCH 23390 was unable to antagonise the anorectic effect of SK&F 38393 
(Terry and Katz, 1992), questions were raised as to whether the compound's effect is 
exclusively due to action at D lID5 sites. The introduction of the potent and selective 
isochroman D1-like receptor agonist A-68930 (DeNinno et a1., 1990) provided further 
opportunity to study the role of this receptor subtype in feeding behaviour. AI-Naser 
and Cooper (1994), using microstructural analysis, showed it to significantly reduce 
food consumption. In particular, it had a modest effect on eating rate but markedly 
reduced the frequency of feeding bouts. Moreover, it significantly increased 
groommg. 
Unlike D1-like agonists, which only inhibit food intake, D2-like agonists have 
been shown to produce biphasic effects. For example, selective D2-like agonists such 
as N-0437 and PHNO increase eating at low doses (Martin-Iversen and Dourish, 
1988; Clifton et a1., 1989; Rusk and Cooper, 1989b), but have been shown to inhibit 
eating at high doses (Clifton et a1., 1989). Their main anorectic effect, within a meal, 
is to reduce the rate of eating (Rusk and Cooper, 1989b). In addition to its effect on 
feeding, N-0437 was also shown to suppress grooming, but stimulated oral responses 
such as licking and gnawing (Rusk and Cooper, 1989b). Table 4.1 summarises the 
95 
Chapter 4: The Role of Dopamine On Feeding and Locomotor activity ... 
main findings. Most of the relevant behavioural pharmacology so far has involved DA 
receptor subtype stimulation, i.e. the use of selective agonists. However, antagonists 
of each receptor subtype also produce clear behavioural effects. 
4.3.2 'D1-Like' and 'D2-Like' Antagonists 
The Dl-like antagonist SCH 23390 has been shown to reduce food intake both 
in food-deprived rats (Gilbert and Cooper, 1985; Zarrindast et aI., 1991; Terry and 
Katz, 1992) and in free-feeding animals (Clifton et aI., 1991; Naruse et aI., 1991). 
There have also been reports that SCH 23390 reduces operant responding for food 
reinforcement (e.g. Rusk and Cooper, 1994). In contrast, D2-like antagonists can 
produce biphasic effects on food intake, with low doses enhancing food intake and 
high doses suppressing it, e.g. spiperone (Cooper and Sweeney, 1980) sulpiride 
(Parada et aI., 1988) haloperidol (Hobbs et aI., 1994) and raclopride (Terry, 1996). 
Smith and Hsiao (1995) also showed that raclopride can reduce sucrose preference in 
rats, indicating that central DA D2-like mechanisms may be involved in the mediation 
of food reward. 
D1-like and D2-like antagonists have not been studied thoroughly in terms of 
the microstructural parameters that contribute to their anorectic effects. In the only 
study to date, Terry (1996) showed that the D1-like antagonist SCH 39166 did not 
affect total food intake, but significantly reduced feeding bout frequency. This 
reduction was compensated by a dose-dependent (but non-significant) increase in the 
mean duration of each bout. However, changes in other aspects of motor behaviour 
such as locomotion, rearing and grooming make the results difficult to interpret with 
regards to specificity of the behavioural effects on feeding. 
D2-like antagonists present further problems due to their biphasic dose-effect 
on feeding behaviour. StUdying the effect ofraclopride on palatable food consumption 
by non-deprived rats, Terry (1996) showed that the low dose hyperphagic effect 
resulted mainly from increases in the number of feeding bouts and mean bout 
duration, whereas the high dose hypophagia was a product of increased latency to eat 
and reduced number of feeding bouts. However, as the hypophagic effect occurred at 
and above doses of rac10pride that significantly disrupted other aspects of motor 
behaviour, it is difficult to assume behavioural specificity of the D2-like antagonist 
anorectic effect. Studies with the D2-like antagonist YM-09151-2, have shown little 
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TABLE 4.1 
Summary of effects of selective dopamine receptor subtype agonists and antagonists on feeding 
and locomotor activity in the rat (except where mentioned). 
ACTION DRUG FEEDING BEHAVIOUR LOCOMOTOR ACTIVTY 
Dl-like AGONISTS: 
SKF 38393 .,\.. Gilbert & Cooper (1985) t Szechtman et al (1991) 
Martin-Iversen & Dourish (1988) t &.,\.. Tirelli & Terry (1993) 
Rusk & Cooper (1989a) [Mice] 
SKF 75760 .,\.. Rusk & Cooper (1989a) 
SKF 82958 & .,\.. Terry & Katz (1992) 
SKF 77434 
A-68930 .,\.. Cooper & AI-Naser (1994) 
D2-like AGONISTS: 
Apomorphine"\" Barzaghi et al; (1973) t &.,\.. Stahle & Ungerstedt (1986) 
Bromocriptine .,\.. Hawkins et al; (1986) 
N-0437 
PHNO 
Dl-like ANTAGONISTS: 
SCH 23390 
SCH 39166 
D2-like ANTAGONISTS: 
Haloperidol 
t (low doses) .,\.. (high doses) 
Clifton, Rusk & Cooper (1989) 
Rusk & Cooper (1989b) 
t(low doses) .,\.. (high doses) 
Martin-Iversen & Dourish (1988) 
.,\.. Koechling et al; (1988) 
Naruse et al; (1991) 
Clifton Rusk & Cooper (1991) 
.,\.. Terry & Katz (1994) 
Panocka et al; (1995) 
.,\.. Naruse et al; (1991) 
YM-09151-2 .,\.. feeding rate t meal size 
Remoxipride & t food intake 
Raclopride Clifton, Rusk & Cooper (1991) 
Raclopride 
Sulpiride 
.,\.. sucrose preference 
Smith et al; (1995) 
t Parada et al; (1988) 
~ 
t /.,\.. = Increase or Decrease behaviour. 
97 
.,\.. (low doses) 
Rusk & Cooper (1989b) 
.,\.. Bruhwyler et al; (1990) 
Cabib et al; (1991) [mice] 
Meyer at al; (1993) 
.,\.. Bakshi & Kelley (1991) 
.,\.. Horita et aI; (1995) 
Wise & Carlezon (1994) 
.,\.. Cabib et al; (1991) 
[mice] 
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effect on total food intake, but cause substantial dose-related decreases in feeding rate 
and an enhancement of both meal size and duration (Clifton et aI., 1991). In the same 
study, a second DA D2-like antagonist, remoxipride, produced similar effects on 
feeding patterns, and in addition raised food intake during the 2 hr after drug 
administration. Another D2-like antagonist, raclopride, produced a short-term rise in 
food intake and a slowing of feeding rate, with a non-significant increase in meal size 
at intermediate doses. 
In summary, D1-like agonists consistently produce anorexia by specifically 
affecting meal duration through an effect on meal frequency, but more drugs need to 
be studied. Similarly, D1-like antagonists can reduce food intake, perhaps also 
through an effect on meal frequency, but disruptions of feeding occur in conjunction 
with decrements in motor behaviour. D2-like agonists and antagonists present greater 
interpretative difficulties: both classes of drugs produce biphasic effects on intake, 
with low doses enhancing food intake and high doses suppressing it. Both classes tend 
to reduce eating rate, and the enhanced feeding reported following low doses of a D2-
like antagonist most often reflects an increase in average meal duration. 
4.4 Animal Models to Measure Feeding and Locomotor Activity 
4.4.1 Feeding Behaviour 
A plethora of drugs inhibit food intake when administered to experimental 
animals. One of the most contentious issues in the psychopharmacology of appetite 
concerns the identification of mechanisms underlying an observed reduction of eating. 
Often in such experiments the only measure taken is the amount of food consumed 
over brief time periods following acute drug treatment. This information is important, 
but it is insufficient to allow any conclusions to be drawn about the specificity of 
action of the drug on feeding behaviour. 
A. Food Deprivation, Food Intake and Drug Effects 
The simplest experimental paradigm that has been used to examine drug 
effects on food intake involveS' administration of the drug to food-deprived rats and 
the subsequent determination of food intake over a brief test period. This procedure is 
simple and convenient for the experimenter, but can be criticised on several grounds. 
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1. A period of food deprivation followed by a brief period of food access does not 
involve a normal behavioural repertoire. 
2. Deprivation may result in physiological changes, both in the periphery and the 
brain, which may impair the efficacy of the drugs used to alter feeding, e.g. periods 
of food deprivation have been shown to influence brain neurotransmitter synthesis 
and metabolism (Fletcher, 1989). 
3. Finally, and perhaps most important, the observation that a drug alters total food 
intake does not provide any insight into the specific effects of the drug on 
behaviour. 
Feeding behaviour is different from food intake in the sense that it can be defined 
accordingly to 'contextual', and 'temporal' dimensions. In the rat, feeding is an 
episodic activity in which periods of eating (meals) are separated from each other by 
periods of other behaviours. A meal has a clearly determined beginning and end, and 
can be defined operationally in terms of its initiation, duration and termination. 
Blundell (1979) suggests that the terms hunger, appetite, satiation and satiety can be 
related to these separate facets of the meal. Hunger is defined as the process that 
indicates that eating is imminent, and is inferred from the initiation of a meal. 
Appetite is the process that maintains feeding and guides the selection of foods based 
upon the hedonic value of those foods. Satiation refers to the termination of feeding 
resulting from the act of food ingestion itself, whereas satiety is the state of inhibition 
over further eating. In order to understand the nature of the effects of drugs on feeding 
behaviour, it is necessary to use experimental procedures that supply more 
information than just the quantity of food consumed in a brief period of time. 
B. The Microstructure of Feeding 
Blundell and Latham (for review see Blundell, 1983) have pioneered the use 
of a technique to examine the continuous changes in the 'microstructure' of feeding 
behaviour. The technique involves recording instances and durations of feeding bouts 
and the intervals between feeding bouts. The typical experimental procedure involves 
adapting the animal to a food-deprivation schedule. Once food intake has stabilised, 
the animal is injected with drug and placed in the test cage with access to food. The 
animal is then observed, usually for 30 min or Ih, and the occurrence and duration of 
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various behaviours (e.g. Table 4.2) are recorded either manually or with a keyboard 
connected to a microcomputer. In addition to recording feeding bouts, it is possible to 
record instances of general activity, grooming, resting and drinking. At the end of the 
test session, the amount of food consumed is determined. Once data collection has 
been completed, the data can be broken down into various behavioural categories and 
feeding parameters. Essentially, each behaviour is described in terms of its duration 
and frequency across the test period. Several other parameters can be derived to 
describe feeding, and these are listed in Table 4.3. 
Microstructural analysis of feeding behaviour permits identification of 
differing mechanisms of drug action not apparent from pharmacological studies of 
food intake alone. This procedure, therefore, provides a methodology for the 
preliminary identification of drugs that appear to reduce food intake via processes 
linked to natural mechanisms of satiety. 
4.4.2 Locomotor Activity 
In investigating a particular neural system or a certain class of drugs, most 
information can be gained by studying a range of behaviours. Not only can one 
measure a drug's effects on motivational behaviours such as feeding, as mentioned 
above, analysis of spontaneously emitted behaviour such as locomotor activity can 
also produce useful information. The term 'locomotion' means movement from one 
location to another. In rodents, an important component of spatial exploration is 
locomotion, and it is one of the most prominent in the rat's repertoire of spontaneous 
behaviours. The most commonly-used procedure for measuring locomotor activity is 
the photocell cage (Figure 4.1). The prototype consists of a box or cage, usually 
rectangular and large enough for the rat to walk around, with two photocells placed on 
the long axis of the cage, each consisting of an emitter and receiver interfaced to a 
microcomputer. Each photocell beam, when broken, registers a count which is 
recorded by the computer. The scores are usually collected in specified bins. This 
method is adopted here. There are many factors that influence the general activity 
level of animals; these factors must be taken into account when testing for drug effects 
(Cambell, 1960; Prescott, 1970; File and Day, 1972; Evans, 1974; Robbins, 1977; 
File, 1978; File, 1985) . 
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Table 4.2. Behavioural categories used for observational analysis. (From: 
Halford, Wanninayoke and Blundell, 1998). 
Eating 
Grooming 
Locomotion 
Rearing 
Resting 
Biting, gnawing or swallowing food from wet mash 
directly or from front paws 
Licking of the body, feet and/or genitals. Scratching of 
coat or head with hind leg. Stroking whiskers with 
paws, biting of the tail 
Walking around the cage or circling. Movements 
involving all four limbs 
Front paws raised from the tank floor and either 
placed on the side of the tank or placed in front 
ofthe body 
Relaxed position with head curled to body or resting on 
the bottom of the cage, stretched out either on side or 
belly 
Table 4.3. Parameters derived from the microstructural analysis of feeding 
behaviour. 
Total food intake (g) 
Total time spent eating (min) 
Latency to onset of first feeding bout (min) 
Number of feeding bouts 
Bout size (g) 
Bout duration (min) 
Rate of eating (g/min) 
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Figure 4.1. Prototype model for measuring locomotor activity in a photocell cage. The photocells are placed along the 
axis of the cage where 'beam' breakages register a count which is received by a microcomputer. 
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CHAPTERS: 
A COMPARISON OF THE EFFECTS OF NOVEL 
'D2-LIKE' RECEPTOR SUBTYPE ANTAGONISTS ON FEEDING AND 
LOCOMOTOR ACTIVITY IN THE RAT 
5.1 Aims 
The main purpose of the experiments described in the present chapter is to 
investigate the effects of two novel D2-like receptor subtype antagonists on feeding and 
locomotor activity in the rat. The contributions of DA D3 and D4 receptors to these 
effects have not been determined due to the limited availability of compounds acting 
specifically at these receptors. The development of two drugs selective for these 
receptors, U-99194A and L-745,870, respectively, now allows for such characterisation to 
be made. These compounds were subsequently compared with the prototypical D2-like 
antagonist sulpiride (Kebabian and CaIne, 1979; Seeman and Van Tol, 1994) and the 
recently developed antagonist amisulpride, a structural analog to sulpiride. No previous 
studies have looked at the roles of these novel D2-like receptors in feeding behaviour. 
The receptor binding profiles ofU-99194A and L-745,870 have been described in section 
3.1; however, it is necessary to describe briefly the binding affinities of the comparison 
compounds of sulpiride and amisulpride. 
Sulpiride has been hypothesised to have a higher affinity for presynaptic than for 
postsynaptic D2 receptors at low doses (Robertson and MacDonald, 1985), and to show a 
similar affinity for D2 and D3 postsynaptic receptors at high doses (Sokoloff, 1990). 
Sulpiride has also been widely used as a prototypical D2-like antagonist in many 
behavioural studies (e.g. Arnt, 1985; Parada et al., 1988; Cabib et al., 1991; Bakshi and 
Kelley, 1991; Inoue et aI., 1995; Neisewander et ai., 1995; Baker et aI., 1996). 
Amisulpride is a novel antipsychotic agent that shows clinical efficacy against both the 
positive and negative symptoms of schizophrenia. It is a benzamide derivative with a 
unique neurochemical and psychopharmacological profile (Perrault et al., 1997). The 
compound has selective affinity for human D3 and D2 receptor subtypes in vitro, and ex-
~ 
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vivo binding studies have shown it to be twice as selective for D3 as for D2 receptors 
(Scatton et aI., 1997). At low doses it preferentially blocks presynaptic DA autoreceptors 
(therefore increasing DA release) while postsynaptic DA receptor antagonism is evident 
at higher doses (Scatton et aI., 1997; Schoemaker et aI., 1997). Moreover, it has been 
claimed that amisulpride interacts preferentially with limbic DA D2-like receptors rather 
than with striatal D2-like receptors (Schoemaker et aI., 1997) a characteristic that may 
explain its low incidence of extrapyramidal side effects (Perrault et aI., 1997). 
Ligand binding studies in vitro using rat brain have shown that both sulpiride and 
amisulpride have a high affinity for DA receptors but no significant affinity for 5-HT 
receptors, histamine HI, muscarinic and a-adrenergic receptors, or a variety of other 
receptors and drug recognition sites (Scatton et aI., 1994). Amisulpride selectively 
recognises the DA D2 and D3 subtypes with similar affinity (Ki values of2.8 and 3.2 nM 
respectively) but has no affinity (Ki value of > 1000 nM) for Dl, D4 and D5 receptor 
subtypes (Scatton et aI., 1997). Ki values for sulpiride at D2 and D3 receptor subtypes 
have been reported as 15 and 13 nM, respectively (Seeman and Van Tol, 1994). In effect, 
we have four different compound which all belong to the D2-like subfamily but show 
differing specificities for the various DA receptor subtypes, i.e. amisulpride, with equal 
affinity for D2/D3 sites at both pre and post-synaptic receptors; sulpiride, also with equal 
affinity for D2/D3 sites, but which binds specifically to D2 sites pre-synaptically; U-
99194A, selective for D3 receptors; and L-745,870 selective for D4 receptors. 
All drugs were compared using a similar procedure in which locomotor activity 
was measured at the same time as feeding to see if drug effects on feeding occurred at 
doses that produced no effects on simple measures of motor behaviour. Also, locomotor 
activity tends to be among the first behaviours affected by drug action when measuring 
multiple behaviours. These experiments were intended to characterise the overall effects 
of these compounds on feeding and locomotion as a prelude to experiments using a 
microstructural analysis of behaviour. 
_..-/ 
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5.2 Materials and methods 
5.2.1 Subjects: 
Male Sprague-Dawley rats, eight per experiment (Charles River, Margate, Kent) and 
weighing 320-360g, were housed in pairs with free access to water under a 12 hr 
light/dark cycle (lights on 07:00). They were maintained on a restricted diet of 15g 
standard food pellets, adjusted on test days so that regardless of any effect of the test 
drug, all rats received the same food allowance per day. All testing was between 12:00 
and 14:00 hours. 
5.2.2 Apparatus: 
The test food was presented in a shallow plastic petri-dish, 9 cm in diameter, with a rim 
1.5cm high and weighing approximately 109; it was secured with 'velcro-tape' to the 
floor of the experimental cages (Ebenezer, 1990). Testing was conducted in experimental 
cages measuring 53 x 32 x 18 cm high. Water was available ad lib in the test boxes from 
a spout connected to an externally mounted bottle. The highly palatable diet (Gilbert and 
Cooper, 1985) consisted of 50 ml sweetened condensed milk (Nestle) mixed with 200 ml 
tap water and 150 ml powdered rodent lab chow (No1 ground rat maintenance diet, 
Special Diet Services Ltd; Essex, UK). Locomotor activity was measured in the same test 
boxes, each bisected by two photo-cell beams (Retroreflective Scan System, model RS 
348-38, RS Components, Corby, Northants, UK). The photobeams were fixed 
horizontally at a height of 7 cm and spaced 25 cm apart from each other and 3.5 cm from 
each end of the box. One locomotor activity count was registered each time a rat crossed 
between the two beams. Multiple interruptions of the same beam were recorded but not 
analysed here. 
5.2.3 Procedure: 
Rats were removed from the colony room to a separate room in their home cages and 
given familiarisation sessions in the experimental cages prior to drug studies. They were 
adapted to eating the sweetened wet mash for 120 min in the absence of external 
disturbance until baseline levels of food intake were consistent (4 sessions with at least 48 
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hrs between testing). On experimental sessions, rats were injected i.p. with either 
physiological saline (control) or the test drug and placed back in their home cages. The 
test food was presented to the rats 30 min after injection of the antagonists, with the 
exception of sulpiride, for which there was a" 60 min interval. The dishes and their 
contents were weighed before being presented to the rats and at 30, 60, 90 and 120 min 
afterwards. The subtraction of post-from pre-feeding values was the measure of food 
intake. Water consumption was also measured at the same time points. Locomotor 
. 
crossings were recorded automatically by PC throughout the 2 hr test session, and then 
collated into 30 min intervals for analysis using a purpose-written data extraction 
programme. A repeated measures design was used, with each rat receiving all treatments 
in a random order and with a period of at least 48 hrs between successive tests. 
5.2.4 Drugs: 
Amisulpride (Synthelabo Recherche, Bagneaux, France) was dissolved in distilled water 
with a few drops of 1M HCI solution and NaOH to give a pH of 7.S. (-) Sulpiride (Tocris 
Cookson, Bristol, England , UK) was dissolved in distilled water and a few drops of 
acetic acid to give apH of6.S. L-74S,870 (3-( [4-chlorophenyl) piperazin-1-yl] methyl)-
IH-pyrrolo [2,3-b] pyridine; Tocris Cookson, Bristol, England, UK) and U-99194A 
Maleate (S,6,-Dimethoxy-2-(di-n-propylamino)indan maleate; RBI Chemicals, Natick 
MA, USA) were dissolved in distilled water. All control conditions used appropriate 
vehicles and all drugs were injected i.p. at 1 ml/kg. 
5.2.5 Data analysis: 
Results were analysed using a two-way analysis of variance for repeated measures 
(ANOV A) followed by post-hoc t-tests (Student-Newman Keuls and Dunnett's multiple 
comparisons tests). Time samples were analysed not only for the entire 2 hr period (in 30 
min bins) but also for the first 30 min of the test session, since 20-30 min has been a 
common test duration in similar studies using other drugs, and a 30 min period is also to 
be used for microstructural studies later. EDso values and their 9S% confidence lim~ts 
were calculated using standard ANOV A and linear regression techniques on data from the 
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linear portion of the dose-response curves. A significant difference in EDso values was 
obtained when comparisons presented non-overlapping 95% confidence limits. Relative 
potency estimates were calculated to give the dose of standard drug (mg/kg) equal to 1 
mg/kg of comparison drug; a significant difference was assumed if the 95% confidence 
limits did not include 1.0. 
5.3 Results 
5.3.1 Experiment 1: Effects of U-99194A and L-745,870. 
The effects ofU-99194A on food intake and locomotor activity are shown in Figure 5.1. 
Administration ofU-99194A did not affect food intake over 2 hrs [Main effect of dose: 
F(3,21) = 1.89, P = 0.162 NS]. However, there was a significant time effect [F(3,21) = 
311.68, P<O.OI] and a dosextime interaction [F(9,63) = 3.34, P<O.OI]. Post-hoc tests did 
not reveal any significant differences between individual doses ofU-99194A and vehicle 
control over the 2 hr test session. However, when the data for the first half hour of the test 
session were analysed, an effect of drug on food intake was seen [F(3,21) = 5.25, 
P<O.OI]. Post-hoc tests, on the other hand, did not reveal any significant differences 
between individual doses ofU-99194A and vehicle control. 
U-99194A did not significantly affect locomotor activity over the full experiment 
[F(3,21) = 2.79, P>0.05]. There was a significant time effect [F(3,21) = 26.98, P<O.OI] 
but no dosextime interaction [F(9,63) = 1.14, P = 0.352 NS]. None of the doses of U-
99194A affected total locomotor activity over the full 2 hr test period. Data analysed over 
the first half hour, however, indicated a main effect on locomotor activity [F(3,21) = 
3.19, P<0.05], with post-hoc tests indicating that the 10.0 mg/kg dose caused a significant 
reduction in locomotor activity over the first 30 min (P<0.05). 
The effects of L-745,870 on food intake and locomotor activity are shown in 
Figure 5.2. Administration of L-745,870 reduced food intake; main effect 'of dose: 
F(3,21) = 3.50, P<0.05. There was also a significant time effect [F(3,21) = 102.08, 
P<O.OI] and a dosextime interaction [F(9,63) = 4.08, P<O.OI]. Post-hoc tests revealed that 
-----
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the 10.0 mg/kg dose of L-745,870 produced a significant decrease in feeding (P<O.Ol) 
compared with vehicle controls over the full test session. When the data within the first 
30 min of the test session were analysed, an effect of drug on food intake was also seen 
[F(3,21) = 13.20, P<O.Ol]. Post-hoc tests again showed that the 10.0 mg/kg dose of L-
745,870 produced a significant decrease in feeding (P<O.Ol) compared with vehicle 
controls. 
Administration ofL-745,870 also resulted in a dose-related decrease in locomotor 
activity [F(3,21) = 17.36, P<O.Ol]; there was also a significant time effect [F(3,21) = 
18.29, P<O.Ol] and a dosextime interaction [F(9,63) = 3.73, P<O.Ol]. Post-hoc tests 
revealed that the 3.0 and 10.0 mg/kg doses ofL-745,870 produced significant reductions 
in locomotor activity (P<O.Ol) compared with vehicle controls over the full test session. 
Data analysed within the first 30 min also revealed an effect of L-745,870 [F(3,21) = 
34.78, P<O.Ol], and post-hoc tests showed that the 3.0 and 10.0 mg/kg doses produced 
significant reductions in locomotor activity over 30 min (P<O.Ol) compared with vehicle 
controls, mirroring the effects over the full test period. 
EDso values could not be calculated for the effects ofU-99194A due to the drug's 
inability to reduce behaviours below 50% of vehicle control levels. Higher doses of the 
drug were not used because they are unlikely to be D3 selective. With regards to L-
745,870, only locomotor activity was reduced enough for its EDso value to be calculated 
(Table 5.1). This dose, 3.43 mg/kg is above the range considered selective for the D4 
receptor (doses of < 1 mg/kg being selective for the site, Patel et aI., 1996a; 1997). 
No effect of these compounds on water intake was found (results not shown). 
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* P<O.OS COMPARED TO VEHICLE CONTROL 
Fi~lIre 5.1. Effects orthe D3 recepto r antagoni st U-99 194A on feed ing (top panel) and locomotor activity (bottom panel) in food-
deprived ra ts. N = 8 at all po in ts. Data were recorded fro m en try to the experimental cages (time 0 min ) onwards. 
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TABLE 5.1. 
EDso values (mg/kg) for the effects of four dopamine receptor subtype antagonists 
on two behaviours (feeding and locomotor activity) during the first 30 min of the test 
session. 
FEEDING 
DRUG EDso(95% CL) 
U-99194A 
L-745,870 
Amisulpride 
Sulpiride 
R.P. -, 
R.P. = Relative potency. 
LOCOMOTOR ACTIVITY 
EDso(95% CL) 
3.43 (2.40-4.90) 
13.49 (7.47-24.36) 
68.64 (10.05-468.97) 
2.94 (0.51-29.77) 
(-) = No value calculated due to food intake or locomotor activity not being altered by 
more than 50% of control levels. 
111 
Chapter 5: A Comparison of the Effects of Novel 'D2-like' ... 
5.3.2 Experiment 2: Effects of sulpiride and amisulpride. 
The effects of sulpiride on food intake and locomotor activity are shown in Figure 5.3. 
Administration of sulpiride did not result in a main effect of drug on food intake [F(3,21) 
= 1.33, P = 0.292 NS], although there was a significant time effect [F(3,21) = 151.38, 
P<O.OI] and a dosextime interaction [F(9,63) = 2.58, P<0.05]. There was no significant 
effect of any dose on total food consumed over the 2 hr test period. However, analysing 
the data over the first 30 min alone revealed an effect of drug on food intake [F(3,21) = 
3.77, P<0.05]. Post-hoc tests revealed that the 5.0 mg/kg and 50.0 mg/kg doses of 
sulpiride produced significant increases in feeding (P<0.05) compared with vehicle 
control conditions. 
In contrast, administration of sulpiride resulted in a decrease in locomotor activity 
over the 2 hr test period [F(3,21) = 14.35, P<O.OI] with a significant time effect [F(3,21) 
= 34.46, P<O.OI] and a dosextime interaction [F(6,63) = 2.18, P<0.05]. Total locomotor 
activity was suppressed at 50.0 mg/kg (P<O.OI) compared with vehicle controls. 
Analysing the data over the first 30 min alone also revealed a main effect of drug on 
locomotor activity [F(3,21) = 18.13, P<O.OI]. Post-hoc tests showed that 50.0 mg/kg 
produced a significant reduction in locomotor activity (P<O.OI). 
The effects of amisulpride on food intake and locomotor activity are shown in 
Figure 5.4. Administration of amisulpride did not produce a main effect on food intake 
over the fu112 hr test session [F(3,21) = 1.93, P = 0.156 NS]. There was a significant ti?1e 
effect [F(3,21) = 250.10, P<O.OI] and a dosextime interaction [F(6,63) = 2.22, P<0.05]. 
Similar to the results obtained with sulpiride, amisulpride failed to significantly affect 
total food intake over the 2 hr test period at any of the doses used. However, analysing the 
data from the first 30 min revealed an effect on food intake [F(3,21) = 3.71, P<0.05]: 
Post-hoc tests showed this to be due to a significant increase in feeding produced by the 
5.0 mg/kg dose of ami suI pride (P<0.05 compared with vehicle control). 
In contrast, administration of amisulpride resulted in a decrease in locomotor 
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activity [Main effect: F(3,21) = 10.24, P<O.Ol], a significant time effect [F(3,21) = 44.27, 
P<O.Ol] and a dosextime interaction [F(9,63) = 5.11, P<O.Ol]. Total locomotor activity 
was significantly suppressed at 50.0 mglkg (P<O.Ol) compared with vehicle controls. 
Analysing the data from the first 30 min also revealed an effect on locomotor activity 
[Main effect: F(3,21) = 23.63, P<O.Ol]. Post-hoc tests showed that the 50.0 mg/kg dose 
also produced a significant reduction in locomotor activity compared with vehicle 
controls (P<O.Ol) over the first 30 min of the test session. 
A further experiment was carried out using 100 mglkg of amisulpride (results not 
shown), a dose believed to block postsynaptic receptors (Scatton et aI., 1997). The results 
showed no significant decrease in food intake either in the first 30 minutes (Vehicle: 29.6 
g mean food intake; amisulpride: 26.7 g), or over the whole session. However, there was 
a significant decrease in locomotor activity (P<O.Ol) in comparison with vehicle control. 
ED 50 values for the two drugs (Table 5.1) showed that amisulpride is more potent (~ 3 
times) than sulpiride in suppressing locomotor activity. No value could be calculated for 
feeding due to the drugs' failure to change food intake by more than 50%. 
113 
40 
:§ 35 I 
w 30 I ~ 
« 
..... 25 
~ 
0 20 
0 
0 15 
u.. 
Z 10 
« 
w 
:E 5 
0 , 
* 
* 
0- 30 30 - 60 
Chapter 5: A Comparison of the Effects of Novel 'D2-like' ... 
60-90 
• VEHICLE 
o SULPIRIDE 0.5rrg/kg 
III SULPIRIDE 5.0rrg/kg 
o SULPIRIDE 5O.0rrg/kg 
90 - 120 
TIME AFTER PRESENTATION (MIN) 
* P<O.OS COMPARED TO VEHICLE CONlROL 
40 
• VEHICLE 
0:: 35 
0 
30 
o SULPIRIDE 0.5rrg/kg 
..... 1 0 • SULPIRIDE 5.0rrg/kg :ECI) 25 0 ..... D SULPIRIDE 5O.0rrg/kg 
U Z 20 o=> ** 
-l0 15 ~ zU 
« 10 ~ -,fiJ:L~ w :E 5 o i c-
0-30 30 - 60 60-90 90 - 120 
TIME AFTER PRESENTATION (MIN) 
* P<O.OS, ** P<O.01 COMPARED TO VEHICLE CONlROL 
Figure 5.3. Effects of the D2-like receptor antagonist Suipiride on feed ing (top panel) and locomotor activity (bottom panel) in 
food -deprived rats. N = 8 at all point s. Data were recorded from entry to the experimental cages (time 0 min) onwards. 
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5.4. Discussion 
The results show that sulpiride has similar effects to amisulpride on feeding 
behaviour, producing an increase in food intake at low doses but no apparent effect at the 
higher doses tested. Also, the locomotor activity data showed that both drugs caused a 
dose-dependent decrease in activity. Other D2-like antagonist drugs have been shown 
previously to produce a similar biphasic effect on eating, i.e. an increase in food intake at 
low doses followed by a decrease at higher doses. Hence, the effects of the standard D2-
like compounds used in the present study are typical of what has been found before. For 
example, spiperone (Cooper and Sweeney, 1980), pimozide (Lawson et aI., 1984), YM 
09151-2 and remoxipride (Clifton et aI., 1991), haloperidol (Hobbs et aI., 1994) and 
rac10pride (Terry,1996) have all been shown to increase feeding when administered at 
low doses. Similarly, many of the above D2-like compounds have been shown to 
decrease locomotor activity (e.g. Bakshi and Kelley, 1991; Wise and Carlezon, 1991; 
Horita et aI., 1995). 
Here, we report for the first time the effects ofU-99194A and L-745,870, drugs 
which display relatively high affinity and selectivity for D3 and D4 receptors 
respectively. U-99194A produced a significant main effect on feeding over the first 30 
min, but did not produce any significant changes in food intake over the full 2 hr test 
session. There was also a small but significant reduction in locomotor activity at the 
highest dose. In contrast, L-745,870 inhibited food intake at the highest dose, and caused 
a dose-dependent decrease in locomotor activity. 
It is interesting to note that U-99194A showed a similar feeding profile to 
sulpiride and amisulpride. All three drugs (but not L-745,870) produced an increase in 
food intake at low doses and a decrease at higher doses. These results may suggest that 
the D3 receptor subtype within the D2-like receptor subfamily may be responsible for this 
behavioural profile, as amisulpride and sulpiride bind to D3 and D2 receptor subtypes. A 
microstructural study of the effects of U-99194A is needed in order to identify the 
features of behaviour responsible for the drug's effect on feeding (Chapter 6), and to 
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determine whether it operates in a similar manner to other D2-like antagonists. 
In contrast, a number of studies have investigated the role of the D3 receptor in 
locomotor activity. Other drugs sometimes considered to be D3 receptor antagonists, such 
as (+)-AJ76 and (+)-UH232, which display 3-5 times higher affinity for D3 than D2 
receptors, have been shown to produce dose-dependent increases in locomotor activity 
accompanied by increases· in DA release (Svensson et aI., 1986), suggesting the 
involvement of presynaptic receptors. Recently, the finding that U-99194A (30-fold D3 
over D2 selectivity) increases locomotor activity without any concomitant effects on DA 
release has led to the hypothesis that the D3 receptor is postsynaptic, and that its blockade 
leads to stimulation of locomotor activity (Waters et aI., 1993; Waters et aI., 1994). 
Kling-Petersen et ai. (1995) also showed that U-99194A produced an increase in activity 
when injected into the NAC or the lateral ventricle, but not in the ventral tegmental area. 
The findings by these authors conflict with the present results, probably due to 
methodological differences between the studies. In one study (Waters et aI., 1993), U-
99194A increased locomotor activity in rats at doses of25 Ilmol/kg (s.c.) and above; this 
minimum dose corresponds to approximately 10 mg/kg in the present study, a dose that 
decreases locomotor activity. In this study, locomotor activity and food intake were 
measured simultaneously, whereas Waters et ai. (1993) measured locomotor activity in 
rats which were habituated to their environment for 60 minutes before administration of 
the drug. Gendreau et ai. (1997), while studying the effects of D3 receptor involvement 
on emotional reactivity in mice, found that after habituation to the activity chamber prior 
to drug administration, U-99194A increased locomotion and rearing at lower doses (5, 10 
mg/kg) but reduced these behaviours at higher doses (20, 30 mg/kg) . However, in mice 
exposed to the activity chamber for the first time, the same drug produced only weak 
motor activation at lower doses and an early decrease in motor behaviour at higher doses 
that was followed by an increase in locomotion later in the test session. The latter study 
and the present one are the only ones to date to suggest that the selective D3 antagonist 
U-99194A can reduce motor activity, albeit using different doses and species. Clearly 
there are discrepancies in the results for this compound as to whether or not it stimulates 
~ 
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locomotor activity. A microstructural study of this compound could again help identify 
the nature of the drug's effect on locomotor activity. 
We also examined for the first time the effects of the selective D4 receptor 
antagonist L-745,870 on feeding and locomotor activity. Given the drug's negligible 
effect in behavioural tests of antipsychotic activity (Bristow et aI., 1996) and on cocaine's 
discriminative stimulus effects (reported in Chapter 3), and the limited effects of other 
selective D4 antagonist compounds such as U-IOB87 (Merchant et aI., 1996), it was 
surprising to see this drug affecting feeding in the present study. However, caution is 
needed since the decrease in food intake coincided with a decrease in locomotor activity. 
More importantly, the effects on feeding occurred at a dose unlikely to be D4-specific, 
and at which other D2 receptor subtypes are occupied (Bristow, personal 
communication). Similarly, the EDso value obtained for locomotor activity (3.43 mg/kg) 
is at the upper end of the selectivity range, i.e. doses of below 1 mg/kg are presumed 
selective for the D4 receptor subtype (Bristow, personal communication). Again, this 
result reinforces the finding that the decreases in feeding and locomotor activity which 
OCCUlTed with compounds belonging to the D2-like subfamily may be attributed to 
binding at the D21D3 receptor subtypes and not the D4 receptor SUbtype. 
It has been suggested that activation of central D2-like receptors is necessary for 
the normal positive reinforcing effects of sucrose on sham feeding, since selective D2-
like receptor antagonists (including sulpiride) suppress sucrose sham-feeding in the rat 
(Schneider et aI., 1986).· This effect appears to be centrally mediated because 
domperidone, a DA antagonist restricted to peripheral receptors, has no effect on either 
sham or real feeding (Duong and Weingarten, 1993). However, sulpiride and amisulpride 
have been shown to potentiate food-induced conditioned place preference, perhaps 
indicating enhanced incentive properties of the primary reinforcer (Guyon et aI., 1993). 
The authors hypothesised that neuroleptics such as amisulpride and sulpiride can increase 
the ability of rats to experience pleasure through potentiation of the release of DA 
triggered by food presentation. This could be due to the higher affinity of these 
compounds for D2 (or D3) autoreceptors which were blocked at concentrations below 
------
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those that block postsynaptic receptors. 
Amisulpride blocks the tenninal DA autoreceptor and behavioural experiments 
are consistent with this finding. For example, there is evidence that apomorphine-induced 
yawning and hypo locomotion maybe presynaptically mediated (e.g. Di Chiara et aI., 
1976; Yamada and Furukawa, 1980; Dourish and Hutson, 1985), and amisulpride 
preferentially blocks these effects at low doses (Perrault et aI., 1997). The wide separation 
between doses of amisulpride that antagonise the different apomorphine-induced effects 
may be related to a preferential blockade of pre-synaptic D2/D3 receptors involved in 
apomorphine-induced hypomotility and yawning (Schoemaker et aI., 1997). This 
hypothesis is supported by neurochemical studies in vivo showing that amisulplide 
increases the release of DA in the olfactory tubercle evoked by electrical stimulation of 
the ascending dopaminergic pathways in the rat (an index of nerve tenninal D21D3 
autoreceptor blockade) at doses very close to those that antagonise hypomotility induced 
by apomorphine, i.e. ~ 10 mg/kg (Schoemaker et aI., 1997). An interaction of amisulpride 
at low doses with presynaptic DA autoreceptors was also supported by an increase in 
extracellular DA levels in the striatum and nucleus accumbens of the rat (Schoemaker et 
aI., 1997). Much higher doses were needed (i.e. 40-80 mg/kg) to decrease striatal ACh 
levels (an index of postsyanptic D2 receptor blockade), as well as to reverse 
apomorphine-induced hypennotility or stereotypies (Schoemaker et aI., 1997). 
This may help explain the behavioural effects of this drug on feeding behaviour: 
at low doses there is an increase in food intake as a result of D21D3 pre-synaptic 
blockade. But this doesn't explain why its structural analog sulpiride at relatively high 
doses (50 mg/kg, presumably a preferential postsynaptic dose) caused an increase in food 
intake and did not suppress feeding as would be expected from this hypothesis. Clearly, 
there is a distinction in behavioural effects between the low and high doses of these D2-
like antagonists on feeding behaviour. However, there are claims that autoreceptors may 
not be involved in these sorts of effect (for review, see Stahle, 1992). Stahle (1992) 
argues against the hypothesis that stimulation of DA autoreceptors is the mechanism by 
which DA agonists induc9awning and suppression of exploration. The relation between 
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reduced extracellular DA levels (assessed by microdialysis) and the behavioural effects of 
DA agonists, a DA synthesis inhibitor and a granule storage blocker have been shown to 
be highly inconsistent (Stahle, 1992). In addition, amphetamine co-treatment can increase 
DA levels while yawning and suppression of exploration are still induced. Stahle (1992) 
suggested that autoreceptors are not the mediators of these behavioural effects, and 
proposed instead that postsynaptic receptors mediate DA agonist-induced yawning and 
suppression of exploration. Hence, we cannot be certain that the stimulation of feeding 
obtained here is necessarily due to autoreceptor-mediated action. 
The exact anatomical sites for feeding behaviour cannot be determined from this 
study; however, Parada at al. (1988) reported that sulpiride injected into the lateral 
hypothalamus caused an increase in feeding at low doses. While dose-dependent 
enhancement of feeding duration was also obtained following injection of haloperidol 
into the nucleus accumbens, injection of sulpiride in the ventrolateral striatum reduced 
feeding duration (Bakshi and Kelley, 1991; Inoue et al., 1995). 
With regards to locomotor activity, no biphasic effects were obtained with either 
sulpiride or amisulpride: both drugs caused dose-dependent decreases in activity. This 
conflicts with the findings by Perrault et al. (1997) who reported only a slight decrease in 
locomotor activity at 100 mg/kg amisulpride, with an EDso > 100 mglkg compared with 
13.49 mg/kg obtained in the present study. Their explanation for the drug's low potential 
for decreasing locomotor activity highlighted three biochemical properties which 
characterise this drug: (A) high specificity for D2 and, perhaps more importantly, D3 
limbic receptors. By using [3H] raclopride, a high affinity radioligand for the DA D2 and 
D3 receptors, Schoemaker et al. (1997) showed that amisulpride (and its analog sulpiride) 
displayed a preferential affinity for limbic D21D3 receptors; (B) selectivity for limbic 
areas: for example, few D3 receptors are found in the striatum. The drug's EDso for 
inhibiting in vivo [3H] raclopride-specific binding in the rat striatum was 43.6 mg/kg, 
compared with 17.3 mg/kg in the limbic system; and (C) preferential blockade of pre-
synaptic D2/D3 receptors (as mentioned earlier); by increasing DA release, it may relieve 
blockade of striatal posts¥}1aptic D2 receptors. As amisulpride and sulpiride decreased 
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locomotor activity in the present study at doses believed to be acting post-synaptically 
(i.e. 40-80 mg/kg, and at doses which are believed to occupy 70-80 % striatal D2 
receptors) this decrease in behaviour can only be attributed to blockade of striatal D2 
receptors. 
Amisulpride was more potent than sulpiride in suppressing locomotor activity, 
and more potent than in the study by Perrault et al. (1997). However, it is difficult to 
compare the present results with those of Perrault, since in their study food intake was not 
measured simultaneously with locomotor activity. Also, their rats were not habituated as 
they were in the present study, and so they produced high baseline levels of activity 
which makes comparisons difficult to conclude. However, it is worth noting the 
difference in potency between amisulpride and sulpiride. This may be due to amisulpride 
having a greater affinity for the D21D3 receptor subtypes (5-fold more selective compared 
to sulpiride): its behavioural potency mirrors this effect, amisulpride being nearly three 
times more potent than sulpiride at suppressing locomotor activity. 
In conclusion, the experiments suggest that the D3 receptor antagonist U-99194A 
produces similar behavioural effects to other D2-like receptor antagonists. However, the 
D4 receptor antagonist L-745,870, at doses specific for the D4 receptor subtype, does not 
produce a similar profile; only at doses that occupy D2 receptors were significant effects 
on feeding and locomotor activity observed. 
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CHAPTER 6: 
DOPAMINE D3 AND D4 RECEPTOR ANTAGONISTS: MICROSTRUCTURAL 
ANALYSES OF THEIR EFFECTS ON FEEDING AND ASSOCIATED 
BEHAVIOURS IN THE RAT 
6.1 Introduction And Aims Of Experiments 
Studies focusing on DA and ingestive behaviour have largely been concerned with 
the effects of DA D2-like receptor antagonists. Due to the lack of selective drugs, the 
possible involvement of D3 and D4 receptor subtypes has been overlooked. However, the 
data from the previous chapter indicated that U-99194A produced a significant effect on 
food intake in the first 30 min of the test session. The same drug also caused a slight 
reduction in locomotor activity at the highest dose tested (10.0 mg/kg). The selective D4 
antagonist, L-745,870, in comparison, also produced an effect on food intake, evident at 
10.0 mg/kg, and a dose-related decrease in locomotor activity. 
Although the measurement of food consumption by quantity may shed light upon 
certain features of energy balance, the moment-to-moment, psychological processes that 
control feeding behaviour cannot be obtained by such measures. Consequently, feeding 
can be described in greatest detail by taking account of its microstructure (Blundell, 
1983). The procedure involves exhaustively observing the behaviour of rats under drug 
during a fixed time-period and recording various categories of behaviour (Table 4.2 and 
4.3). The purpose of such fine analysis is to reveal potentially subtle differences between 
the effects of drugs that may not be revealed by a simple measure of the amount of food 
consumed. The microstructural approach therefore generates results which can be used 
not only to discriminate between drug actions, but also to suggest their underlying 
behavioural mechanisms of action. In this respect, the involvement of D3 and D4 
receptors in feeding and locomotor activity requires further investigation. 
The aim of the next experiments is to assess the effects of U-99194A and L-
745,870 using a microstructural analysis of behaviour. Comparisons will be drawn with 
the effects of other DA D2-like antagonists on food intake. In addition to feeding, a 
_.-/ 
number of other behavioural responses were observed. This allows more detailed 
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comparisons to be made with other DA D2-like antagonists, and more generally provides 
a fuller characterisation of the behavioural profiles associated with the actions of the 
drugs. The information obtained will not only be informative per se, but will also provide 
data concerning doses that are necessary prior to drug combination studies with cocaine 
(chapter 8). 
6.2 Materials and methods 
6.2.1 Subjects: 
Sixteen male Sprague-Dawley rats, eight per experiment, (Charles River, Margate, Kent), 
weighing 320-360g were housed in pairs with free access to water under a 12 hr 
light/dark cycle, lights on 07:00. They were all maintained on a restricted diet of 15g 
standard food pellets per day, adjusted on test days so that regardless of the effect of drug 
all rats received the same food allowance per day. All testing was between 12:00 and 
14:00 hours. 
6.2.2 Drugs: 
U-99194A Maleate (5,6,-Dimethoxy-2-(di-n-propylamino)indan maleate) and L-745,870 
(3-( [4-chlorophenyl) piperazin-l-yl] methyl) -IH-pyrrolo [2,3-b] pyridine) were obtained 
from RBI Chemicals (Natick MA, USA) and Tocris Cookson (Bristol, UK) respectively. 
They were both dissolved in distilled water, administered intraperitoneally at doses of 1, 
3 and 10 mg/kg and injected 30 min prior to test. 
6.2.3 Procedure: 
The pre-treatment adaptation period, food preparation and apparatus were the same as 
described in section 5.2.3. Thirty minutes following drug administration, the animal was 
transferred to the observation box containing a plastic petri dish with a freshly-prepared 
sample of the sweetened mash. Throughout the 30 min observation period, an observer 
kept a continuous record of the animal's behaviour. Each episode of behaviour was 
recorded by entering the start and end into a microcomputer (Elonex PC) where a 
purpose-built software programme recorded each observed behaviour. The software 
logged the duration and sequence of each key-press. Five keys were assigned to five non-
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overlapping response categories, which consisted of: (i) feeding, i.e. biting, chewing and 
ingesting the sweetened mash; (ii) locomotor activity, horizontal activity, horizontal 
movement about the test box employing all four limbs; (iii) rearing, front limbs raised or 
resting on the side of the observation box; (iv) grooming, i.e. licking, scratching or biting 
at any part of the body surface; (v) stationary, resting or immobile, i.e. not engaged in any 
of the preceding activities. The software provided an analysis of the total duration (min) 
for each response category, the frequency of individual bouts for each category, and the 
mean duration of individual bouts for 5-min interval bins over a total duration of 30 
minutes. Food intake was calculated by successive weighings (to the nearest 0.1 g, any 
spillage was collected). The local rate of eating (g/min) was calculated for each test by 
dividing the amount of food consumed by the total duration of feeding. The latency to 
initiate feeding was timed from the start of the session until the moment the animal made 
contact with the sweetened mash. The observers were pre-trained to recognise and record 
all behavioural categories as shown in Table 4.2. 
6.2.4 Design and statistical analysis: 
The data were analysed by one-way analysis of variance (ANOV A) for repeated measures 
where the drug doses were administered to the rats in a 'Latin Square' design. 
Comparisons between the results for individual drug-treatment conditions and the vehicle 
control condition were made using Dunnett's t-test. 
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6.3 Results 
6.3.1 The 03 antagonist 
(a) Food Intake and Feeding Microstructure. 
U-99194A (1-10 mg/kg) produced a significant effect on food intake over the 30-min 
observation period [F(3,21) = 4.83, P<0.05], although post-hoc tests revealed that only 
the highest dose differed significantly from vehicle (a modest 20 % reduction with respect 
to control levels; Fig. 6.1 a). There was no significant effect of the drug on the latency to 
initiate feeding (Fig. 6.1 b); a trend towards an increase is shown, but the effect failed to 
reach statistical significance (P>0.05). Likewise, analysing the other feeding parameters, 
U-99194A failed to affect total time spent feeding (Fig. 6.1d), mean bout duration (Fig. 
6.1e) or bout frequency (Fig. 6.lf and Table 6.1). However, even though there were no 
significant effects on mean bout duration or bout frequency, a noticeable trend was 
apparent for both measures. While mean bout duration showed a biphasic response, i.e. an 
increase to 3 mg/kg followed by a decrease at 10 mg/kg, bout frequency showed the 
opposite trend. The only microstructural parameter significantly affected was local rate of 
eating [F(3,21) = 3.90, P<0.05; Fig. 6.1c], reduced by 17 % with respect to control levels 
at 10 mg/kg (P<0.05). 
(b) Locomotor Activity. 
U-99194A produced no significant effects on any of the parameters of locomotor activity 
during the observation period (Table 6.1). However, duration of locomotor activity and 
bout frequencies did show biphasic profiles, tending to decrease and then increase to 
baseline levels. 
(c) Rearing. 
U-99194A significantly reduced the duration of rearing activity [F(3,21) = 3.79, P<0.05], 
largely due a significant reduction in the frequency of individual bouts [F(3,21) = 5.06, 
P<O.OI; Table 6.1]. Duration of individual rearing bouts showed little change with dose. 
Total rearing duration decfeased by 60 % at 10 mg/kg (P<O.OI), and at the same dose, 
mean bout frequencies also decreased by 60 % (P<O.OI). 
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(d) Grooming. 
U-99194A had no significant effect on any of the parameters of grooming behaviour 
(Table 6.1). 
(e) Immobility. 
U-99194A had no significant effect on any parameter of immobility behaviour during the 
observation period (Table 6.1). 
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Figure 6.1. Effects of the dopamine D3 receptor antagonist U-99194A on feeding parameters: A: Total 
food intake B: Latency to start eating C: Eating rate D: Total duration E: Mean bout duration F: Bout 
frequency. N= 8 at all points~* P<O.05, ** P<O.Ol compared to vehicle control, V (comparisons by 
Dunnett's t-tests). 
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Results are shown in terms of Mean +/- S.E.M. (N=8). F-ratios and levels of significance are shown for one-way ANOVA. 
Levels of significance for individual dose comparisons against control conditions: * P <0.05; ** P <0.01 (Dunnett's t-test). 
Table 6.1. Microstructural analysis of non-feeding behaviours following administration of the D3 antagonist U-99194A. 
Behaviours significantly affected are highlighted in grey. 
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6.3.2. The 04 antagonist 
(a) Food Intake and Feeding Microstructure. 
L-745,870 (1-10 mg/kg i.p.) had no effect on total food intake during the 30-min 
observation period [F(3,21) = 2.59, NS; Fig. 6.2a]. It also had no effect on the latency to 
initiate feeding or the total time spent feeding (Table 6.2; Fig. 6.2b and 6.2d). There was a 
significant reduction in the local rate of eating [F(3,21) = 4.57, P<0.05; Fig. 6.2c], with a 
reduction by 30 % at, 10 mg/kg. In addition, the frequency of feeding bouts was 
significantly reduced [F(3,21) = 12.02, P<O.OOI; Fig. 6.2f]. Surprisingly, mean bout 
duration showed an opposite trend [F(3,21) = 4.49, P<0.05; Fig. 6.2e]; at 10 mg/kg, L-
745,870 significantly increased the mean bout duration. Overall, the reductions in eating 
rate and bout frequency were cancelled out by an increase in mean bout duration, 
resulting in a negligible net effect on food intake. 
(b) Locomotor activity. 
At doses of 3 and 10 mg/kg, L-745,870 significantly reduced the duration of locomotor 
activity, as a result of a reduction in the frequency of individual bouts (Table 6.2), with 
duration of individual bouts of locomotion showing little change. Mean bout frequency 
decreased by 37 % at 3 mg/kg and 63% at the highest dose of 10 mg/kg. At 
corresponding doses, total duration of locomotor activity decreased by 47 % and 70 % 
respectively. 
(c) Rearing. 
L-745,870 had no significant effect on the total duration of rearing or mean bout duration, 
although there was a significant reduction in the frequency of rearing (Table 6.2). This 
occurred at the highest dose of 10 mg/kg, and corresponded to a reduction of 
approximately 58 %. 
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(d) Grooming. 
There was a significant decrease in total duration of grooming, although the frequency of 
grooming bouts was very similar between doses; there was a significant decrease in mean 
bout duration with the highest dose having a prominent effect (Table 6.2). 
(e) Immobility. 
L-745,870 (1-10 mg/kg) had no significant effect on any parameters of immobility during 
the observation period (Table 6.2). 
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Figure 6.2. Effects of the dopamine D4 receptor antagonist L-745,870 on feeding parameters: A: T{)tal 
food intake B: Latency to start eating C: Eating rate D: Total duration E: Mean bout duration F: Bout 
frequency. N= 8 at all points.i __ * P<O.05, ** P<O.Ol, compared to vehicle control, V (comparisons by 
Dunnett's t-tests). 
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ults are shown in terms of Mean +/- S.E.M. (N=8). F-ratios and levels of significance are shown for one-way ANOVA. 
ILevelS of significance for individual dose comparisons against control conditions: * P <0.05; ** P <0.01 (Dunnett's t-test). 
Table 6.2. Microstructural analysis of non-feeding behaviour following administration ofthe D4 antagonist L-745,870. Behaviours 
significantly affected are highlighted in grey. 
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6.4. Discussion 
Microstructural analysis helps us to identify the behavioural changes· which 
underlie the effects of drugs on feeding behaviour. The present results provide a detailed 
behavioural analysis of the effects of selective DA D3 and D4 receptor antagonists in 
food-deprived rats, and can be compared with results for compounds that are less 
selective within the DA Dl-like and D2-like receptor sub-families (Table 6.3). 
The results indicate that a significant anorectic effect was detected at 10 mglkg U-
99194A. The reduction in feeding could not be attributed to a reliable increase in the 
latency to initiate feeding, or to effects on bout duration or frequency, but seems 
primarily due to a significant reduction in the rate of feeding. With regards to the DA D4 
antagonist, there was no evidence that L-745,870 (1-10 mg/kg) significantly affected total 
food intake. The overall duration of feeding and the latency to initiate feeding were 
unaffected by the D4 antagonist. Nevertheless, at 1, 3 and 10 mglkg, L-745,870 
significantly reduced feeding bout frequency, with the highest dose also decreasing eating 
rate. Paradoxically, mean bout duration was shown to increase, therefore tending to 
cancel out the effect of frequency and resulting in a negligible net effect on total food 
intake. This finding goes against our previous results where we showed that the 10 mg/kg 
dose of L-745,870 produced a significant decrease in feeding (P<O.OI) that continued 
over the full 2 hr test period. Nevertheless, the present results do suggest a trend towards 
a decrease, so the highest dose may be 'borderline' in terms of reliably reducing food 
intake. 
Comparisons with the effects of less-selective D2-like receptor antagonists 
suggest that D3 or D4 receptor blockade is not an important contributor to the effects of 
these drugs (Table 6.3). Thus traditional D2-like antagonists have only one feature in 
common with the present results for the D3 antagonist: a decrease in the local rate of 
eating (Clifton et aI., 1991). Terry (1996), looking at palatable food consumption by non-
deprived rats, demonstrated a biphasic dose-effect of rac10pride (D21D3 antagonist) on 
feeding, with increased intake at low doses; the only parameters significantly affected 
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"D I-Like" Receptor Subfamily "D2-Like" Receptor Subfamily Present results 
Agonist Ant~gonist Agonist Antagonist D3 D4 
Behavioural Responses: 
\ 
(antagonists) 
Food Intake 4, 0 4, t(LD) 4,(HD) 4, 0 
Latency 0 0 0 t(HD) 0 0 
Eating Rate 4, 0 4, -J, 4, ,J., 
Total Duration 4, 0 0 0 0 0 
Mean Bout Duration t t 0 t(LD) 0 t 
Bout Frequency 4, 4, 0 t(LD) ,J.,(HD) 0 ,J., 
KEY: t = Increase ,J., = Decrease o =No Effect HD = High Dose LD=LowDose 
Table 6.3. Summary of effects of dopaminergic drugs on ingestive behaviour (from Terry, 1996; and present results) 
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were feeding duration and the latency to start eating. The iow-dose hyperphagia reflected 
modest increases in the number of feeding bouts and mean bout duration, whereas the 
high dose hypophagia was a product of increased latency to eat and reduced number of 
feeding bouts. This behavioural profile is very different from that of U-99194A, which 
suggests that even though rac10pride binds to the D3 receptor subtype, its effect on 
feeding cannot be attributed exclusively to action at the D3 receptor subtype within this 
subfamily. Analysing U-99194A's effects on feeding microstructurally therefore suggests 
that the drug affects feeding via different processes in comparison with less selective D2-
like antagonists, even though all such drugs have a similar feeding profile. 
In fact, U-99194A produces effects most similar to those of the D2-like agonists 
(Table 6.3; also Terry, 1996). In a very recent study that makes an ethologically-based 
comparison of the behavioural effects of GR 103691, nafadotride and U-99194A (all 
putative selective DA D3 receptor antagonists) it was shown that U-99194A caused a 
dose-dependent stimulation of episodes of non-stereotyped sniffing, locomotion, chewing 
and eating of faecal pellets, with some stimulation of rearing and reduced levels of 
grooming (Clifford and Waddington, 1998). The topography of response to U-99194A 
overlapped somewhat with the profiles ofD2-like agonists (as is the case for the feeding 
profiles reported in the present study) and Dl-like agonists. In addition, the behavioural 
effects of U-99194A were antagonised by pre-treatment with the prototypical D2-like 
antagonist, haloperidol. On this basis, the ethogram of U-99194A is more similar to, 
though not identical with, that of the D2-like agonists. As yet, however, there is little 
direct evidence to suggest either agonist or partial agonist activity for U-99194A at any of 
the D2-like receptors, although the possibility cannot be excluded. 
The selective D4 antagonist, L-745,870, on the other hand, produced effects most 
similar to those of Dl-like antagonists. However, certain features of the behavioural 
effects did display some similarities with ligands for other DA receptor SUbtypes. 
Whereas a decrease in the rate of feeding mirrored D2-1ike agonist effects (Rusk and 
Cooper, 1989) the closest overall similarity of effects was with aDA Dl-like antagonist. 
Terry and colleagues demonstrated that SCH 39166 (a selective Dl-1ike antagonist) 
caused a decrease in the number of meals consumed, which was compensated by a dose-
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dependent increase in mean duration of eating bouts (Terry, 1996). There has been 
considerable interest in the possibility that D1-like and D2-like receptors interact to 
modulate each other's effects. The similarity of behavioural effects induced by these 
selective DA receptor subtype antagonists suggests a possible D1-D4 interaction in the 
control of food intake. This may be supported by the fact that D4 receptors are expressed 
in midbrain nuclei, amygdala and frontal cortex (Hadley, 1996), while there is still debate 
as to whether they are expressed in nucleus accumbens and basal ganglia (Defagot and 
Antonelli, 1997); thus the two receptors may show co-localisation. Further experiments to 
see whether the selective D4 antagonist, L-745,870, can attenuate the hypophagic effects 
ofD1-like agonists may provide evidence for such an interaction. 
Alternatively, a compensatory mechanism may be initiated by the drug, such that 
a decrease in the number of meals is compensated by increases in mean duration as a 
result of a non-specific response to disruption of feeding. However, as yet, there are no 
reports of other classes of anorectic compound showing a similar profile. 
U-99194A had no effect on any parameter of locomotor activity at doses up to 10 
mg/kg. Once again, the results conflict with previous work (see Chapter 5), in which U-
99194A was shown to increase locomotor activity without any concomitant effects on 
DA release. This has led to the claim that the D3 receptor subtype is functionally relevant 
at the post-synaptic level, and that its blockade leads to activation of locomotor activity 
(Waters et aI., 1993, 1994). The results also contrast with the previous experiment, in 
which a decrease in photocell beam interruptions was recorded at 10 mglkg. Again this 
could be due to methodological differences, since the previous study measured photocell 
beam disruptions; the present experiment characterised the behaviour by continuous 
observation in terms of total duration, mean bout duration and bout frequencies. 
However, further analysis of data from the previous study, counting individual beams 
breaks rather than consecutive beam disruptions, showed that a decrease did not occur for 
this measure (72 beam crossings for vehicle control, versus 69, 76 and 64 for the 1, 3 and 
10mglkg doses, respectively). This is consistent with the lack of effect across doses 
obtained here, and suggests that at the highest dose the animals were moving 
predominantly locally, at one end of the experimental cage. Clearly there are 
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discrepancies for this compound as to whether or not (and how) it affects locomotor 
activity; as mentioned earlier (section 5.4), the effect may depend not only on methods of 
analysis but also the species used and the test procedure. 
Other anomalous results were obtained for rearing and grooming behaviour. U-
99194A clearly caused a dose-dependent decrease in total rearing duration and bout 
frequency; however, Accili et al. (1996) reported an increase in locomotor activity and 
rearing in an exploratory test using D3 'knock-out' mice. This suggests that blockade of 
the D3 receptor subtype by antagonist compounds such as U-99194A produces a different 
behavioural profile from that which occurs when the receptor is 'knocked out' 
genetically. A direct comparison between the studies is difficult to make. It could be that 
the null-mutant organism might not only lack the product of a single gene for the D3 
receptor subtype, but might also express a number of physiological and behavioural 
processes that have been altered during development to compensate for the effect of the 
null mutation. Therefore, one might expect an array of complex phenotypical changes not 
directly related to the function of the gene of interest. However, studies investigating the 
effects of D3 antagonists in D3 'knockout' animals would be useful to confirm whether 
these compounds are genuinely specific for these receptors. 
L-745,870 caused a substantial reduction in the overall time devoted to locomotor 
activity and in locomotor bout frequency. This cannot be attributed to more time spent 
feeding or resting, as the animals spent similar time intervals for each behavioural 
parameter regardless of dose used, and there were no significant differences between 
them (Table 6.2). The results may therefore suggest a specific behavioural effect: 
reducing locomotor activity via DA D4 receptor blockade, since it occurred at the low 
dose of 3 mg/kg. However, this is still a high dose in terms of selectivity for the D4 
receptor subtype, and the involvement of sigma sites and D2 receptors cannot be ruled out 
(see Table 4.1). The D4 antagonist decreased grooming bout duration and total time spent 
grooming; this occurred at the highest dose and may therefore have involved blockade of 
D2 receptors. This is in agreement with work by Terry (1996), in which the DA D21D3 
antagonist raclopride reduced all parameters of grooming behaviour. Not only is this 
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evident with D2-like antagonists, it also occurs with D2-like agonists such as N-0437 
(Rusk and Cooper, 1989). 
This is the only study so far that has looked (microstructurally) at the behavioural 
effects of a D4 antagonist. However, one study using a different selective DA D4 
antagonist, NRA0045, reported that it decreased spontaneous locomotor activity at doses 
up to 10 mg/kg i.p. (but not below 50% of control levels). In addition, locomotor 
hyperactivity induced by methamphetamine was dose-dependently antagonised by 
NRA0045 (EDso = 0.4 mg/kg), whereas methamphetamine-induced stereotyped behaviour 
(at a higher dose) was not affected by NRA0045 (Okuyama et aI., 1997a,b). As this drug 
also blocks 5-HT2a receptors, and the authors fail to specify the drug's selectivity for D4 
receptors at this dose, it is difficult to conclude that the effects are mediated solely by 
binding to the D4 receptor subtype. The present results suggest that this is unlikely. 
Since the identification of the DA D3 and D4 receptor subtypes, some progress 
has been made in understanding the functional roles of these novel receptors (e.g. for a 
review concerning D3 receptors: Shafer and Levant, 1998). In summary, the present study 
examined the effects of the selective D3 antagonist U-99194A and the selective D4 
antagonist L-745,870 on feeding and other behaviours. At doses that occupy post-
synaptic D3 receptors, feeding is marginally affected by U-99194A; effects on intake and 
rate of eating only occurred at the highest dose. The drug produced negligible effects on 
locomotor activity and grooming, but rearing was significantly reduced at the highest 
dose. Comparisons with the effects of less selective D2-like receptor antagonists suggest 
that D3 receptor blockade is not an important contributor to the effects of D2-like 
antagonists when analysed microstructurally. D4 receptor blockade produced a different 
profile of effects. There was no reduction in food intake at D4 receptor-selective doses; 
however, microstructural analysis showed that a significant decrease in the number of 
meals consumed was compensated by an increase in mean duration of feeding bouts. The 
local rate of eating declined only at the highest dose. Unlike the D3 antagonist, L-7 45,870 
also caused a substantial reduction in locomotor activity at doses that did not affect 
rearing. Comparisons with the effects of less-selective D2-like receptor antagonists 
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suggest that D4 receptor blockade is not an important contributor to those effects. In fact, 
L-7 45,870 produced effects more similar to those of D I-like antagonists. 
The results reveal clear dissociations between the effects of D3 and D4 receptor 
blockade on specific behaviours, but suggest only subtle effects on feeding. Neither D3 
nor D4 blockade alone mimics the effects of previously-tested D2-like receptor 
antagonists. 
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CHAPTER 7: 
CHARACTERISATION OF THE EFFECTS OF COCAINE ON FEEDING AND 
ASSOCIATED BEHAVIOURS IN THE RAT 
7.1 Introduction And Aims 
A decrease in food intake following acute administration of cocaine has been 
demonstrated using a variety of feeding paradigms (Heffner et aI., 1977; Woolverton et 
aI., 1978; Balapole et aI., 1979; Bedford et aI., 1980; Blavet and De Feudis, 1982). 
Specifically, Balapole et aI. (1979) showed that the effect of cocaine (10-25 mg/kg i.p.) 
on food intake was relatively transient, occurring only in the first hour post-injection. 
Others have shown dose-related (3.45-27.6 mg/kg i.p.) reductions in food consumption 
produced by cocaine in food-deprived rats (Heffner et aI., 1977; Bedford et aI., 1980), 
and Foltin et aI. (1983) found that cocaine (4-32 mglkg i.p.) could also produce dose~ 
dependent reductions in the consumption of sweetened milk by non-deprived rats. 
Cooper and Van der Hoek (1993) were the first to investigate the microstructutral 
changes in feeding that occur following cocaine administration (5.6-30 mg/kg). They 
found that cocaine increases the latency to initiate feeding, but did not affect the local rate 
of ingestion when feeding occurred. The authors concluded that cocaine may act during 
the appetitive phase that precedes consumption to reduce food incentive, but that food 
ingestion that occurs during the consummatory phase is not necessarily affected. They 
also reported increases in the frequency of locomotion. 
Rapoza and Woolverton (1991) reported that cocaine 16 mglkg suppressed milk 
intake to a greater extent than water intake, suggesting that cocaine has a more specific 
inhibitory effect on food intake. Wolgin and Hertz (1995) addressed this issue by 
investigating the effects of acute and chronic cocaine on milk intake in bottle-fed 
(dependent on appetitive behaviour) and cannula-fed (consummatory behaviour) rats; 
they showed decreased intakes in cannula-fed rats at the higher dose, suggesting that 
cocaine can also affect consummatory responses. 
Although a microstructural approach to studying the effects of cocaine has been 
presented, to date no reports have provided behavioural data relevant to identify' the 
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receptor subtypes by which cocaine affects feeding and associated behaviours in the rat; 
this is an issue that warrants further research. In addition to its anorectic effect, one of the 
defining behavioural characteristics of cocaine as a psychomotor stimulant is its ability to 
elicit increases in motor activity. These motor-increasing effects in mammals are similar 
to those produced by other psycho stimulants, particularly amphetamine. At low doses, 
these drugs produce an alerting response, consisting of increases in exploration, 
locomotion, grooming and rearing (Scheel-Kruger et aI., 1977; Snoddy and Tessel, 1985). 
As the dose is increased, locomotor activity decreases and the behavioural patterns 
become stereotyped, often involving continuous repetition of· one or a few items of 
behaviour. In rats, the repetitive behaviours induced by amphetamine and cocaine include 
head bobbing, gnawing, sniffing and licking (Scheel-Kruger et aI., 1977). The 
neurobiology of the motor-activating effects of cocaine has been the subject of numerous 
investigations for over two decades. The majority of evidence indicates that the 
neurochemical effects of cocaine underlying its ability to increase motor activity involve 
dopaminergic systems (Costall and Naylor, 1979; Scheel-Kruger et aI., 1977; Beninger, 
1983). There is now substantial evidence linking cocaine-induced locomotor activation to 
blockade of DA reuptake (Scheel-Kruger, 1971; Scheel-Kruger et aI., 1977; Snoddy and 
Tessel, 1985). The most recent and compelling evidence for this hypothesis comes from 
studies ofDA transporter 'knockout' mice. In contrast to wild-type mice, the mutant mice 
showed no change in locomotor activity when administered a high dose of cocaine (Giros 
et aI., 1996). This is presumably because, in the absence of the DA transporter, cocaine 
had no effect on extracellular DA concentration. The locomotor stimulating effects of 
cocaine have been ascribed largely to enhancement of dopaminergic transmission in the 
nucleus accumbens. This was first suggested by Kelly and Iversen (1976), who 
demonstrated reductions in cocaine-induced locomotor behaviour following 6-0HDA 
lesions of the mesolimbic DA pathway. Further supporting this hypothesis are more 
recent studies showing that locomotor activity can be elicited by direct microinjection of 
cocaine into the nucleus accumbens (Delfs, Schreiber and Kelley, 1990), and that the 
locomotor effects of systemically-administered cocaine can be significantly attenuated by 
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injection of sulpiride (the D2-like antagonist) into the accumbens (Neisewnader, O'Dell 
and Redmond, 1995). 
However, as for the effects of cocaine on feeding, no studies have been carried out 
looking at the involvement of novel D2-like receptor subtypes on such behaviours. Since 
cocaine has been reported to affect feeding behaviour in a variety of feeding paradigms 
and to elicit increases in motor activity, the initial experiments of this chapter were 
carried out to investigate whether these results could be replicated in our laboratory using 
a paradigm which has yielded consistent effects in previous studies. An experiment was 
conducted to characterise the dose(s) of cocaine which reliably produce anorexigenic 
effects in the rat. Locomotor activity was measured at the same time as feeding to see if 
effects on feeding occurred at doses which also elicit increases in activity. An additional 
experiment was carried out looking at the effects of cocaine on locomotor activity without 
the presence of food. This was to examine whether concomitant feeding alters cocaine's 
dose-response profile for locomotion. Finally, a microstructural study of c,?caine's effects 
on feeding and a range of typical behaviours was conducted. The data from this final 
experiment will be important for the later studies into the receptor mechanisms by which 
cocaine affects feeding and associated responses; specifically, it will be used to justify 
dose selection for experiments to test the involvement of DA D2-like receptors in the 
cocaine-induced behaviours. 
7.2 Materials and methods 
7.2.1 Subjects: 
Twenty-four male Sprague-Dawley rats (eight per study; Charles River, Margate, Kent) 
weighing 320-360g were housed in pairs with free access to water under a 12 hr 
light/dark cycle, lights on 07:00. They were all maintained on a restricted diet of 15 g of 
standard food pellets, adjusted on test days so that, regardless of the effect of drug, all rats 
received the same food allowance per day. All testing was between 12:00 and 14:00 
hours. 
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7.2.2 Apparatus and procedure: 
The apparatus and procedure for experiment 1 were as described in sections 5.2.2 and 
5.2.3. The apparatus and procedure for microstructural analysis in experiment 2 was as 
described in section 6.2.3. 
7.2.3 Drugs: 
(-)-Cocaine HCI (Sigma Chemicals, Poole Dorset) was dissolved in 0.9% saline solution 
and administered intraperitoneally at doses of 3, 10 and 30 mg/kg. Cocaine was injected 
at a volume of 1 ml/kg, 10-min prior to the rat being placed inside the experimental 
cages. 
7.2.4 Data analysis: 
The data were analysed by two-way analysis of variance (ANOV A) for repeated 
measures where the drug doses were administered to the rats in a 'Latin Square' design: 
the two factors were drug and time in the first experiment. The microstructural analysis 
data for the second experiment were analysed using one-way ANOV A. Subsequent 
comparisons were by Dunnett's post-hoc t-tests for simple main effects and main effects 
of dose. All comparisons between the results for individual drug treatments and the saline 
control condition for both experiments were also made using Dunnett's post-hoc t-tests. 
The Greenhouse-Geisser correction for violations of compound symmetry and sphericity 
(Kirk, 1982) did not alter the final significant F-values, so for clarity the original F-values 
and degrees of freedom are given. 
7.3 Results 
7.3.1 EXPERIMENT 1: Effect of cocaine on food intake and locomotor activity. 
The effects of cocaine on food intake and locomotor activity are shown in Figs. 7.1 and 
7.2. Administration of cocaine resulted in a dose-related decrease in food intake [F(3,21) 
= 15.13, P<O.Ol]. There was a significant time effect [F(3,21) = 40.49, P<O.Ol] and a 
dosextime interaction [F(9,63) = 12.73, P<O.OI]. Post-hoc tests revealed that the 10 
mg/kg and 30 mg/kg doses of cocaine produced significant reductions in feeding during 
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the first 30 min after administration (P<O.OI), and the 30 mg/kg dose continued to have 
an effect throughout the first 60 min of the test session (Fig. 7.1A). Administration of 
cocaine also resulted in a dose-related increase in locomotor activity [F(3,21) = 9.84, 
P<O.OI) with a significant time effect [F(3,21) = 60.15, P<O.OI] and a dosextime 
interaction [F(9,63) = 5.19, P<O.OI]. 
To investigate the extent to which behavioural competition from feeding may 
have influenced the locomotor effects of cocaine, an additional experiment was carried 
out where locomotor activity was measured without the presence of food (Fig. 7.2). The 
effect of dose was greater when locomotor activity was measured on its own. When 
locomotor activity was measured without feeding, 30 mg/kg produced more consecutive 
beam interruptions (-287) compared to when feeding and locomotor activity were 
measured simultaneously (-158) in the first 30 min of the test session. The dose effect 
was significant [F(3,21) = 13.44, P<O.OI], as were the time effect and the dosextime 
interaction [F(3,21) = 17.22, P<O.OI and F(9,63) = 3.35, P<O.Ol, respectively]. Post-hoc 
tests revealed that only the 30 mglkg dose produced significant increases in locomotor 
activity (P<O.OI) in both experiments (with and without the presence of food) and this 
was the case for the first 90 and 45 min of the respective experiments (Fig. 7.1B and Fig. 
7.2, respectively). Planned comparisons revealed that total food intake over the full test 
period was only significantly suppressed at the highest dose of cocaine (P<O.OI). 
Locomotor activity was also increased significantly only at the highest dose in both 
experiments. 
In summary, cocaine produced two distinct effects: hypophagia and 
hyperlocomotion. Locomotor activity was most sensitive to the highest dose of cocaine, 
with activity being increased throughout the 90 min test session. Feeding was affected in 
the first 30 min of the session at both 10 and 30 mg/kg. By comparing the two 
experiments, it can be concluded that cocaine causes hypophagia and hypermotility in 
rats, and concomitant feeding does not qualitatively alter cocaine's dose-response profile 
for locomotion. 
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7.3.2 EXPERIMENT 2: A microstructural analysis of the effects of cocaine. 
(a) Food Intake and Eating Microstructure. 
During the adaptation period in which the animals were trained to eat the 
sweetened wet mash diet, the food-deprived rats consistently consumed over 20 g within 
the 30 min test period. Cocaine (3-30 mg/kg i.p.) produced a dose-dependent reduction in 
food consumption [F(3,21) = 17.14, P<0.0001] with significant reductions at all doses 
(Fig. 7.3a(i)). There was also a significant lengthening of the latency to start feeding 
[F(3,21) = 21.06, P<0.0001] and a significant effect on eating rate [F(3,21) = 19.05, 
P<0.0001]; see Figs. 7.3a(ii) and (iii), respectively. 
Likewise, analysing the other feeding parameters, cocaine resulted overall in a 
reduction in the time devoted to feeding [F(3,21) = 10.04, P<0.0005]. Total duration of 
feeding can be divided further into the frequency of eating bouts and the mean duration of 
individual bouts. There was a significant reduction in mean bout duration [F(3,21) = 
3.16, P<0.05], and in the frequency of eating bouts [F(3,21) = 5.79, P<0.005; Figs. 
7.3a(iv), (v) and (vi)]. Hence cocaine's ability to prolong the latency to start feeding, 
together with the reduction in mean bout duration and the frequency of eating episodes 
resulted overall in a reduction in the time devoted to eating. 
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(b) Locomotor Activity. 
Cocaine significantly increased the total duration of locomotor activity [F(3,21) = 
14.92, P<O.OOOI], with significant effects being observed at 10 and 30 mg/kg (Fig. 
7.3b(i)). Cocaine also produced a significant increase in mean bout duration [F(3,21) = 
4.39, P<0.05] for which the highest dose alone showed a significant effect by post-hoc 
tests (Fig. 7.3b(ii)). There was also a significant effect on the frequency of locomotor 
bouts [F(3,21) = 12.94, P<O.OOOI] with 10 mg/kg producing a significant effect in 
comparison with saline (Fig. 7.3b(iii)). 
(c) Rearing. 
There was no effect of cocaine on total duration or mean bout duration of rearing 
behaviour (Fig. 7.3c(i) and (ii)), but cocaine significantly altered rearing bout frequency 
[F(3,21) = 8.06, P<O.OOI]; this effect was primarily attributable to the 10 mg/kg dose 
(Fig. 7.3c(iii)) which was compensated in terms of total duration by the reduced mean 
bout duration. 
(d) Grooming and resting/immobility. 
There was a significant reduction in total duration of grooming [F(3,21) = 6.98, 
P<0.005]. This change was largely due to dose dependent reductions in the frequency of 
grooming episodes [F(3,21) = 10.26, P<0.0005] and in individual bout duration [F(3,21) 
= 8.50, P<O.OOI]. Significant effects were seen at the highest dose only (Fig. 
7.3d(i),(ii),(iii)). The two highest doses of cocaine also resulted in a decrease in time 
spent immobile (Fig. 7.3e(i),(ii),(iii)) presumably due to the increases in time devoted to 
locomotor activity and rearing. 
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7.4 Discussion 
Cocaine (3-30 mglkg) produced a dose-dependent reduction in palatable food 
consumption in food-deprived rats. These results are consistent with earlier findings (See 
Section 7.1). The minimum dose to produce a significant reduction was 3 mglkg. 
Locomotor activity was measured at the same time as feeding to see if the effects on 
feeding occurred at doses which could elicit increases in activity. The findings from this 
experiment also confirm previous work that cocaine causes an increase in activity. An 
additional experiment was also carried out looking at the effects of cocaine on locomotor 
activity without the presence of food reward. Comparing· the two experimental 
procedures, locomotor activity counts were much higher in the latter (158 vs. 280 in the 
first 30-min). It has been suggested that food-deprivation can increase the reinforcing 
efficacy of drugs of abuse, including cocaine (Carroll et aI., 1981). Bell et al. (1997) also 
showed that relative to food-satiated rats, food-deprived rats can exhibit greater 
conditioned preference for a cocaine-paired environment during tests of conditioned place 
preference and greater cocaine-induced locomotor activity. The food-deprivation variable 
may partly explain the increase in locomotor activity observed in experiment 2 where 
food was not available to the animal. However, the main reason for the difference must be 
attributed to the presence of a competing behaviour. Nevertheless, two distinct behaviours 
were observed in experiment one: cocaine causes hypophagia and hypermotility in rats 
and concomitant feeding does not alter cocaine's dose-response profile for locomotion. A 
microstructural study of cocaine was then conducted to identify the features of behaviour 
responsible for cocaine's effect on feeding and locomotor activity following cocaine 
administration. 
The findings from this experiment showed that the reduction in food consumption 
at the highest dose tested was due to a contribution of factors: a prolonged latency to 
induce feeding together with a reduction in the rate of eating. Furthermore, a significant 
reduction in the time devoted to feeding was also observed. The significant reductions in 
the frequency of feeding bouts and mean bout duration were major contributors to the 
reduction in feeding duration at 30 mg/kg. Ultimately, the anorectic effect of cocaine at 
the highest dose depended on the latency and the rate of eating, this bringing about the 
154 
Chapter 7: Characterisation of the Effects of Cocaine on Feeding ... 
reduction in the number of eating bouts and mean bout duration. The reductions at 3 and 
10 mg/kg, on the other hand, were caused by a dose-related change in the rate of eating 
and a reduction in the time devoted to feeding. The frequency of feeding bouts was not a 
contributor to the reduction in feeding duration at these doses, but rather due to a dose-
dependent reduction in mean bout duration. 
The locomotor stimulant effects of cocaine were also measured; locomotor 
activity duration was increased at 10 and 30 mg/kg. At 30 mg/kg cocaine, the mean bout 
duration was markedly increased . leading to large increases in total duration of 
locomotion. At 10 mg/kg cocaine, the frequency of bouts of locomotion was responsible 
for an increase in total duration. In contrast, there were no significant effects of cocaine 
on total duration or mean bout duration of rearing behaviour, but cocaine significantly 
affected rearing bout frequency, an effect that was primarily attributable to the 10 mg/kg 
dose. Cocaine also reduced grooming throughout the 30-min test period, and completely 
suppressed it at 30 mg/kg. This was due to cocaine shortening both mean bout duration 
and bout frequency. 
The results of the present study differ only slightly from those of Cooper and van 
der Hoek (1993). In their study, it was shown that cocaine suppressed feeding in a dose-
dependent manner (significantly at 10 mg/kg and greater), and this was due in the main to 
a reduction in the frequency of feeding bouts. In contrast, the mean bout duration of 
eating bouts was unaffected, except at the highest dose, 30 mg/kg. In addition, the rate of 
eating was not significantly affected by cocaine at any dose. In effect, cocaine delayed the 
initiation of feeding, thus bringing about the reduction in the number of eating bouts. The 
effect of cocaine on locomotor activity and rearing was very much the same as in the 
present study. Another feature of their study was the marked suppression of grooming at 
the lowest dose of 5.6 mg/kg, whereas this was only observed at the highest dose in the 
present study. Comparing each other's data shows that results obtained by Cooper and van 
der Hoek (1993) are very similar to the present study, even though different procedures 
were used: Cooper and van der Hoek (1993) used non-deprived rats, whereas the present 
study used food-deprived rats of a different strain (i.e. Sprague-Dawley vs. Male Hooded 
rats). 
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Comparisons with other DA re-uptake inhibitors and selective DA D1-like and 
D2-like agonists reveal similarities and differences between them. Microstructural 
analyses of the rat's anorectic response to amphetamine have shown it to be primarily due 
to a delay in initiation of feeding (Blundell and Latham, 1980; Cooper and Sweeney, 
1980; Willner and Towell, 1982). The more selective DA uptake inhibitor, GBR 12909, 
also reduced food intake through a reduction in feeding duration and produced a non-
significant trend towards an increased eating rate (Van der Hoek and Cooper, 1994). The 
latency parameter, however, was not reported. Also, other aspects of behaviour were 
significantly changed; in particular, there was a marked increase in stereotyped sniffing. 
Thus, it is possible that behavioural competition could account for the anorectic effects of 
GBR 12909. The microstructural data for cocaine also differ from those reported for the 
selective DA D2-like receptor agonist N-0437 (Rusk and Cooper, 1989) and the selective 
DA D1-like receptor agonist SK&F 38393 (Cooper et aI., 1990). N-0437 did not reduce 
the duration of feeding, but caused a decrease in food intake by selectively reducing the 
rate of eating. SK&F 38393, on the other hand, reduced the frequency of feeding bouts 
together with the local rate of eating, effects that were accompanied by a compensatory 
increase in the mean bout duration. Therefore, cocaine's effects cannot be matched with 
the effects of either selective DA D1-like or DA D2-like receptor stimulation. At the time 
of writing, no selective agonist drugs specific for DA D2, D3 or D4 receptors have been 
synthesised. However, DA antagonist drugs have been developed that bind to these 
receptor subtypes; the next experiments were designed to investigate D2-like receptor 
involvement in cocaine's anorectic and stimulant effects using receptor-subtype selective 
antagonists. 
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CHAPTERS: 
MICROSTRUCTURAL ANALYSIS OF 'D2-LIKE' RECEPTOR SUBTYPE 
ANTAGONISTS IN COMBINATION WITH COCAINE 
8.1 Introduction And Aims 
Although a microstructural analysis of cocaine's effects has been presented, to 
date no studies have examined DA receptor subtype involvement in cocaine's effects 
on feeding and associated behaviours in the rat. As cocaine is an indirect DA agonist, 
its behavioural effects may involve activation of one or a subset of the DA receptor 
SUbtypes. Previous experiments in this thesis looking at the DS effects of cocaine have 
shown that DA D2-like receptors are differently involved (Chapter 3); it is now 
possible to assess the generality of these results by examining other behavioural 
effects of cocaine. 
In the previous chapter, a microstructural approach to the study of feeding was 
used to characterise the dose( s) at which cocaine affects feeding and related 
behavioural responses. It was concluded from these data that cocaine produces a dose-
dependent reduction in palatable food consumption, together with an increase in 
locomotor and rearing activity, accompanied by a marked suppression of grooming. 
The minimum dose to produce these effects was 10 mg/kg, and so this dose was 
chosen here. This was also the main training dose used in the earlier drug 
discrimination experiments (as presented in Chapter 3). 
The necessity ofD2-like stimulation for the expression of cocaine's effects on 
feeding and related behaviours was examined by administering the D2/D3 selective 
antagonist raclopride (Kohler et aI., 1985; Anderson, 1988) in combination with 
cocaine, and comparing its effects for the first time with the effects of the selective D3 
and D4 antagonists, U-99194A and L-745,870, respectively. However, a common 
feature of D2-like antagonists is a biphasic action on ingestive behaviour (see section 
4.3.2). This presents special difficulties in the design and interpretation of 
combination studies with D2-like antagonists. Doses used for the combination 
experiments were chosen from studies that specifically characterised the effects of 
these drugs on the microstructure of feeding and associated behaviours. For example, 
. ..-/ 
using an identical procedure, Terry (1996) demonstrated a biphasic dose-effect of 
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raclopride on feeding, and the only dose which consistently did not significantly alter 
feeding or other aspects of motor behaviour was 0.1 mg/kg; i.e. this was the highest 
dose which produced negligible effects on its own. Similarly, for the D3 and D4 
antagonist compounds U-99194A and L-745,870 (characterised in Chapter 6) doses of 
3 and 1 mg/kg, respectively, were chosen for the combination experiments, since 
these were at the threshold of being behaviourally active on their own, and more 
importantly are selective for their respective receptor sUbtypes. 
For comprehensive analysis of the interactive effects, the 10 mg/kg dose of 
cocaine was compared with the combination of the submaximal dose of the D2-like 
antagonists with cocaine, also with each of the D2-like antagonists when tested alone, 
and with vehicle. There were six time intervals. Therefore, the data were analysed 
using a 2 (cocaine vs. saline) x 2 (antagonist vs. vehicle) x 6 (time intervals) 
ANOVA. 
8.2 Materials and methods 
8.2.1 Subjects: 
Twenty-four male Sprague-Dawley rats (eight per study; Charles River, Margate, 
Kent) weighing 320-360 g were housed in pairs with free access to water under a 12 
hr light/dark cycle, lights on 07:00. They were all maintained on a restricted di~t of 15 
g of standard food pellets, adjusted on test days so that, regardless of the effect of 
drug, all rats received the same food allowance per day. All testing was between 12:00 
and 14:00 hours. 
8.2.2 Apparatus and procedure: 
The pre-treatment adaptation procedure and food preparation were as described in 
section 5.2.3. The following experiments were carried out using a similar procedure to 
that described in section 6.2.3 for microstructural analysis, except that the software 
used. to log the duration and sequence of each key press was now the "Observer" 
(Version 3.0, Noldus, Netherlands). This offered the advantage for the data to be 
recorded in 5-min interval bins for a total of 30 minutes, which was not possible in the 
previous studies. Locomotor activity was also measured the same way as described in' 
section 5.2.3, so allowing comparison with the visual observations; again the data 
_...-/ 
were analysed in 5- min intervals using a purpose-written data extraction programme. 
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8.2.3 Drugs: 
(-)-Cocaine HCI, (Sigma Chemicals, Poole Dorset) and S (-)-Raclopride L-tartrate 
(RBI chemicals, St. Albans, Herts, UK) were dissolved in 0.9% saline solution and 
administered intraperitoneally at doses of 10 (cocaine) and 0.1 mg/kg (raclopride) 
respectively. U-99194A Maleate (5,6,-Dimethoxy-2-(di-n-propylamino) indan 
maleate; RBI Chemicals, Natick MA, USA) and L-745,870 (3-( [ 4-chlorophenyl) 
piperazin-l-yl] methyl)-lH-pyrrolo [2,3-b] pyridine; Tocris Cookson, Bristol, 
England, UK) were dissolved in distilled water and administered intraperitoneally at 
doses of 3 and 1 mg/kg respectively. All drugs were injected ata volume of 1 ml/kg 
and all the DA D2-like receptor subtype antagonists were injected 30 min prior to the 
cocaine injection. 
8.2.4 Data analysis: 
The data were analysed by a 2 x 2 x 6 model ANOV A for repeated measures. The 
ANOV As incorporated cocaine dose and antagonist dose as between-subject factors 
(two levels each) and time interval (30 min duration; six levels: 5-min intervals) as a 
within-group factor. All drug doses were administered to the rats in a 'Latin Square' 
design and comparisons between the results for individual drug-treatments and vehicle 
controls were made using Dunnett's post-hoc t-tests. Post-hoc analyses were only 
carried out ifthere were significant treatment interactions. 
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8.3 RESULTS 
8.3.1 EXPERIMENT 1: Combination study with the 02/03 antagonist. 
(a) Food Intake and Eating Microstructure. 
Effect of Cocaine: 
During the pre-test adaptation period, the food deprived rats consumed on 
average 20 g within the 30 min test session. Table 8.1 revealed that cocaine produced 
a pronounced reduction in food consumption [F(1,7) = 81.93, P<O.Ol] (Fig. 8.1a(i)). 
These reductions were not due to any significant change in the local rate of eating, as 
indicated in Fig. 8.1a(iii), but cocaine's effect on the latency to start feeding was very 
close to being significant [F(1,7) = 4.93, P = 0.065] (Fig. 8.1a(ii)). As Table 8.1 
indicates, the explanation for the reduction in food intake is that cocaine produced a 
reduction in the total duration of feeding [F(1,7) = 66.39, P<O.Ol] (Fig. 8.1 
a(iv)A&B). The total duration can be further subdivided into the frequency of eating 
bouts and their mean bout duration. Cocaine significantly suppressed mean bout 
duration [F(1,7) = 32.83, P<O.Ol] (Fig. 8.1a(v)A&B), but had no effect on the 
frequency of eating bouts (Fig. 8.la(vi)A&B). Hence, cocaine acted to increase the 
latency to start feeding and to reduce mean bout duration, and this in turn led to a 
reduction in the time devoted to feeding. 
Effect of Antagonist: . 
The analysis indicates that the administration of raclopride did not have an 
effect on any feeding parameter (Table 8.1). 
Cocaine and Antagonist Interaction: 
. Analysing the results using 2 x 2 x 6 ANOV A with factors antagonist, cocaine 
and time (Table 8.1) revealed no significant interactions between raclopride and 
cocaine for total duration nor mean bout duration. Instead, the analysis showed a 
significant interaction between raclopride and cocaine and time for feeding bout 
frequency only [F(5,35) = 5.64, P<O.Ol]. Post-hoc t-tests revealed that pre-treatment 
with raclopride at 0.1 mg/kg attenuated the cocaine-induced decrease in feeding bout 
frequency at time intervals 5-10 and 10-15 min (Fig. 8.1 a(vi)A). Collapsing across the 
30 min period for this behavioural parameter also revealed an interaction between' 
raclopride and cocaine [F(1,7) = 7.29, P<O.Ol]. However, post-hoc t-tests revealed no 
. .--
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significant difference between rac10pride plus cocaine and cocaine alone when total 
bout frequency was collapsed over the 30 min session (Fig. 8.1a(vi)B). 
In effect, rac10pride at 0.1 mg./kg only affected cocaine moderately on one 
parameter of feeding microstructure, that of feeding bout frequency. However, as 
other parameters were not affected by pre-treatment with rac1opride, the effect on 
feeding bout frequency was not sufficient to attenuate the overall effect of cocaine on 
food intake. 
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Figure 8.1(a) Effects of pre-treatment with a D2/D3 antagonist on cocaine-induced 
feeding parameters: (i) total food intake (ii) latency to start eating (iii) eating rate 
(iv)A&B total duration (v)A&B mean bout duration (vi)A&B bout frequency. N=8 at 
all points; ** P<O.Ol compared to saline-controls; + P<O.05 compared to saline-
cocaine (comparisons by Dunnett's t-tests) 
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TABLE 8.1. 2 (cocaine vs, saline) x 2 (antagonist vs, saline) x 6 (time intervals) ANOVA on behavioural scores from microstructural analysis ofraclopride in combination with cocaine 
RESPONSE CATEGORY Antag. Coco Antag. * COCo Time Antag. * Time Coco * Time Antag. * Coco * Time 
F (1,7) F (1,7) F (1,7) F (5,35) F (5,35) F (5,35) F (5,35) 
FEEDING 
FOOD INTAKE 1.56 NS 81.93 P<O.OI 0.21 NS 
LATENCY 1.82 NS 4.93*NS 2.03NS 
RATE, 0.93NS 1.15 NS 1.05NS 
\ 
TOTAL DURATION 1.28 NS 66.39 P<O.OI 0.39NS 16.05 P<O.OI 2.60 P<0.05 24.96 P<O.OI 1.94NS 
BOUT DURATION 0.71 NS 32.83 P<O.Ol 2.33NS 4.45 P<O.OI 1.77NS 9.37 P<O.OI 0.17NS 
BOUT FREQUENCY 0.37 NS 1.55NS 7.29 P<O.OI 27.18 P<O.Ol 1.09 NS 0.39 NS 5.64 P<O.01 
LOCOMOTOR ACTIVITY 
LOCOMOTOR COUNTS 4.71* NS 44.03 P<O.OI 1.36NS 58.29 P<O.Ol 1.07 NS 14.81 P<O.OI 0.35NS 
TOTAL DURATION 7.84 P<0.05 51.90 P<O.OI 2.93 NS 27.00 P<O.OI 1.03 NS 19.25 P<O.OI 0.98NS 
BOUT DURATION 2.74 NS 0.09NS 0.03 NS 1.45 NS 0.76NS 1.46 NS 1.49NS 
BOUT FREQUENCY 5.46 P<0.05 63.34 P<O.OI 3.72 NS 37.09 P<O.OI 1.11 NS 17.58 P<O.OI 0.60NS 
REARING 
TOTAL DURATION 3.85NS 23.21 P<O.OI 2.47NS 3.93 P<O.OI O.13NS 4.44 P<O.OI 0.13 NS 
BOUT DURATION 6.43 P<0.05 0.31 NS 0.54NS 2.56 P<0.05 0.50NS 2.39 NS 1.03 NS 
BOUT FREQUENCY 5.17P<0.05 43.81 P<O.OI 5.69P<0.05 20.31 P<O.OI 1.84 NS 12.53 P<O.OI O.84NS 
GROOMING 
TOTAL DURATION 2.40 NS 0.73NS 4.01 NS 2.71 P<0.05 0.65NS 0.37NS 0.93NS 
BOUT DURATION 1.35 NS 0.01 NS 6.86 P<0.05 2.63 P<0.05 0.44 NS 0.46 NS 0.97NS 
BOUT FREQUENCY 2.88NS 3.20NS 15.91 P<O.Ol 4.04 P<O.Ol 0.47NS 1.70 NS 1.47NS 
(* P = 6.50) 
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(b) Locomotor Activity. 
Effect of Cocaine: 
Analysing the results using 2 x 2 x 6 ANOVA (Table 8.1) revealed that cocaine 
significantly increased mean locomotor counts throughout the first 25 min of the test 
session [F(1,7) = 44.03, P<O.Ol] (Fig. 8.lb (i)A&B). The duration of individual bouts 
showed little change, but there were large increases in the frequency of bouts [F(1,7) = 
63.34, P<O.Ol] which was the sole contributor to cocaine significantly increasing the total 
duration of locomotor activity [F(1,7) = 51.90, P<O.Ol]. The time-course for cocaine's 
effects indicates that total duration and bout frequency of locomotor activity were 
enhanced throughout the observation period (Fig. 8.lb(ii)A&B and Fig. 8.lb(iv)A&B 
respectively. 
Effect of Antagonist: 
The analysis also indicates that administration of raclopride at 0.1 mg/kg is 
producing a significant effect on total duration and bout frequency of locomotor activity 
[respectively; F(1,7) = 7.84, P<0.05; F(1,7) = 5.46, P<0.05]. However, this was not 
sufficient to produce an overall effect of raclopride on locomotor counts, but the value 
was close to being significant [F(1,7) = 4.71, P = 0.065]. The respective graphs show that 
raclopride causes a decrease in locomotor activity compared with vehicle treatment, but 
post-hoc t-tests did not reveal any significant effects at any specific time intervals, nor 
when the data was collapsed across the 30 min period (Fig. 8.1 b(ii)A&B and Fig. 
8.1 b(iv)A&B, respectively). 
Cocaine and Antagonist Interaction: 
Table 8.1 revealed no significant interactions between raclopride and cocaine, nor 
between cocaine, antagonist and time on any behavioural parameter for locomotor 
activity. 
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Figure 8.1 b. 
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Figure 8.1(b) Effects of pre-treatment with a D21D3 antagonist on cocaine-induced 
locomotor activity parameters: (i)A&B totallocomotor counts (ii)A&B total duration (iii) 
A&B mean bout' duration (iv) A&B bout frequency. N=8 at all points; * P<O.05, 
** P<O.Ol compared to saline-controls (comparisons by Dunnett's t-tests) 
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(c) Rearing. 
Effect of Cocaine: 
Cocaine increased the total duration of rearing [F(1,7) = 23.21, P<O.Ol] which 
corresponded with increases in the frequency of rearing bouts [F(1,7) = 43.81, P<O.Ol]. 
There was no significant effect of mean bout duration. Time course analysis indicates the 
cocaine's effects on total duration and bout frequency of rearing activity were enhanced 
throughout the observation period (Fig. 8.1c(i)A&B and Fig. 8.1c(iii)A&B respectively). 
Effect of Antagonist: 
Rac10pride produced significant effects on mean bout duration and bout frequency 
[respectively; F(1,7) = 6.34, P<O.OS; F(1,7) = S.17, P<O.OS]. However, there was no 
overall effect of rac10pride on total duration of rearing activity (Table 8.1). 
Cocaine and Antagonist Interaction: 
There was no significant interaction between rac10pride and cocaine, nor between 
cocaine, antagonist and time for total duration and mean bout duration for rearing activity 
(Table 8.1). However, when behavioural counts were collapsed across the 30 min period, 
an interaction between rac10pride and cocaine was seen for rearing bout frequency [F(I,7) 
= S.69, P< O.OS]. Post-hoc t-tests revealed that pre-treatment with rac10pride at 0.1 mg/kg 
produced a significant overall attenuation of the effects of cocaine for rearing bout 
frequency (Fig. 8.1 c(iii)B). However, there was no interaction with time for this 
behavioural parameter [F(S,3S) = 0.84, NS] as shown in Fig. 8.1c(iii)A. 
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Figure S.le. 
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Figure 8.l{e) Effects of pre-treatment with a D21D3 antagonist on cocaine-induced 
rearing activity parameters: (i)A&B total duration (ii)A&B mean bout duration (iii)A&B 
bout frequency. . N=8 at all points; * P<O.05, ** P<O.Ol compared to saline-controls; 
+ P<O.05 compared to saline-cocaine (comparisons by Dunnett's t-tests) 
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(d) Grooming. 
Effect of Cocaine: 
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ANOV A revealed that cocaine did not significantly affect any parameter of 
grooming activity (Table 8.1). 
Effect of Antagonist: 
ANOV A showed that raclopride did not significantly affect any parameter of 
grooming activity (Table 8.1). 
Cocaine and Antagonist Interaction: 
A significant interaction was observed for mean bout duration [F(I,7) = 6.86, 
P<0.05] and bout frequency [F(I,7) = 15.91, P<O.Ol], but not for total duration, over the 
30 min period (Fig. 8.1d(ii)B and Fig. 8.1d(iii)B, respectively). Post-hoc t-tests revealed 
that pre-treatment with raclopride at .0.1 mg/kg produced a significant attenuation of the 
effects of cocaine on grooming mean bout duration (P<0.05) and bout frequency 
(P<O.Ol). 
This interaction may explain why a significant effect of cocaine on grooming, 
which was strongly evident in Chapter 7, was not shown in the present analysis. The 
results shown in Fig. 8.1d indicate that cocaine produced a decrease in grooming activity, 
as did raclopride when administered alone. However, pre-treatment with raclopride 
produced an attenuation of cocaine's effects and hence an interaction between the two 
drugs. When the mean effect of cocaine treatment is compared to all conditions where 
cocaine is not administered, the values are very equal resulting in a non-significant main 
effect of cocaine on grooming activity. 
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Figure S.ld. 
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Figure 8.l(d) Effects of pre-treatment with a D21D3 antagonist on cocaine-induced 
grooming activity parameters: (i)A&B total duration (ii)A&B mean bout duration 
(iii)A&B bout frequency. N=8 at all points; * P<O.05 compared to saline-controls; 
+ P<O.05, ++ P<O.Ol compared to saline-cocaine (comparisons by Dunnett's t-tests) 
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8.3.2 EXPERIMENT 2: Combination study with the selective 03 antagonist, U-99194A. 
(a) Food Intake and Eating Microstructure. 
Effect of Cocaine: 
Analysing the results by a 2 x 2 x6 ANOV A with factors antagonist, cocaine and 
time (Table 8.2) revealed that cocaine produced a reduction in food consumption [F(1,7) 
= 41.14, P<O.Ol; Fig. 8.2a(i)]. Similar to the results from Experiment 1, the reduction was 
due to a combined effect on the latency to induce feeding [F(1,7) = 7.60, P<0.05; Fig. 
8.2a(ii)] and a reduction in the total duration of feeding [F(1,7) = 43.60, P<O.Ol; Fig. 
8.2a(iv)A&B]. The primary cause of the effect on total duration of feeding was the 
significant effect on mean bout duration [F(1,7) = 11.30, P<0.05; Fig. 8.2a(v)A&B], as 
there was no significant effect of cocaine on the frequency of eating bouts (Table 8.2). 
Effect of Antagonist: 
The analysis indicates that administration of the selective D3 antagonist U-
99194A at 3 mg/kg did not affect any of the behavioural parameters for feeding,· except 
for mean bout duration which decreased [F(1,7) = 6.62, P<0.05; Fig. 8.2a(v)A; Table 
8.2]. These results are consistent with the results described in section 6.3.1, except for the 
effect on mean bout duration. 
Cocaine and Antagonist Interaction: 
Analysing the results by a 2 x 2 x 6 ANOVA with factors antagonist, cocaine and 
time (Table 8.2) revealed no significant interactions between U-99194A and cocaine for 
any behavioural parameter of feeding over the whole 30 min period. Instead, the analysis 
showed a significant interaction between U-99194A, cocaine and time for total duration 
[F(5,35) = 4.53, P<O.Ol] and mean bout duration [F(5,35) = 3.40, P<0.05], but not for 
bout frequency. However, post-hoc t-tests failed to show any significant differences 
between pre-treatment with U-99194A plus cocaine and cocaine plus saline at any time 
interval for either parameter. Perhaps some potentiation of the decreases in scores 
occurred when U-99194A was combined with cocaine at certain time points, both for 
total duration (Fig. 8.2a(iv)A) and mean bout duration parameters (Fig. 8.2a(v)A). This 
might contribute to the interaction observed for these parameters for U-99194A, cocaine 
~ 
and time. However, from the figures it is clear that the effects are complex. 
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Figure 8.2a. 
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Figure 8.2(a) Effects of pre-treatment with a selective D3 antagonist on cocaine-induced 
feeding parameters: (i) total food intake (ii) latency to start eating (iii) eating rate 
(iv)A&B total duration (v)A&B mean bout duration (vi)A&B bout frequency. N=8 at all 
points; * P<O.05 , ** P<O.Ol compared to saline-controls (comparisons by Dumlett's t-
tests) 
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TABLE _8.2. 2 (cocaine vs. saline) x 2 (antagonist vs. saline) x 6 (time intervals) ANOVA on behavioural scores from microstructural analysis of U-99194A in combination with cocaine 
RESPONSE CATEGORY Antag. COCo Antag. * COCo Time Antag. * Time Coco * Time Antag. * Coco * Time 
F (1,7) F (1,7) F (1,7) F (5,35) F (5,35) F (5,35) F (5,35) 
FEEDING 
FOOD INTAKE 1.01 NS 41.14 P<O.Ol 0.03NS 
LATENCY 4.19NS 7.60 P<O.OS 3.75NS 
RATE 2.51 NS 0.07NS 1.16 NS 
TOTAL DURATION 4.S9NS 43.60 P<O.Ol 0.10 NS 13.26 P<O.Ol 0.76NS 23.23 P<O.Ol 4.53P<0.01 
BOUT DURATION 6.62 P<O.OS 11.30 P<0.05 O.ONS 3.38 P<O.OS 0.89NS 4.63 P<O.Ol 3.40 P<0.05 
BOUT FREQUENCY 0.29NS 1.19 NS 0.02NS 12.27 P<O.Ol 0.50NS 10.93 P<O.Ol 1.07NS 
LOCOMOTOR ACTIVITY 
LOCOMOTOR COUNTS 4.10 NS 21.59 P<O.Ol 3.76NS 63.52 P<O.Ol 1.58 NS 14.23 P<O.Ol 0.88NS 
TOTAL DURATION 5.44 P<0.05 42.60 P<O.Ol 1.26NS 37.25 P<O.Ol 1.25NS 9.07 P<O.Ol 0.42 NS 
BOUT DURATION 0.84NS 9.33 P<0.05 0.22 NS 1.61 NS 0.22NS 1.99NS 1.18 NS 
BOUT FREQUENCY 11.08 P<0.05 23.31 P<O.Ol 2.30NS 46.20NS 0.25NS 12.86 P<O.Ol 1.48 NS 
REARING 
TOTAL DURATION 0.16NS 16.73 P<O.Ol 0.67NS 14.74 P<O.Ol 0.47NS 5.23 P<O.Ol 3.10P<0.05 
BOUT DURATION 2.40 NS 0.93 NS 1.S7NS 2.34 NS 0.56NS 0.54NS 2.62 P<0.05 
BOUT FREQUENCY 6.09 P<0.05 19.05 P<O.Ol 1.93 NS 56.78 P<O.Ol 0.20NS 15.24 P<O.Ol 1.29NS 
GROOMING 
TOTAL DURATION 0.45NS 25.25 P<O.Ol 0.46NS 1.33 NS 1.70 NS 0.86NS 0.85NS 
BOUT DURATION 0.05NS 45.09 P<O.Ol 0.05NS 1.17NS 2.47NS 0.46NS 1.15NS 
BOUT FREQUENCY 0.03NS 15.75 P<O.Ol 0.03 NS 1.05 NS 2.04NS 2.80 P<0.01 0.63 NS 
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(b) Locomotor Activity. 
Effect of Cocaine: 
Table 8.2 show that, as in experiment 1, cocaine significantly increased mean 
locomotor counts [F(I,7) = 21.59, P<O.OI; Fig. 8.2b(i) A&B]. This was due to an 
increase in total duration of locomotor activity [F(1,7) = 42.60, P<O.OI], which was 
accompanied by an increase in mean bout duration [F(1,7) = 9.33, P<0.05] and an 
increase in the frequency of bouts [F(I,7) = 23.31, P<O.OI]. The time-course for cocaine's 
effects indicates that total duration and bout frequency of locomotor activity were 
enhanced throughout the observation period (Fig. 8.2b(ii)A&B and Fig. 8.2b(iv)A&B, 
respectively]. 
Effect of Antagonist: 
Administration ofU-99194A produced a significant increase in total duration and 
bout frequency oflocomotor activity [respectively: F(1,7) = 5.44, P<0.05; F(I,7) = 11.08, 
P<0.05] that were evident in the first 10 min of the test session (Fig. 8.2b(ii&iv)A). 
However, this was not sufficient to produce an overall effect ofU-99194A on locomotor 
counts [F(I,7) = 4.10, NS]. This conflicts with the results described in section 6.3.1, 
where no significant effects on locomotor activity were seen with any dose. The 
discrepancy in results may be explained due to the different procedures used for the 
respective studies. Whereas in the present study one characterised one dose in 5 min bins; 
the results in chapter 6 analysed a number of doses of the drug and the data were 
collapsed in a 30 min session. The subtle effects of the drug observed in the 5 min bins 
undoubtedly would be lost in the latter procedure. 
Cocaine and Antagonist Interaction: 
As shown in Table 8.2, there were no significant interactions between U-99194A 
and cocaine, nor between cocaine, antagonist and time on any behavioural parameter for 
locomotor activity. The results shown in Fig. 8.2b(i)A&B suggests that the U-99194A 
pre-treatment did not attenuate the hypermotility effects of cocaine, instead U-99194A 
appeared to potentiate locomotor activity when combined with cocaine, an e(fect not 
produced with rac1opride. 
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Figure 8.2Cb) Effects of pre-treatment with a selective D3 antagonist on cocaine-induced 
locomotor activity parameters: (i)A&B total locomotor counts (ii)A&B total duration 
(iii)A&B mean bout duration (iv)A&B bout frequency, N=8 at all points; ** P<O.Ol 
compared to saline-controls (comparisons by DUlmett's t-tests) 
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(c) Rearing. 
Effect of Cocaine: 
Cocaine increased the total duration of rearing [F(1,7) = 16.73, P<0.01], an effect 
which corresponded with increases in the frequency of rearing bouts [F(1,7) = 19.05, 
P<0.01]. There was no significant effect of mean bout duration. Time course analyses 
indicated that cocaine's effects on total duration and bout frequency were enhanced 
throughout the observation period (Fig. 8.2c(i)A&B and Fig. 8.2c(iii)A&B, respectively). 
This is consistent with the results from Experiment 1. 
Effect of Antagonist: 
The only parameter significantly affected by U-99194A was bout frequency 
[F(1,7) = 6.09, P<0.05] which showed an increase largely due to the cocaine and 
antagonist condition; but this did not influence total duration of rearing (Table 8.2). Bout 
frequency was significantly reduced in the earlier experiment (chapter 6), albeit at the 
slightly higher dose of 10 mg/kg, with not much difference at 3 mg/kg. 
Cocaine and Antagonist Interaction: 
There was a significant interaction between U-99194A, cocaine and time for total 
duration and mean bout duration [respectively: F(5,35) = 3.10, P<0.05; F(5,35) = 2.62, 
P<0.05]. Post-hoc t-tests, on the other hand, did not reveal any significant differences 
between the combination of U-99194A plus cocaine and cocaine treatment only, for 
either parameter, at any specific time interval (Fig. 8.2c(i)A and Fig. 8.2c(ii)A). 
Collapsing data across the 30 min period did not reveal any significant interactions 
between U-99194A and cocaine on any parameter of rearing activity. 
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Figure S.2e. 
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Figure 8.2( c) Effects of pre-treatment with a selective D3 antagonist on cocaine-induced 
rearing activity parameters: (i)A&B total duration (ii)A&B mean bout duration (iii)A&B 
bout frequency. N=8 at all points 
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(d) Grooming. 
Effect of Cocaine: 
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Table 8.2 shows that cocame produced a decrease in the total duration of 
grooming [F(1,7) = 25.25, P<0.01] which corresponded with decreases in mean bout 
duration [F(1,7) = 45.09, P<0.01] and bout frequency [F(1,7) = 15.75, P<0.01]. 
Effect of Antagonist: 
U-99194A did not produce any significant effects on any behavioural parameter 
of grooming activity. 
Cocaine and Antagonist Interaction: 
The analysis revealed no significant interactions between U-99194A and cocaine 
for grooming activity, or between U-99194A, cocaine and time (Fig. 8.2d(i-iii) and Table 
8.2). 
190 
Chapter 8: Microstructural Analysis of D2-Like Receptor Subtype ... 
Figure S.2d. 
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Figure S.2(d) Effects of pre-treatment with a selective D3 antagonist on cocaine-induced 
grooming activity parameters: (i)A&B total duration (ii)A&B mean bout duration (iii) 
A&B bout frequency. N=8 at all points 
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8.3.3 EXPERIMENT 3: Combination study with the selective 04 antagonist, L-745,870. 
(a) Food Intake and Eating Microstructure. . 
Effect of Cocaine: 
In agreement with the results from the prevIOUS two experiments, cocame 
produced a reduction in food consumption [F(1,7) = 11.79, P<0.05]. This was due to a 
combined effect of an increased latency to induce feeding [F(1,7) = 6.02, P<0.05] and a 
reduction in the total duration of feeding [(Fl,7) = 9.30, P<0.05]. The only notable 
exception is that for this group, there was no effect of mean bout duration, rather a 
significant effect on the rate of eating was observed [(Fl,7) = 9.83, P<0.05]; (Fig. 8.3a(i-
vi». However, post-hoc t-tests revealed no significant effects between cocaine treatment 
and vehicle controls when specific comparisons between conditions were made. 
Effect of Antagonist Treatment: 
The analysis indicated that L-745,870 did not affect any of the behavioural 
parameters for feeding (Table 8.3). 
Cocaine and Antagonist Interaction: 
Analysing the results using 2 x 2 x 6 ANOV A with factors antagonist, cocaine 
and time (Table 8.3) revealed no significant interactions between L-745,870 and cocaine 
or between L-745,870, cocaine and time for any behavioural parameter of feeding (Fig. 
8.3a(iv-vi)A&B). 
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Figure 8.3(a) Effects of pre-treatment with a selective D4 antagonist on cocaine-induced 
feeding parameters: (i) total food intake (ii) latency to start eating (iii) eating rate 
(iv)A&B total duration (v)A&B mean bout duration (vi)A&B bout frequency_ N=8 at all 
points; * P<O_05 compared to saline-controls (comparisons by Dmmett's t-tests) 
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TABLE 8.3. 2 (cocaine vs. saline) x 2 (antagonist vs. saline) x 6 (time intervals) ANOYA on behavioural scores from microstructural analysis ofL-745,870 in combination with cocaine 
RESPONSE CATEGORY Antag. Coco Antag. * Coco Time Antag. * Time Coco * Time Antag. * Coco * Time 
F (1,1) F (1,7) F (1,1) F (5,35) F (5,35) F (5,35) F (5,35) 
FEEDING 
FOOD INTAKE 0.02 NS 11.79 P<O.OS 0.89 NS 
LATENCY \ 0.49NS 6.02 P<O.OS 0.49 NS 
RATE 0.14 NS 9.83 P<O.OS 2.0SNS 
TOTAL DURATION 0.08 NS 9.30 P<O.OS 0.03NS 16.42 P<0.01 1.20 NS IS.S1 P<0.01 0.90NS 
BOUT DURATION 0.71 NS 3.67NS 0.02NS 3.07 P<O.OS 1.03 NS 3.31 P<O.OS 1.02 NS 
BOUT FREQUENCY 1.7S NS 0.01 NS 0.51 NS 27.01 P<0.01 1.09 NS 9.61 P<0.01 0.31 NS 
LOCOMOTOR ACTIVITY 
LOCOMOTOR COUNTS 0.38 NS 16.01 P<0.01 0.06NS 29.37 P<0.01 0.93 NS 9.60 P<0.01 0.30 NS 
TOTAL DURATION 0.04 NS 4S.89 P<0.01 0.19 NS 48.09 P<0.01 0.20 NS 8.89 P<0.01 1.S2 NS 
BOUT DURATION 0.04NS 6.23 P<O.OS 0.49NS 0.70 NS 0.74NS 1.23 NS 1.21 NS 
BOUT FREQUENCY 0.14 NS 20.48 P<0.01 0.18 NS 27.88 P<0.01 0.21 NS 14.S6 P<O.01 0.6SNS 
REARING 
TOTAL DURATION 0.09NS 20.S0 P<0.01 1.00 NS 9.70 P<0.01 0.69NS 2.S7 P<O.OS 1.08NS 
BOUT DURATION 0.76NS 0.99NS 1.07NS 3.27 P<O.OS 0.20NS 2.76 P<O.05 1.35 NS 
BOUT FREQUENCY O.04NS 22.S4 P<0.01 0.26NS 22.S7 P<0.01 0.1SNS 13.44 P<0.01 0.6SNS 
GROOMING 
TOTAL DURATION 1.36 NS 11.96 P<0.05 1.32 NS 1.92 NS 2.36NS 1.12NS 2.77NS 
BOUT DURATION 0.10 NS 4.S7NS 0.07 NS 2.44NS 1.89 NS 1.94 NS 1.96NS 
BOUT FREQUENCY' 1.89 NS 6.94 P<O.OS 0.14 NS 1.47 NS 1.12 NS 3.29 P<O.OS 1.41 NS 
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Effect of Cocaine: 
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Once again, as m the previOUS two experiments, cocame significantly 
increased mean locomotor counts [F(1,7) = 16.01, P<0.01] (Fig. 8.3b(i)A&B). This 
was again due to an increase in total duration of locomotor activity [F(1,7) = 45.89, 
P<0.01], which was accompanied by an increase in mean bout duration [F(1,7) = 6.23, 
P<0.05] and an increase in the frequency of bouts [F(1,7) = 20.48, P<0.05; Fig. 
8.3b(ii-iv)A&B]. The time course for cocaine's effects also mirrored previous 
experiments in that total duration and bout frequency of locomotor activity were 
enhanced throughout the observation period. 
Effect of Antagonist: 
L-745,870 did not affect any of the parameters of locomotor activity (Table 
8.3). 
Cocaine and Antagonist Interaction: 
The 2 x 2 x 6 ANOV A also revealed no significant interactions between L-
745,870, cocaine and time, or between L-745,870 and cocaine, for any parameter of 
locomotor activity (Fig. 8.3b(ii-iv)A&B). 
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Figure 8.3(b) Effects of pre-treatment with a selective D4 antagonist on cocaine-
induced locomotor activity parameters: (i)A&B total locomotor counts (ii)A&B total 
duration (iii)A&B mean bout duration (iv)A&B bout frequency. N=8 at all points; 
* P<O.05, ** P<O.Ol compared to saline-controls (comparisons by Dunnett's t-tests) 
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(c) Rearing. 
Effect of Cocaine: 
Table 8.3 shows that cocaine produced an increase in the total duration of 
rearing [F(I,7) = 20.S0, P<O.OI] which corresponded with increases in the frequency 
of rearing bouts [F(I,7) = 22.S4, P<O.OI]. Time course analysis indicates that 
cocaine's effects on total duration and bout frequency of rearing activity were 
enhanced throughout the observation period (Fig. 8.3c(i)A&B and Fig. 8.3c(iii)A&B, 
respectively). This is also consistent with· the results from the previous two 
experiments. 
Effect of Antagonist: 
The D4 antagonist L-74S,870 did not produce any significant changes in any 
parameter of rearing activity (Table 8.3). 
Cocaine and Antagonist Interaction: 
There were no significant interactions between L-74S,870, and cocaine and 
time, or between L-74S,870 and cocaine, for any parameter of rearing activity (Fig. 
8.3c(i-iii) and Table 8.3). 
(d) Grooming. 
Effect of Cocaine: 
As in experiment 2, cocaine produced a decrease in the total duration of 
grooming [F(l,7) = 11.96, P<O.OS] which corresponded with a decrease in bout 
frequency [F(I,7) = 6.94, P<O.OS; Table 8.3]. 
Effect of Antagonist: 
L-74S,870 did not produce any significant effects on any behavioural 
parameter of grooming (Table 8.3). 
Cocaine and Antagonist Interaction: 
There were no significant interactions between the two drugs, or between the 
two drugs and time (Fig. 8.3d(i-iii) and Table 8.3). 
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Figure 8.3c. 
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Figure 8.3(c) Effects of pre-treah11ent with a selective D4 antagonist on cocaine-
induced rearing activity parameters: (i)A&B total duration (ii)A&B mean bout 
duration (iii)A&B bout frequency. N=8 at all points 
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Figure 8.3d. 
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Figure 8.3(d) Effects of pre-treatment with a selective D4 antagonist on cocame-
induced grooming activity parameters: (i)A&B total duration (ii)A&B mean bout 
duration (iii)A&B bout frequency, N=8 at all points 
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8.4 Discussion 
The present study was designed to examine the roles of DA D2-like receptors 
in cocaine's effects on food intake and associated behaviours in the rat. Cocaine (10 
mg/kg, i.p.) was administered to food-deprived rats trained to eat a palatable, 
sweetened mash. Food intake and associated behaviours were recorded over a 30 min 
period. Cocaine produced distinct behavioural effects which were generally very 
consistent throughout the experiments (see Tables 8.1, 8.2 and 8.3 for comparisons). 
There was a pronounced reduction in food consumption, which was caused by an 
increase in the latency to induce feeding, with decreases in mean bout duration, which 
overall resulted in a decreased time devoted to feeding. The only notable exception 
was in Experiment 3 (Table 8.3), where there was no indication of a significant effect 
on mean bout duration by cocaine. Instead, a significant effect on the rate of eating 
was observed. Despite this anomalous result, the observational results for cocaine's 
feeding profile were consistent throughout of three independent experiments. This was 
also the case for the experiment described in section 7.3.2 although latency was 
significantly affected at 30 mg/kg rather than 10 mg/kg. Time course data indicated 
that cocaine's ,duration of action was 20 min. Measures of total duration and mean 
bout duration were suppressed initially, and then rose to baseline levels towards the 
end of the test. Vehicle treatment, on the other-hand, produced the highest level of 
feeding at the start of the test, ~ith the level of feeding subsequently diminishing as 
the animals became satiated. 
Cocaine also significantly increased mean locomotor counts throughout the 
first 25 min of the test session. The duration of individual bouts showed little change 
in the first experiment (Table 8.1), however significant effects of this parameter were 
found in the latter two experiments (Table 8.2 and 8.3). Consistently throughout, there 
were large increases in the frequencies of bouts, which was the sole contributor to 
cocaine significantly increasing the total duration of locomotor activity at 10 mg/kg. 
The time course for cocaine's effects indicates that total duration and bout frequency 
of locomotor activity were enhanced throughout the observation period. Once again, 
.~ 
the effects of cocaine on locomotor activity mirrored the earlier results (see section 
7.3.2). A similar profile also occurred for rearing activity, which corresponded with 
increases in the frequency of rearing bouts. There was no significant effect of mean 
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bout duration (also see section 7.3.2). Time course analysis indicated that cocaine's 
effects on total duration and bout frequency of rearing activity were enhanced 
throughout the observation period. 
Grooming behaviour was also affected by cocame, with significant 
suppression of nearly all parameters recorded, the only exception being in the first 
experiment (Table 8.1). This may well be due to the effect being masked by the strong 
interaction with rac1opride. Although no significant outcomes were reported in section 
7.3.2 for the effects of 10 mg/kg cocaine on grooming, a similar profile was obtained. 
The effects of a series of D2-like receptor antagonists with differing 
selectivities for D2, D3 and D4 receptors, given as pre-treatments to cocaine, were 
then compared. The D21D3 antagonist rac10pride (0.1 mg/kg) produced only a 
marginal attenuation of cocaine's effects on feeding. In effect, rac10pride only altered 
one parameter of cocaine's effect on feeding microstructure, that of feeding bout 
frequency. There was a significant interaction between raclopride, cocaine and time 
for this parameter, with post-hoc t-tests revealing attenuation by rac10pride at time 
intervals 5-10 and 10-15 min. Collapsing across the 30 min period, there was also an 
interaction between rac10pride and cocaine for this parameter. Because other 
parameters of feeding, such as total duration and mean bout duration, were not 
affected by pre-treatment with rac1opride, the effect on feeding bout frequency was 
not sufficient to attenuate overall the effect of cocaine on food intake. 
Recently, Rapoza and Woolverton (1991) examined the role of DA receptors 
in the effect of cocaine on sweetened milk intake. Cocaine produced dose-dependent 
decreases in milk consumption, and rac10pride attenuated the effects of at least one of 
cocaine's effective doses. Stimulation ofD21D3 receptors, therefore, may be involved 
in cocaine's suppressant effects on milk ingestion. However, the present results 
suggests that D2-like receptors playa minor role in cocaine's suppressant effects on 
food intake. The differences in results between their study and the present one might 
relate to the differences in the diets used in the two studies (i.e. liquid diet of 
sweetened condensed milk versus a mash diet). However, it might also be a result of 
-~ 
the more conservative method of selecting behaviourally inactive doses used here: in 
this study a dose was used that had minimal effects on its own (Terry, 1996); Rapoza 
and Woolverton reported attenuation by doses of the antagonist which themselves 
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induced hypophagia (i.e. 0.3 and 1.0 mg/kg). Combination studies using. selective 
antagonists with cocaine become difficult to interpret when the antagonist itself has 
strong, significant effects when administered alone. This is particularly relevant when 
choosing compounds from the D2-like subfamily, due to their common feature of 
inducing biphasic effects on food intake (see section 4.3). The need to characterise 
raclopride administered alone is therefore essential when carrying out full interaction 
studies with cocaine. This is particularly important in relation to antagonism of 
cocaine's anorectic effect. The only dose of nlclopride which consistently produced 
minimal disruption of the parameters of feeding and other aspects of motor behaviour 
was 0.1 mg/kg (Terry, 1996), and so it was chosen as the optimum dose for the 
combination study here. Table 8.1 reinforces this dose selection as the results clearly 
show that raclopride did not affect any feeding parameters when this dose was 
administered alone although it is apparent that the dose has marginal behavioural 
activity from its effects on locomotion and rearing. Other D2-like antagonist drugs, 
such as sulpiride and haloperidol, were not used as no data for such drugs have been 
published in terms of their microstructural profiles of effects on feeding and 
associated behaviours; therefore, choosing a reliable dose for the combination study 
would have presented difficulties. Additionally, one advantage of choosing raclopride 
over sulpiride concerns pharmacokinetics rather than pharmacodynamic effects 
(sulpiride does not cross the blood brain barrier as easily as raclopride, and it requires 
a 60 min pre-treatment time, therefore presenting methodological problems 111 
observing the individual animal's behaviour within a suitable time period). 
In agreement with the feeding data, raclopride produced only a marginal 
attenuation of cocaine's effects on locomotor and rearing activity, with the only 
interactions observed being for rearing bout frequency when behavioural counts were 
collapsed across the 30 min period. The results imply that the blockade of D21D3 
receptors should not be effective in alteririg cocaine-induced locomotor and rearing 
activity. There are reports in both mice and rats that show other D2-like antagonists 
(e.g. sulpiride and haloperidol, which have similar affinities for D2 and D3 receptors, 
.~ 
when compared with raclopride) to be less effective at reversing cocaine-induced 
locomotor behaviours at non-sedative doses (Cabib et aI., 1991; Ushijima et aI., 
1995). But there is some inconsistency in the literature, since some other studies have 
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demonstrated effective antagonism by D2-like antagonists. In particular, localisation 
studies by Tella (1994) and Neisewander et aI. (1995) have produced conflicting 
results compared with systemic administration studies. Infusion of cocaine directly 
into the nucleus accumbens can elicit locomotor activity that can be reversed by 
systemic administration of the non-selective DA antagonist cis-flupenthixol (Delfs et 
aI., 1990). Sulpiride not only reverses cocaine-induced stereotypies when infused into 
the caudate putamen (Arnt, 1985), it also reverses cocaine-induced locomotion when 
infused into the nucleus accumbens (Neisewander et aI., 1995; Baker et aI., 1996). 
The results of these studies suggests that blockade of D2-like receptors by sulpiride, in 
the nucleus accumbens, is sufficient to reverse cocaine-induced locomotion. The 
discrepancy as to whether D2-like antagonists can attenuate cocaine-induced 
locomotor activity seems to depend on whether these compounds are administered 
systemically or locally into specific regions of the brain. 
Consistent with the present data suggesting that D21D3 receptors may be 
marginally involved in cocaine-induced motor behaviours, Tirelli at aI. (1997) have 
demonstrated negligible interactions between cocaine and D2-like agonists on 
locomotor acti.vity, suggesting a lack of involvement of D2-like receptors in such 
behaviour. In their study, cocaine did not reliably alter the hypoactivity produced by 
any of three D2-like agonists: 7-0H-DPAT, quinpirole and RU 24213. These 
compounds are all D2/D3 agonists (Sokoloff et aI., 1990; Levesque et aI., 1992; 
Levant et aI., 1995) and target similar receptors to raclopride. By demonstrating 
negligible interactions between cocaine and D2-like agonists in mice, the study is 
consistent with the present one failing to demonstrate any necessary involvement of 
D2/D3 receptors in one of the behavioural effects of cocaine, using different species 
and investigating antagonist drugs instead of agonists. 
One of the most striking effects of raclopride pre-treatment with cocaine was 
its marked attenuation of cocaine-induced decreases in grooming behaviour. A 
significant interaction was observed for mean bout duration and bout frequency, but 
not for total duration. The data implies that grooming behaviour may provide a 
~ 
particularly sensitive index of cocaine's action at D21D3 receptors. Since cocaine 
significantly suppresses grooming and raclopride was able to attenuate this profile, it 
is possible that stimulation of D2/D3 receptors exclusively is sufficient to account for 
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cocaine's effects on grooming. Consistent with the idea that this may be a D2-like 
mediated effect, D2-1ike receptor agonists such as N-0437 have been shown to 
suppress grooming significantly (Rusk and Cooper, 1989); indeed, residual Dl-like 
stimulation by cocaine-potentiated dopamine after D2/D3 blockade may be expected 
to elevate grooming. 
Behavioural and pharmacological studies of the DA D3 receptor have 
prompted several hypotheses regarding its function. The D3 antagonist, U-99194A at 
3 mg/kg, produced negligible attenuation of cocaine's effects on food intake. If 
anything, the results suggested a potentiation of the anorectic effect when U-99194A 
was given with cocaine. This profile was evident at certain time intervals (particularly 
late in the session) for total duration and mean bout duration, which led to significant 
interactions between U-99194A, cocaine and time for these parameters, but not for 
bout frequency. In comparison with rac1opride, which also has affinity for D3 
receptors, U-99194A plus cocaine produced a different profile on food intake. This 
potentiation by U-99194A of cocaine's effects on food intake suggests that 
concomitant D2 blockade by rac10pride eliminates this trend. 
Recentl.y, reports have emerged that a post-synaptic SUb-popUlation ofDA D2-
like receptors (possibly the D3 molecular isoform of the receptor) can mediate 
decreases in spontaneous locomotor activity (see section 1.3.2). This is based on the 
evidence that purported antagonists with selectivity for the D3 receptor subtype, such 
as U-99194A, sometimes increase locomotor activity without affecting DA release 
(Waters et aI., 1993; Svensson et aI., 1994). Therefore, it was interesting to note the 
behavioural effects of pre-treatment with a sub-maximal dose of U-99194A with 
cocaine. There were no significant interactions between U-99194A and cocaine on 
any parameter for locomotor activity, although U-99194A appeared to potentiate (to 
some extent) locomotor activity when combined with cocaine, an effect not produced 
by rac1opride. In contrast, there was a significant interaction between U-99194A, 
cocaine and time for total duration and mean bout duration for rearing activjty, for 
which a potentiating profile was observed. This is the first report of a potentiating 
~ 
effect of aDA D3 receptor antagonist with cocaine, albeit rather modest. 
There is evidence in the literature, however, showing that DA putative D3-
preferring agonists interact with effects mediated by other DA receptors. For 
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example, Thorn et ai. (1997) demonstrated that low doses of the DA D31D2 receptor 
agonist, quinelorane, could antagonise amphetamine-stimulated-hyperactivity. In 
addition, quinelorane had no significant effect on amphetamine-enhanced DA release 
suggesting that the behavioural response to quinelorane is not evoked by autoreceptor 
stimulation. In another study, the putative DA D3-receptor agonists 7-0H-DPAT and 
PD 128907 significantly suppressed SK&F 81297 (Dl-like agonist) induced 
hyperactivity at high doses, suggesting that these D3 agonists may influence 
specifically D I-receptor mediated behaviours via post-synaptic D3 receptors (Mori et 
aI., 1997). Thus, the D3 receptor may have some modulatory control over the 
behavioural effects of cocaine, perhaps rearing activity. In particular, by removing this 
tonic control by administration of an antagonist selective for this receptor subtype, 
greater stimulation of either Dl-like or D2-like receptor subtypes may occur, and 
hence the effects of cocaine may be potentiated. The results also revealed no 
significant interactions between U-99I94A and cocaine for grooming activity, 
suggesting that the decrease in grooming induced by cocaine is not mediated by the 
D3 receptor subtype. Instead, the attenuation produced by raclopride reinforces the 
conclusion tha~ this is a D2 receptor-mediated effect. 
Finally, the D4 receptor antagonist L-745,870 failed to antagonise any of the 
effects of cocaine on behaviour. This is consistent with previous work on this 
compound where it has been shown to have no effects in tests of antipsychotic activity 
(Bristow et aI., 1996) nor on cocaine's DS effects (Chapter 3). For L-745,870 to act 
exclusively as a DA D4 receptor antagonist in vivo is dependent on the dose 
administered. At doses up to 1 mglkg p.o. in rats, any effects observed with this 
compound are likely to be mediated via D4 receptor antagonism, since at this dose L-
745,870 will occupy> 90% of D4 receptors in the CNS (Patel et aI., 1996b). 
Therefore, the results suggest that the D4 receptor subtype does not contribute to 
cocaine-induced behaviours, and this lack of effect cannot be attributed to the dose of 
L-745,870 being non-selective or having no significant receptor occupancy. 
In conclusion, the results of the present study suggests that indirect stimulation 
-~ 
of receptors of the D2-like subfamily may not be important to cocaine's effects on 
food intake and locomotor activity. The D2/D3 antagonist raclopride produced only 
marginal attenuation of cocaine's effects on food intake, locomotor and rearing 
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activity, but it clearly attenuated suppreSSIOn of grooming by cocame, strongly 
suggesting that this is a D2-mediated effect. The D3 antagonist U-99194A, produced a 
modest potentiating effect on certain parameters of cocaine-induced hypophagia and 
rearing. This result implies that stimulation of D3 receptors by cocaine may inhibit 
activity, and removing this effect by blocking the D3 receptor may subtly potentiate 
some cocaine-induced behaviours. Finally, the selective D4 antagonist L-745,870 
failed to alter any of the behavioural effects induced by cocaine, and in agreement 
with studies of cocaine's DS effects, suggests a total lack of involvement of this 
receptor subtype in cocaine's effects on feeding, locomotor activity, rearing or 
grooming. 
214 
CHAPTER 9: 
'MICROSTRUCTURAL ANALYSIS OF A 'DI-LIKE'RECEPTOR 
SUBTYPE ANTAGONIST IN COMBINATION WITH COCAINE' 
Chapter 9: Microstructural Analysis of a Dl-Like Receptor Subtype ... 
CHAPTER 9: 
MICROSTRUCTURAL ANALYSIS OF A 'DI-LIKE' RECEPTOR SUBTYPE 
ANTAGONIST IN COMBINATION WITH COCAINE 
9.1 Introduction And Aims 
In the previous chapter, it was demonstrated that DA D2-like receptors do not 
seem to be necessarily involved in certain effects of cocaine on feeding, locomotor 
and rearing in the rat, since blockade of these receptors is not always sufficient to 
reverse cocaine-induced effects. The effect most strongly attenuated by the D21D3 
antagonist rac10pride was cocaine's suppression of grooming. The limited abilities of 
the D2-like antagonists to attenuate the behaviours induced by cocaine prompts an 
assessment of the specificity of these results by investigating the involvement of DA 
Dl-like receptors using similar methods. The purpose of the present study was 
therefore to examine whether DA D1-like receptors playa key part in cocaine's 
effects on such behaviours. This was examined by administering the Dl-like selective 
antagonist SCH 39166 (Chipkin et aI., 1988). SCH 39166 was chosen over the other 
prototypical Dl-like receptor antagonist SCH 23390 (Iorio et aI., 1983) because SCH 
39166 possesses a higher selectivity for Dl vs. 5-HT2 and 5-HTlc receptors. The ratio 
ofKi's for 5-HT2 and D1 receptors is about 90 for SCH 39166 and about 30 for SCH 
23390. Moreover, the ratio ofKi's for 5-HT1C and Dl is about 700 for SCH 39166 and 
about 75 for SCH 23390 (Chipkin et aI., 1988; McQuade et aI., 1991). 
As described in section 4.3.2, D1-like antagonists have been shown to reduce 
food intake both in food-deprived rats (Gilbert and Cooper, 1985; Zarrindast et aI., 
1991; Terry and Katz, 1994) and in free-feeding animals (Clifton et aI., 1991; Naruse 
et aI., 1991). Biphasic effects seen with the D2-like antagonists on ingestive behaviour 
do not arise with drugs acting at D1-like receptors. Therefore, for food intake, the Dl-
like antagonist effect on feeding is less problematic when designing combination 
studies with cocaine, since both drugs act in the same direction, i.e. decrease intake. 
For example, Terry and Katz (1994), investigating the effects of the Dl-like receptor 
antagonists SCH 23390 and SCH 39166 on feeding behaviour, showed that doses of 
0.3 mg/kg and above produced inhibition of food intake. Consistent with this notion, 
Terry (1996) characterised further the anorectic effects of SCH 39166 using a 
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microstructural study and showed that 0.3 mg/kg significantly reduced some aspects 
of feeding (notably, a significant reduction in the number of meals consumed). In 
addition, this effect coincided with significant reductions in other kinds of motor 
behaviour: locomotion, rearing and grooming. Therefore, based on these prior studies, 
it was decided that 0.03 and 0.1 mg/kg doses of SCH 39166 would be used for 
combination with cocaine (in a balanced 'Latin Square' design for repeated measures) 
as microstructural analyses have shown these to be below the threshold of 
behaviourally activity when administered alone. 
9.2 Materials and methods 
9.2.1 Subjects: 
Eight male Sprague-Dawley rats (Charles River, Margate, Kent) weighing 320-360 g 
were housed in pairs with free access to water under a 12 hr light/dark cycle, lights on 
07:00. They were all maintained on a restricted diet of 15 g of standard food pellets, 
adjusted on test days so that, regardless of the effect of drug, all rats received the same 
food allowance per day. All testing was between 12:00 and 14:00 hours. 
9.2.2 Apparatus and procedure: 
The experiment used a procedure similar to that described in section 8.2.2. 
9.2.3 Drugs: 
(-)-Cocaine HCI, (Sigma Chemicals, Poole Dorset) and SCH 39166 HCI ( (-)-trans -
6,7,7a,8,9,13b-hexahydro-3-chloro-2 hydroxy-N-methyl -5H-benzo [d] naptho-{2,1-
b}azepine) (Schering Corporation, Bloomfield NJ, USA) were dissolved in 0.9% 
saline solution and administered intraperitoneally at doses of 10 mg/kg cocaine and 
0.03,0.1 mg/kg SCH 39166. All drugs were injected at a volume of 1 mllkg and the 
DA Dl-like receptor subtype antagonist was injected 30 min prior to the cocaine 
injection. 
9.2.4 Data analysis: 
The data were analysed by two-way ANOV A for repeated measures, where drug 
treatment (4 levels) and time (6 levels) were incorporated as within-subject factors. A 
.---
one-way ANOV A was calculated when behavioural data were collapsed across the 
30-min period. All drug doses were administered to the rats in a 'Latin Square' design 
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and comparisons between the results for individual drug treatments against vehicle 
controls were made using 'Dunnett's post-hoc t-tests. 
9.3 Results 
(a) Food Intake and Eating Microstructure. 
During the pre-test adaptation period, the food-deprived rats consumed on 
average 20 g wet mash within the 30 min test session. One-way ANOV A revealed an 
overall effect of treatment on food consumption [F(3,21) = 12.55, P<O.OI]; (Fig. 
9.1a(i)). Pre-treatment with SCH 39166 at 0.1 mg/kg produced a significant 
attenuation of cocaine-induced hypophagia (P<0.05). In fact, mean food intake after 
pre-treatment with SCH 39166 was 18.7 g, a value close to saline levels (20.9 g). At 
0.03 mg/kg, SCH 39166 failed to affect cocaine-induced hypophagia. Although non-
significant results were obtained for latency to induce feeding [F(3,21) = 1.55, NS; 
Fig. 9. 1 a(ii)], the results suggests an increase in the latency to start feeding after 
cocaine, and a dose-related attenuation by the Dl-like antagonist. There was a 
significant effect on eating rate [F(3,21) = 3.72, P<0.05; Fig. 9.1a(iii)]; post-hoc t-
tests revealed that there were no significant differences between vehicle controls and 
cocaine treatment, or cocaine plus the Dl-like antagonist, on the rate of eating (Fig. 
9.1 a(iii)). 
A two-way ANOV A for total duration of feeding revealed a significant effect 
of treatment [F(3,21) = 18.86, P<O.OI]. However, there was no significant effect of 
time [F(5,35) = 1.78, NS] but a significant drugxtime interaction [F(15,105) = 6.28, 
P<O.OI]. Fig. 9.1a(iv) illustrates the effect of treatment on total feeding duration. 
Saline treated rats spent most time feeding early in the test session, with decreasing 
levels through to the end of the session. In contrast, Post-hoc t-tests revealed that 
cocaine treated rats spent little time feeding in the early phase of the session (probably 
related to the latency effect), with some indication of recovery in the latter stages. Pre-
treatment with SCH 39166 at 0.1 mg/kg significantly attenuated cocaine's effects 
throughout the test session, with baseline levels being restored during time-bins 10-15 
min. As the sessioIl.-entered the latter stages, the lowest dose of SCH 39166 also 
attenuated the effects of cocaine at times 15-25 min (P<O.Ol compared to Sal-Coc 
data). 
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Feeding mean bout duration and bout frequency also followed a similar 
profile. There were significant effects of treatment for mean bout duration and bout 
frequency [respectively; F(3,21) = 16.12, P<O.Ol and F(3,21) = 3.65, P<0.05]. A 
significant time effect was also shown for the two parameters [respectively; F(5,21) = 
3.06, P<0.05 and F(5,21) = 14.72, P<O.Ol], and significant drugxtime interactions 
[respectively; F(15,105)= 2.39, P<O.Ol and F(15,105) = 3.59, P<O.Ol)] (Fig. 
9.1a(v)&(vi)). For. these parameters, an unusual profile was observed after pre-
treatment with the D1-like antagonist. For mean bout duration, SCH 391666 at 0.1 
mg/kg produced unusually high scores throughout the observation period, which was 
not replicated for the bout frequency parameter. On the other hand, the low dose of 
SCH 39166 given with cocaine produced high scores for bout frequencies, again 
throughout the test session. However, as the mean bout duration was not affected by 
this low dose, it's effect on bout frequency was not sufficient to attenuate cocaine's 
effect on intake overall. The mechanism by which the highest dose attenuated 
cocaine-induced hypophagia was the increase in total duration of feeding, caused 
mainly by an effect on mean bout duration and a small effect on bout frequency. 
These trends were reflected in the data when behavioural counts were 
collapsed across the 30 min period: Post-hoc t-tests revealed that pre-treatment with 
the highest dose of SCH 39166 attenuated cocaine's effects on total duration and 
mean bout duration (P<O.Ol), but had no effect on bout frequency (Fig. 9.1(iv-vi)B). 
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Figure 9.1a. 
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Figure 9.1(a) Effects of pre-treatment with a selective Dl-like antagonist on cocaine-
induced feeding parameters: (i) total food intake (ii) latency to start eating (iii) eating 
rate (iv)A&B total duration (v)A&B mean bout duration (vi)A&B bout frequency , 
N=8 at all points; * P<O.05, ** P<O,Ol compared to saline-controls; + P<O.05, 
++ P<O,Ol compared to saline-cocaine (comparisons by DUlUlett's t-tests) 
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(b) Locomotor Activity. 
Cocaine significantly increased mean locomotor counts throughout· the first 
20-25 min of the test session. There were significant main effects of treatment 
[F(3,21) = 17.0, P<O.OI] and time [F(5,35) = 48.76, P<O.OI] and a drugxtime 
interaction [F(15,105) = 4.57, P<O.OI] (Fig. 9.1b(i)A). A 4x6 ANOVA for the whole 
test session also showed a significant effect of treatment [F(3,21) = 16.74, P<O.OI] 
(Fig. 9.1b(i)B). Pre-treatment with SCH 39166 at 0.1 mglkg attenuated cocaine-
induced locomotor· activity at time intervals 5-20 min of the test session bringing 
locomotor counts back to baseline levels from time 10-15 min onwards. 
There was an effect of treatment on duration [F(3,21) = 18.34, P<O.OI]. There 
was also a significant time effect [F(5,35) = 35.23, P<O.OI] and a drugxtime 
interaction [F(15,105) = 4.62, P<O.OI; Fig. 9.1b(ii)]. SCH 39166 at 0.1 mg/kg 
attenuated total time spent on this behaviour, reducing it to saline levels from 10-15 
min onwards. For mean bout duration, there was a significant main effect of treatment 
[F(3,21) = 3.23, P<0.05], a significant time effect [F(5,35) = 3.74, P<O.Ol] but no 
drugxtime interaction [F(15,105) = 0.83, NS] (Fig. 9.1b(iii)). 
A similar profile was shown for locomotor bout frequency (Fig. 9.1 b(iv)) as 
was shown for total duration of locomotor activity. There was a significant main 
effect of treatment [F(3,21) = 17.34, P<O.Ol] a significant time effect [F(5,35) = 
59.35, P<O.Ol] and a significant drugxtime interaction [F(15,105) = 4.13, P<O.Ol]. 
Once again, SCH 39166 at 0.1 mg/kg produced significant attenuation of cocaine 
induced increases in bout frequencies. Attenuation was greatest for this parameter, in 
that it persisted from the start of the test session through to the end. 
Hence, locomotor bout frequency was the parameter responsible for cocaine's 
effects on locomotor activity counts and total duration for this behaviour. Upon 
administration of the Dl-like antagonist, there was a clear antagonism of this 
parameter, which as a result led to a decrease in total duration (and consequently 
locomotor counts) throughout the observation period. This was also the case when 
behavioural counts were collapsed across the 30 min period (Fig. 9.1 b(ii&iv)B). 
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Figure 9.1(b) Effects of pre-treatment with a selective Dl-like antagonist on cocaine-
induced locomotor activity parameters: (i)A&B total locomotor counts (ii)A&B total 
duration (iii)A&B mean bout duration (iv)A&B bout frequency. N=8 at all points; 
* P<O.05 , ** P<O.Ol compared to saline-controls; + P<O.05, ++ P<O.Ol compared to 
saline-cocaine (comparisons by Dunnettls t-tests) 
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(c) Rearing. 
Rearing activity mirrored locomotor activity, with low levels after saline 
treatment and an increase produced by cocaine (Fig. 9.lc(i-iii)). There was a 
significant main effect of treatment for total duration of rearing [F(3,21) = 5.37, 
P<O.OI] a significant time effect [F(5,35) = 5.29, P<O.Ol] but no significant 
dosextime interaction [F(l5,l05) = 1.20, NS]. For mean bout duration, there was no 
significant main effect of treatment, nor a time effect or a drugxtime interaction. 
However, for rearing bout frequency there was. a significant main effect of treatment 
[F(3,2l) = 13.60, P<0.01], a significant time effect [F(5,35) = 34.68, P<0.01] and a 
significant drugxtime interaction [F(15,105) = 4.0, P<O.OI] (Fig. 9.1c(iii)). Pre-
treatment with the low dose of SCH 39166 failed to antagonise cocaine's effects on 
any parameters of rearing, but the higher dose of 0.1 mg/kg attenuated total time spent 
rearing and mean bout frequency during the early stages of the test session. Therefore 
the antagonism produced by SCH 39166 of cocaine's effects on total time spent 
rearing was via a specific action on bout frequency, not via mean bout duration 
(d) Grooming and restinglimmobility. 
None of the behavioural parameters for grooming were affected by any drug 
treatment when compared with saline treatment (data not shown). There was also no 
significant main effect of time, and no drugxtime interaction for any parameter. 
However, cocaine on its own did produce a decrease in the total duration of grooming 
(P<0.05) which corresponded with decreases in mean bout duration and bout 
frequency (P<0.05 for both) when compared to saline treatment across the 30 min 
period. 
..-? 
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Figure 9.1c. 
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Figure 9.1(c) Effects of pre-treatment with a selective Dl antagonist on cocaine-
induced rearing parameters: (i)A&B total duration (ii)A&B mean bout duration 
(iii)A&B bout frequency. N=8 at all points; * P<O.05, ** P<O.Ol compared to saline-
controls; + P<O.05 , ++ P<O.Olcompared to saline-cocaine (comparisons by Dunnett's 
t-tests) 
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9.4 Discussion 
The primary finding was that the D1-like antagonist SCH 39166 attenuated 
cocaine's suppressant effects on food intake. In fact, mean food intake after pre-
treatment with SCH 39166 (0.1 mg/kg) was 18.7 g, a value close to saline levels (20.9 
g). At 0.03 mg/kg, SCH 39166 failed to affect cocaine-induced hypophagia. The 
mechanism by which the highest dose attenuated cocaine-induced hypophagia was 
attributed to an increase in the total duration of feeding. This was caused mainly by 
the effect on mean bout duration, a large effect on bout frequency at the start of the 
test session, and the probable contribution of a non-significant reduction in the latency 
to start feeding. However, an unusual profile was observed after pre-treatment with 
the D1-like antagonist on these parameters. SCH 39166 at 0.1 mg/kg produced 
unusually high scores for mean bout duration throughout the observation period, but 
not for bout frequency. On the other hand, the low dose of SCH 39166 (which had no 
effect on food intake per se) produced high scores for bout frequency when combined 
with cocaine. As mean bout duration was not affected by this dose, the effect on bout 
frequency was not sufficient to attenuate cocaine's effects on feeding overall, thereby 
explaining the ineffectiveness of this dose. 
Comparing the effects of the D1-like antagonist with those of the D2-like 
antagonists (see Table 9.1) suggest that D1-like receptors playa more important role 
in cocaine's suppressant effects on food intake. In the only study to date looking at 
DA receptor involvement of cocaine's effect on feeding, Rapoza and Woolverton 
(1991) examined the effects of a selective DA D1-like receptor antagonist, SCH 
23390, and a D21D3 receptor antagonist, raclopride, on milk consumption. Both 
antagonists attenuated the effects of at least one of cocaine's effective doses. 
However, as mean food intake was measured only in their study, it is not clear how 
these drugs attenuated cocaine's effects. Also, the use of behaviourally active doses 
(i.e. 0.25 & 0.5 mg/kg SCH 23390, and 0.3 & 1.0 mglkg raclopride, doses which 
themselves induced hypophagia) makes the comparison between studies difficult to 
interpret. Nevertheless, the result showing that our more conservative behaviourally 
inactive dose of SCH~39166 (0.1 mg/kg) attenuated cocaine's suppressant effects on 
food intake, unequivocally demonstrates that the D1-like receptor subtype is an 
important contributor to the mechanisms by which cocaine produces its action. 
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Table 9.1. A comparison of the effects of pre-treatment with selective Dl-like and D2-like antagonists on the microstructural 
effects of cocaine. 
BEHAVIOURAL RESPONSE CATEGORY COCAINE'S EFFECTS Dl-like Antag. D2/D3 Antag. D3 Antag. D4Antag. 
FEEDING 
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LOCOMOTOR ACTIVITY 
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MEAN BOUT DURATION 
BOUT FREQUENCY 
REARING· 
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BOUT FREQUENCY 
GROOMING 
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KEY: (.!-) = decrease (t) = increase (+) = antagonises (-) = potentiates (0) = no effect (+++) = strong (+) = weak (HD) = high dose 
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In agreement with the feeding data, DA Dl-like receptor blockade also had a 
greater effect than DA D2-like receptor blockade in attenuating cocaine induced 
hyperactivity and rearing behaviour (also see Table 9.1). This is consistent with 
reports in both mice and rats that Dl-like antagonists are more effective than D2-like 
antagonists in altering cocaine-induced locomotor behaviours at non-sedative doses 
(e.g. Cabib et aI., 1991; Ushijima et aI., 1995; Le et aI., 1997; O'Neil and Shaw, 
1999). In all these studies it was shown that the Dl-like antagonists (notably SCH 
23390) could reduce hyperiocomotion induced by cocaine at doses that did not 
consistently alter spontaneous activity. Whereas, the D2-1ikeantagonists either had no 
effect at all (spiperone: Le et aI., 1997) or could only reduce the hyperiocomotor 
effects of cocaine at doses in excess of the minimum dose required to attenuate 
spontaneous locomotor activity significantly (e.g. Cabib et aI., 1991; Ushijima et aI., 
1995, O'Neil and Shaw, 1999). These results along with the present study therefore 
indicate that Dl-like but not D2-like receptors playa significant role in cocaine-
induced hyperactivity. It has also been reported that Dl-like receptors are important to 
a range of other cocaine-induced behaviours. For example, McCreary and Marsden 
(1993) sho~ed that DA Dl-like receptors may be more important in the expression of 
sensitisation to the conditioned behavioural effects of cocaine, as behavioural 
sensitisation was antagonised by the selective DA Dl-like antagonist compound, SCH 
23390, but not by the DA D2-like antagonist, haloperidol. This was supported by 
DeVries et al. (1998) who showed that infusion of a Dl-like receptor agonist into the 
nucleus accumbens enhances cocaine-induced behavioural sensitisation. However, 
there is some inconsistency in the literature, as Mattingly et ai. (1996) showed that co-
administration of either haloperidol or SCH 23390 can block the acute locomotor-
activating effects of cocaine, but only haloperidol prevented the development of 
behavioural sensitisation. Localisation studies have also produced mixed results: 
Neisewander et ai. (1998) and Baker et al. (1998) looked at the role of DA Dl-like 
receptors in cocaine-induced behaviours and found, in agreement with previous work, 
that systemic administration of SCH 23390 reversed cocaine-induced locomotion, 
.-/ 
sniffing and cocaine-conditioned place preference, suggesting that stimulation of DA 
Dl-like receptors is necessary for these behavioural changes. However, intra-
accumbens administration of SCH 23390 did not alter cocaine-induced locomotor 
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activity, although it did reverse cocaine-conditioned place preference despite 
occupying 40-60 % of Dl-like receptors in the anterior nucleus accumbens core and 
shell. Hence D I-like receptors located in structures other than the nucleus accumbens 
may be important for cocaine's stimulant properties, which would explain the 
ineffectiveness of intra-accumbens administration of SCH 23390 by Neisewander and 
Baker. A problem that still needs to be resolved concerns the subtypes of Dl-like 
receptors necessary for cocaine-induced locomotion. Using selective antisense 
oligonucleotides, it has been shown that the DA D 1 receptor subtype may play a 
facilitatory role in locomotor activity, whereas the DA D5 receptor subtype within the 
Dl-like subfamily may exert an inhibitory effect (Dziewczapolski et aI., 1998). 
However, as there are no drugs selective for this receptor subtype to date, the roles of 
the DA Dl and D5 receptor subtypes in cocaine-induced behaviours remains poorly 
characterised. 
The only effect of cocaine that SCH 39166 failed to attenuate was inhibition of 
grooming. SCH 39166 at a dose of 0.1 mg/kg had no effect on any of the behavioural 
parameters for grooming, in contrast with the D21D3 antagonist raclopride, which had 
strongly attenuated cocaine-induced decreases in grooming. The results here therefore 
reinforce the conclusion from the previous chapter and suggest that inhibition of 
grooming must be exclusively a D2 mediated effect. It is interesting to note that both 
the selective D2-like receptor agonist N-0437 (Rusk and Cooper, 1989b) and cocaine 
(Cooper et aI., 1993, and section 7.3.2) significantly reduced grooming in similar tests 
of palatable food consumption. Yet the effects were achieved by different means. N-
0437 reduced the frequency of grooming bouts and had no effect on the mean duration 
of grooming; in contrast Cooper at al. (1993) reported that cocaine reduces the bout 
duration of grooming while having little effect on the bout frequency. The results 
described in section 7.3.2 and in the previous chapter also differ with the above two 
studies suggesting that cocaine decreases grooming by disrupting all parameters. Early 
reports on D I-like agonists, on the other hand, demonstrate a differeJ?t picture 
altogether. The Dl-like agonist SKF 38393 induces non-stereotyped grooming 
.-/ (Molloy and Waddington, 1984); the induction of grooming by SKF 38393 has been 
widely confirmed, and has been replicated using other Dl-like agonists such as A-
68930 (Waddington and Daly, 1993; Naser and Cooper, 1994). 
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Hence, although Dl-like agonists (SKF 38393 and A-68930), N-0437 and 
cocaine all reduce feeding behaviour, there is a disjunction regarding grooming. Dl-
like agonists induce grooming, whereas N-0437 and cocaine suppresses it. Therefore 
the ability of raclopride to reverse cocaine-induced suppression of grooming (section 
8.3.1), without affecting locomotion or rearing very much, suggests that inhibition of 
grooming by cocaine is not due to indirect increases in other behaviours (i.e. to 
behavioural competition). This generalisation can be extended by looking at other 
results in the present study using the Dl':'like antagonist. Normalising locomotor 
activity, with SCH 39166 in combination with cocaine, does not allow recovery of 
grooming. Therefore, these behaviours induced by cocaine must be independent and 
mediated via specific receptors, an outcome that has not been demonstrated before. 
In conclusion, at a behaviourally inactive dose the selective Dl-like 
antagonist, SCH 39166, attenuated cocaine-induced hypophagia, hyperactivity and 
rearing, but had no effect on suppression of grooming. These results suggest that 
indirect stimulation of receptors of the Dl-like subfamily may be more important than 
stimulation of receptors of the D2-like subfamily to the locomotor, rearing and 
anorectic effects of cocaine. 
234 
CHAPTER 10: 
'SUMMARY AND FINAL 
CONCLUSIONS' 
Chapter 10: Summary and Final Conclusions: . 
CHAPTER 10: 
SUMMARY AND FINAL CONCLUSIONS 
The recent escalation of cocaine abuse has increased awareness of the need to 
understand the behavioural effects of cocaine and the determinants of those effects. It has 
become widely accepted that CNS DA plays a primary role in the behavioural effects of 
cocaine. However, little is known regarding the DA receptor subtypes that are involved in 
different cocaine-induced behaviours. In animal studies, cocaine can elicit hypophagia, an 
increase in locomotor activity, stereotyped behaviour and it can also function as a 
discriminative stimulus. The aim of this thesis was to examine DA receptor subtype 
involvement in these behavioural effects, in particular the roles of D2-like receptors. The 
major findings and implications of the thesis are described below. 
10.1 Dopamine receptor subtypes and cocaine-induced behaviours 
10.1.1 Involvement in the discriminative stimulus effects of cocaine: 
The DS effects of cocaine are primarily mediated by indirect stimulation of DA 
receptors, but the relative contributions of receptor subtypes within Dl-like and D2-like 
receptor subfamilies have not been fully determined as yet. The first study tested the 
effects of antagonists selective for receptors within the D2-like subfamily (D3 or D4) on 
the DS effects of cocaine, and compared them with the effects of a Dl-like receptor 
antagonist. A second study, using two different training doses (10 mg/kg vs. 3.0 mg/kg), 
tested the effects of three centrally acting D2-like antagonists on cocaine's DS effects: L-
741,626; haloperidol; and rac1opride. L-741,626 is a highly selective antagonist of the D2 
receptor within the D2-like receptor subfamily; the other two drugs have different binding 
affinities for the various D2-like receptors. The effects of the D2-like antagonists were 
then compared with the effects of the Dl-like receptor antagonist, SCH 39166, on 
cocaine's full dose response curve. 
Neither the D4 receptor antagonist L-745,870 (1-10 mg/kg), nor the D3 receptor 
antagonist U-99194A (1-10 mg/kg), substituted for cocaine, and in combination with 
cocaine neither drug shifted the dose-response function for cocaine at any dose, although 
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both reduced rates of responding. If anything, there was perhaps some indication that the 
highest dose of U-99194A potentiated the effect of a low dose of cocaine. On the other 
hand, and in striking contrast, pre-treatment with the D1-like antagonist SCH 39166 (0.1, 
0.3 mg/kg) produced significant, dose-related rightward shifts in the cocaine 
generalisation curve, indicating effective, surmountable antagonism. The results suggest 
negligible involvement of D4 receptors in particular, and support an important role for 
D1-like receptors in cocaine's DS effects. 
Most studies assessing the DS effects of cocaine in rats have used a training dose 
of 10 mg/kg. Typically, such studies have suggested that DA D1-like and D2-like 
receptors both contribute to the DS effects of cocaine. However, the relative contributions 
of DA receptor subtypes to the effects of a lower training dose of cocaine have not been 
so well characterised. Comparing between the two different training doses of cocaine, the 
D1-like and D2-like receptor antagonists were not differentially effective between the two 
training groups. Regardless of cocaine training dose, all four antagonists produced 
significant, parallel, rightward shifts in the dose response function for cocaine's DS 
effects, indicating competitive antagonism. L-7 41,626 was less potent than haloperidol or 
raclopride, and pA2 analysis suggested that antagonism of cocaine's effects by L-741 ,626 
was by a different mechanism from that of haloperidol and raclopride. 
DA D1-like and D2-like receptors within the mesocorticolimbic system have been 
shown to play a significant role in mediating the DS effects of cocaine, with particular 
importance attributed to the roles of the nucleus accumbens and the amygdala, sub sites 
where DA D3 and D4 receptors are expressed, respectively. The present findings showing 
that L-745,870 does not alter the DS effects of cocaine therefore suggests that DA D4 
receptors in amygdala and frontal cortex are probably not important to cocaine's DS 
effects. Further experiments using selective D4 antagonists, or substitution tests using 
selective D4 agonists, when they become available, are needed to determine whether the 
lack of effects is specific to this compound. The finding of negligible involvement of DA 
D3 receptors in cocaine's DS effects contrasts with the current consensus; it challenges 
the orthodox view of the importance of D3 receptors to cocaine's DS effects. Other 
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selective D3 receptor antagonists should therefore also be examined as they become 
available for study. 
In summary, the experiments suggest that DA Dl-like receptors, but not D3 or D4 
receptors from the D2-like subfamily, are critically involved in the DS effects of cocaine 
. at high dose training conditions. The experiments also suggest that D2 receptors within 
the D2-like receptor subfamily are the critical sites mediating the DS effects of cocaine. 
In addition, neither D2 nor DI-like receptor subtypes have preferential involvement at 
either high or low training doses of cocaine. This is an important finding, as Terry et al. 
(1994) suggested that training dose may be an important determinant of the extent to 
which DA receptor subtypes are involved in the DS effects of cocaine. The present results 
may suggest that some of the D2-like agonists used by Terry et al. (1994) may have more 
complex DS effects (quinpirole showed near-full substitution) and that the use of 
selective D2-like receptor antagonists may generate more reliable results. Alternatively, 
the results may reflect an interaction between D I-like and D2-like receptors, whereby 
blockade of D2 receptors reduces Dl-like receptor involvement. Given that quinpirole 
substitutes for cocaine at low training doses, the former explanation may be more likely. 
Before a series of behavioural studies could be developed to investigate DA 
receptor involvement in cocaine-induced hypophagia and other concurrent behaviours, it 
was necessary to examine the effects of selective DA receptor subtype antagonists alone 
on food intake associated behaviours. 
10.1.2 DA D2-like receptor subtypes and ingestive behaviour: 
The contributions of DA D3 and D4 receptors to the effects of non-selective 
dopaminergic drugs on feeding have not been determined due to the limited availability 
of compounds acting specifically at these receptors. The development of drugs selective 
for DA D3 and D4 receptors allowed for characterisation of the effects of drugs that 
target specific receptors within the D2-like receptor subfamily. These novel D2-like 
receptor subtype antagonists were compared with the prototypical D2-like antagonist 
sulpiride, and to a structural analog, amisulpride. At doses that occupy postsynaptic D3 
receptors, feeding was only marginally affected by U-99I94A (1-10 mg/kg); effects on 
_...--' 
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intake and rate of eating only occurred at the highest dose. The drug produced negligible 
effects on locomotor activity and grooming, but rearing was significantly reduced at the 
highest dose. Comparisons with the effects of less-selective D2-like receptor antagonists 
suggested that D3 receptor blockade is not an important contributor to those effects. In 
fact, U-99194A produces effects most similar to those of D2-like agonists. D4 receptor 
blockade by L-745,870 produced a different profile of effects. There was no reduction in 
food intake at D4 receptor-selective doses (1-3 mg/kg); however, microstructural 
analysis showed that a significant decrease in the number of meals consumed was 
compensated by an increase in mean duration of feeding bouts. The local rate of eating 
declined only at the highest dose. Unlike the D3 antagonist, L-745,870 also caused a 
substantial reduction in locomotor activity at doses that did not affect rearing. 
Comparisons with the effects of less-selective D2-like receptor antagonists suggest that 
D4 receptor blockade is not an important contributor of those effects. In fact, L-745,870 
produces effects most similar to those ofD1-like antagonists. 
Sulpiride, a prototypical D2-like antagonist, produced a dose-related increase in 
feeding 30 min after administration (significant at 5.0 and 50.0 mglkg) and a decrease in 
locomotor activity at the highest dose of 50.0 mg/kg. EDso values showed that 
amisulpride' was roughly three times more potent than sulpiride in suppressing locomotor 
activity, a value that is similar to the difference in their binding potencies. Amisulpride 
produced similar results to sulpiride: an increase in feeding 30 min after administration, 
significant at a dose of 5.0 mg/kg, but higher doses (reported to antagonise postsynaptic 
receptors) had no significant effect on food intake, although some decrease was evident. 
In contrast, amisulpride caused a decrease in locomotor activity 30 min after 
administration, evident only at 50.0 mg/kg. The results therefore suggests that as 
amisulpride and sulpiride shared a similar behavioural profile, the additional D3 binding 
affinity reported for amisulpride may not have much bearing on its effects on feeding and 
locomotor behaviour. The results also reveal clear dissociations between the effects of D3 
and D4 receptor blockade on specific behaviours, but suggest only subtle effects on 
feeding. Neither D3 nor D4 blockade alone mimics the effects of previously-tested D2-
like receptor antagonists. 
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10.1.3 Dopamine receptor Involvement in cocaine-induced hypophagia and concurrent 
behaviours: 
Cocaine administered to food-deprived rats trained to eat a palatable sweetened 
mash produced distinct behavioural effects: hypophagia, locomotor hyperactivity, 
increased rearing and decreased grooming. Cocaine suppressed food intake by delaying 
the onset of feeding and suppressing the rate of eating, but this latter parameter was only 
significant at the highest dose, 30 mg/kg. In effect, cocaine's ability to prolong the 
latency to start feeding, together with a reduction in the frequency of eating episodes, 
resulted in an overall reduction in the time devoted to feeding. Cocaine also produced a 
dose-dependent increase in time devoted to locomotor activity and rearing, corresponding 
with increases in bout frequencies for these behaviours. The opposite was the case for 
grooming behaviour: cocaine significantly reduced total duration, largely due to a dose-
dependent reduction in the frequency of grooming episodes and mean bout duration. 
The effects of a series of D2-like antagonists given as pre-treatments to cocaine 
were then compared. Drugs with differing selectivities for D2, D3 and D4 receptors 
(raclopride, U-99194A and L-745,870) produced different outcomes. The D3 (U-
99194A) and the D4 (L-745,870) antagonists failed to alter any of the behavioural effects 
induced by cocaine. In contrast, the D21D3 antagonist raclopride produced only marginal 
attenuation of cocaine's effects on food intake, locomotion and rearing activity. However, 
it clearly attenuated suppression of grooming by cocaine, strongly suggesting that this is a 
D2-mediated effect. This therefore implies that grooming behaviour may provide a 
particularly sensitive index of D21D3 receptor involvement of cocaine's suppressant 
effects. A comparison between U-99194A and raclopride (which also has selectivity for 
DA D3 receptors) suggests that raclopride's marginal attenuation of cocaine's 
suppression of eating, locomotor and rearing hyperactivity must be mediated by DA D2 
receptors. 
The selective Dl-like antagonist SCH 39166 at 0.1 mg/kg, on the other hand, 
reversed cocaine-induced hypophagia by increasing the time devoted to feeding and bout 
frequencies. It also attenuated cocaine-induced hyperactivity and rearing .behaviour by 
decreasing the same parameters, but had no effect in attenuating cocaine's suppressant 
---
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effects on grooming. These results suggest that indirect stimulation of receptors o(the 
Dl-like subfamily may be more important than stimulation of receptors of the D2-like 
subfamily in locomotor activity, rearing and suppression of eating. The results also show 
how different behavioural effects of cocaine can be regarded as independent, and under 
independent receptor control. The ability of raclopride to recover grooming without 
affecting locomotor or rearing activity very much suggests that inhibition of grooming by 
cocaine is not due to indirect increases in other behaviours. This is supported by the 
results from the combination study with SCH 39166 and cocaine, where the Dl-like 
antagonist normalised all behaviours induced by cocaine apart from grooming. Therefore 
one can say that these behaviours induced by cocaine must be working independently and 
through specific receptor control. These are the first results to show such outcome. 
10.1.4 Commonalities between drug discrimination and feeding studies: 
The thesis has focused on the neurobiology of the acute behavioural effects of 
cocaine. The information gained has not only contributed to our understanding of the 
neuropharmacology of abused drugs such as cocaine, but also to our understanding of the 
effects of such compounds on natural rewards such as provided by feeding. The 
activation of ML DA systems appears to be linked to the process of reward (see section 
1.3.2). For example, dopaminergic activity is increased by presentation of a broad range 
of natural rewards (e.g. food, water, sex) and by associated conditioned stimuli (Phillips 
et aI., 1991; Damsma et aI., 1991; Apicella et aI., 1991; Schultz et aI., 1992). DA is 
increased in both the nucleus accumbens and neostriatum by a continuous stimulus for 
food prior to eating and throughout a meal, decreasing to baseline 10-30 min after the 
meal (Phillips et aI., 1991). Therefore, one can ask the question is there an association 
between reinforcement produced by "natural" reinforcers (such as food) and the 
reinforcing effects of drugs of abuse? A common assumption is that food cravings 
experienced with food consumption are due to intense likings for specific food (Berridge, 
1996); in the same way that administration of cocaine has been reported to be followed 
by an increase in cocaine craving (Berridge, 1996); an effect that may. increase the 
likelihood of additional cocaine consumption. If hyperactivation of the DA-related 
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system of 'liking' were induced selectively, the result would be a focused, intense craving 
for a specific target. However, an important difference between drug cravings and food 
cravings is that psycho stimulant drugs produce sensitisation of DA-related systems, a 
process that might be expected to greatly amplify craving (Berridge, 1996). This gives 
drug craving in addiction a degree of intensity that is unlikely to be matched by most 
food cravings, although the process may otherwise be quite similar and therefore would 
provide two behavioural models in which the DA receptor subtype involvement could be 
studied. 
There are several reasons for believing that the DS effects of a drug are important 
processes in addiction. The first relates to the proposed relationship between 
discriminative and subjective effects. Both theory and empirical data support the view 
that drug discrimination procedures in animals are the closest available experimental 
model for such effects (Stolerman, 1992). Secondly, the discriminative effects of drugs 
may directly promote drug-seeking behaviour because such behaviour has been 
associated previously with the perceived effects of drugs. Thus, the ability to perceive 
and identify the characteristic SUbjective effects of drugs may encourage drug-seeking 
behaviour by indicating the effects and potencies of substances that are sampled, and by 
directing the organism towards one substance rather than another. Therefore, analyses of 
the DS effects of cocaine can indicate central actions involved in its subjective effects. 
Since the latter effects of drugs contribute to their abuse, investigation of the DS effects 
of cocaine should help establish the central mechanisms involved in cocaine abuse. It is 
very much the case that repeated drug administration best mirrors normal, social patterns 
of cocaine use; however it is still unclear as to whether either tolerance or sensitisation 
develops to the reinforcing effects of cocaine. What has been shown is that tolerance or 
sensitisation to the DS effects of cocaine does not develop in rats (Wood and Emmett-
Oglesby, 1986; also see section 3.3). Hence, in practice, the drug discrimination model 
can be considered a kind of acute administration protocol, and it is therefore justifiable to 
compare the results from the model with those from acute behavioural tests, such as was 
done here using feeding and locomotor activity. 
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10.2 Future Studies 
In order to effectively study the roles of DA receptor subtypes in the behavioural 
effects of cocaine, appropriately selective pharmacological tools will be necessary. As 
yet, a sufficient number of agonists and antagonists selective for DA D2, D3 and D4 
receptors have not been investigated in a wide enough range of behavioural tests for 
definitive conclusions to be made concerning the functions of these receptor subtypes in 
cocaine-induced behaviours. Hence, to unequivocally prove that the DA D3 and D4 
receptors from the D2-like subfamily are not involved in the DS effects of cocaine, 
experiments using other selective receptor antagonists and agonists (when available) 
should be conducted. It would also be of interest to see whether the ineffectiveness of 
these receptor subtype antagonists on cocaine's DS effects can also be generalised to 
other models relevant to cocaine abuse, such as self-administration and conditioned place 
preference. 
Also, as an adjunct to the drug discrimination studies, an interesting result 
observed in these experiments was the limited involvement of D2-like receptors in 
cocaine-induced hypophagia and locomotor hyperactivity, in comparison with Dl-like 
receptors. The results contrast with many local application studies using D2-like 
antagonist compounds, in which the involvement of these receptors was clearly indicated. 
Therefore, applying these antagonists locally to specific brain regions in studies of 
cocaine's effects on feeding and locomotor activity (perhaps using a similar model to that 
of chapter 8) may shed more light on the discrepancy. In particular, studies using the very 
recently-developed D2-selective antagonist L-7 41,626 may help to address these issues, 
as well to substantiate the novel finding that cocaine-induced decreases in grooming is a 
D2-mediated effect. It would also be of great interest to expand these experiments to see 
whether other stereotyped behaviours induced by cocaine, such as gnawing, scratching 
and head-bobbing, are also mediated by the DA D2-receptor SUbtype. 
More generally, recent progress in molecular biology has offered an alternative to 
the use of pharmacological antagonism in the elucidation of the receptor effects of 
cocaine. It is now possible, through selective targeting of the genome, to obtain mice that 
lack a functional type of receptor ('knockout' mice). With gene-targeting, one can knock 
~----
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out a gene in vivo and create a mutant organism that completely lacks the gene product. 
The promise of gene-targeting is to reveal the in vivo function of the genes of interest 
(e.g. for the DA receptor subtypes) and eventually to conduct experiments similar to 
those described in this thesis to further test whether particular receptor subtypes are 
necessarily involved in the behavioural effects of cocaine. Clearly, a null-mutant 
organism might not only lack the product of a single gene but might also possess a 
number of physiological or behavioural traits that have been altered to compensate for the 
effect of the null mutation. Therefore, comparisons would still be needed with the effects 
of selective agonists and antagonists for each receptor subtype in order to understand 
fully the involvement of such receptors in the behavioural effects of cocaine. 
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